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Abstract
Abstract
The generation of neuronal dendrites and axons is a highly dynamic process. These 
extensive structural changes are regulated by molecules such as GTPases, as well as 
kinases/phosphatases, which provide cyclical control mechanisms. Rho family GTPases 
are regulated, in part, by GAPs such as neurone-enriched chimaerin, and act through 
downstream kinase effectors, including cyclin dependant kinase 5 (Cdk5).
a 2 chimaerin is a Rac GAP and phorbol ester receptor, which also displays 
Cdc42/Rac effector functions. From this study it appears a2 chimaerin exists in an 
auto- inhibited state in the cytosol and that DAG/phorbol ester association, or selected 
mutations translocates a2 chimaerin to the membrane, leading to GAP activation. a2 
chimaerin GAP activity was implicated in PMA induced neurite collapse of N1E-115 
neuroblastoma cells. PMA also promoted the association of a2 chimaerin with target 
proteins Collapsin Response Mediator Protein-2 (CRMP-2) and p35/Cdk5, possibly as a 
result of a conformational change.
The Rac effector, Cdk5 is a proline directed, Ser/Thr kinase, whose activity 
contributes to neurite outgrowth, growth cone collapse and neuronal migration. 
Deregulation of Cdk5 in neurodegenerative diseases is implicated in pathological 
changes. a2-chimaerin GAP domain was shown to interact in vivo both with p35, the 
neuronal activator of Cdk5 and with Cdk5 itself.
CRMP-2 interacted in vivo with a2 chimaerin SH2 domain, for which tyrosine 
phosphorylation was not essential. The functional correlates of these protein interactions 
of a2 chimaerin were investigated in vivo. CRMP-2, which is hyperphosphorylated in 
Alzheimer’s disease was identified as a novel Cdk5 substrate in vitro with CRMP-2 
Ser522 identified as the target site. Phosphorylation of CRMP-2 Ser522, potentially 
primes for GSK-3P phosphorylation of CRMP-2 Ser518 and Thr 514 which alters 
CRMP-2 conformation.
a2 chimaerin was not a Cdk5 substrate but may be tyrosine phosphorylated, 
which could potentially regulate its activity or associations in neuronal cells.
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Introduction
Protein signalling molecules include enzymes, whose catalytic activities are tightly 
modulated, as well as multi-domain adaptor proteins that build and regulate protein 
complexes. Cell signalling is strictly regulated by a variety of mechanisms. The 
eukaryotic cell is highly compartmentalised with internal membranes and organelles, 
providing micro-environments where the local concentration of signalling molecules are 
highly regulated. Protein synthesis is tightly controlled at both the transcription and 
translational level, while degradation is equally finely regulated. Post-translational 
modification of proteins (e.g. phosphorylation, prenylation) and association with 
cofactors (e.g phosphoinositides and cAMP/cGMP) also serve to regulate activity, 
binding properties, subcellular localisation and degradation.
Cells sense and respond to the local environment via surface receptors, which 
upon ligand association, trigger an intracellular signalling cascade. Numerous cell 
signalling pathways converge on the Rho GTPase molecular switches to modulate the 
cytoskeleton.
1.A The Cytoskeleton
. The cytoskeleton is the cells interior scaffold, consisting of three types of protein 
filaments; (actin filaments, microtubules and intermediate filaments) which extend 
throughout the cytoplasm. It is a highly dynamic structure allowing morphological 
alterations in response to environmental stimuli. Morphological changes permit cell 
migration and neurite formation, but the cytoskeleton also provides and maintains the 
framework for the high level of organisation required by eukaryotic cells.
20
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1.A.1 Microtubules
Microtubules are polymerised filaments of tubulin which is itself a heterodimer of a  and 
P tubulin. Tubulin is found in most cell types but is most abundant in the vertebrate 
brain. Microtubules are cylindrical structures with a hollow core formed from a ring of 
13 tubulin heterodimers. Microtubules are polar, with polymerisation more rapid at one 
end (plus end) compared with the other (minus) (Desai et al., 1997). The minus end is 
associated with a distinct microtubule organising centre (MTOC). De novo synthesis of 
microtubules is slow but polymerisation and depolymerisation are rapid events and 
microtubules frequently switch between phases of growth and depolymerisation. The 
energy for this dynamic instability comes from the hydrolysis of GTP-bound by p 
tubulin, which occurs after assembly. GTP hydrolysis weakens the bonds holding these 
structures together thus promoting disassembly. Mature microtubules are found 
modified by acetylation and detyrosination which is thought to promote microtubule 
associating protein (MAP) binding (Westermann et al., 2003). MAPs control 
microtubule stability and the drug taxol also serves to stabilise these dynamic structures. 
MAPs are extremely varied, but in the brain fall into two classes, high molecular weight 
proteins (>200kDa) e.g. MAP-l/MAP-2 and the Tau proteins (55-62kDa). Microtubules 
in axons are uniformly orientated with the plus ends pointing away from the cell body, 
whereas in dendrites the orientations are mixed. Certain forms of Tau are only found in 
axons, where MAP-2 is excluded. MAP-2 only resides in dendrites and the cell body. 
MAPs include microtubule motors e.g. kinesins and dyneins, which use the energy of 
ATP hydrolysis to move along these track structures powering organelle movement and 
mitosis/meiosis. These motor proteins move unidirectionally with dyneins generally 
controlling organelle transport towards the cell interior (towards minus end) and
21
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kinesins governing transport of synaptic vesicles along axons towards nerve terminals 
(toward the plus end).
1.A.2 Actin Filaments
Actin is the most abundant eukaryotic cellular protein, constituting approximately 5% of 
total cell protein, with numerous isoforms (a, P y) in higher eukaryotes. Actin filaments 
(F-Actin) are polymers of the 43kDa actin monomers (globular or G-Actin). These 
monomers, associated with ATP molecules, polymerise in a uniform orientation to form 
a tight helical structure, whereupon ATP is hydrolysed to ADP. Like microtubules, 
actin filaments are polar, polymerising faster at one end (plus end). Polymerisation 
requires both the availability of existing filament ends and actin monomers (Dos 
Remedios et al 2003).
Drugs which bind and stabilise/destabilise actin filaments have also become 
useful tools to study actin behaviour in cells. Cytochalasins are fungal products that 
bind the plus end of filaments preventing further polymerisation while the phalloidins 
are toxins isolated from the Amantia mushroom that bind and stabilise actin filaments.
1.A2.1 Actin binding proteins
More than 162 actin binding proteins have been identified to date, many of which 
compete for the same loci on actin (Dos-Remedios et al., 2003) regulating actin filament 
assembly/disassembly.
The cell maintains a large pool of monomer ATP-actin, poised for rapid 
polymerisation. The small globular protein profilin (Ampe et al., 1988) is one of the 
most highly expressed cytoplasmic proteins and binds ATP-actin monomers (Safer et 
al., 1997). Profilin acts to maintain a pool of actin monomers, which would be rapidly
22
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depleted if plus end filaments were readily available. It is the role of capping proteins 
to prevent this. Capping protein (Cap Z) and gelsolin are the most abundant capping 
proteins, which serve to inhibit the association and dissociation of actin monomers to 
plus end filaments. Uncapping of both CapZ and gelsolin has been demonstrated by 
association with the membrane phosphoinositides (PI(4,5)P2) (Schafer et al., 1996). 
PI(4,5)P2 also binds profilin and serves to dissociate profilin/actin complexes. .
Severing proteins cut existing filaments into smaller ones, generating additional 
plus ends, thus potentially promoting actin polymerisation. Gelsolin, which is 
stimulated by Ca2+, acts to sever existing filaments but then caps the newly generated 
plus end filaments inhibiting elongation. ADF/cofilins (cosediments with F-actin) also 
sever actin filament but are thought to promote depolymerisation rather than assembly 
(Carlier et al., 1997). The short filaments generated from cofilin severing may be 
stabilised and cross-linked by the Arp2/3 complex.
l.A.2.2 Actin filament nucleation
Spontaneous actin filament nucleation is unfavourable due to the instability of actin 
dimers and trimers but accessory proteins serve to catalyse this process. A complex of 
seven proteins, termed the Arp2/3 complex (Machesky et al., 1994), is the most well 
characterised initiator of actin filament nucleation. As well as nucleation, the Arp2/3 
catalyses the branching of actin filaments promoting filament assembly from the sides 
of existing filaments at a strict angle of 70° (Mullins et al., 1998). The Arp2/3 complex 
is intrinsically inactive requiring activation by nucleation promoting factors including 
the WASp/Scar proteins (Higgs et al., 2001).
Formins have also been shown to directly nucleate actin (Pruyne et al 2002) 
independently of the Arp2/3. The conserved forming homology domains (FH1 and
23
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FH2) are both implicated in the control of actin assembly. The proline rich FH1 binds 
profilin (Wantanabe et al 1997) and SH3 and WW containing proteins including Src 
(Tominaga et al., 2000) while the FH2 domain controls actin nucleation in vitro (Pruyne 
et al 2002) and actin assembly in vivo (Evangelesta et al., 2002), through potential 
stabilisation of actin dimmers (Pring et al 2003).
l.A.2.3 Actin filament depolymerisation
The energy from ATP hydrolysis is used to drive actin polymerisation. Hydrolysis of 
ATP, by actin, upon polymerisation marks the filament for depolymerisation by the 
ADF/cofilin family members, which associate more readily with ADP-polymerised 
actin. Kinetically it is the dissociation of the generated phosphate that acts an effective 
timer for destruction. ADF/cofilin association also inhibits the rapid ATP exchange 
observed at the terminal plus end actin subunits, which serves to stabilise filaments. 
Phosphorylation of ADF/cofilins by LIM kinases, reduces their affinity for actin 
monomers and filaments (Blanchoin et al., 2000) thus stabilising actin filaments. 
Tropomyosin is a dimer of two identical a  helixes which form a rigid rod shape capable 
of binding along the length of actin filaments. Tropomyosin association provides 
mechanical support and acts to inhibit ADF/cofilin association, thus strengthening and 
stabilising actin filaments (Bernstein et al., 1982).
Depolymerisation results in disassociation of ADF/cofilin-ADP-actin 
monomers. Profilin exchanges with ADF/cofilin and promotes ATP exchange 
(Blanchoin et al., 1998), replenishing the pool of ATP-actin monomers for 
polymerisation and freeing ADF/cofilin for another round of depolymerisation. 
Treadmilling is the continual flux of actin subunits from the minus end to the plus end.
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l.A.2.4 Actin filament organisation
Dynamic surface extensions are common place in cells and are believed 
generated by forces produced from local actin polymerisation at the plasma membrane. 
Microspikes (5-10jj,M) and filopodia (< 50pM) are thin stiff protrusions of actin 
filaments organised into parallel bundles with their plus end pointing out. Fimbrin and 
villinis a widely distributed protein which organises the actin filaments into tight 
parallel bundles at the leading edge of cells (Bretscher et al., 1980, Bretscher et al 
1979). a  actinin and fascin is also found associated with filament bundles (Tilney et al 
1995). Lamellipodia are thin sheet like extensions generated at the leading edge of 
migrating cells, consisting of a dense meshwork of actin filaments. At branching of 
angles of around 70° (Y-junctions) the Arp2/3 complex is localised (Svitkina et al 
1999). Filamin A is a highly abundant actin crosslinking protein also found in 
lammelipodia at branches of higher angles (X-junctions) (Flanagan et al., 2002). 
Capping protein are also localised to lammelipodia such as gelsolin while cofilins 
localise to the rear of the lammelipodia (Svitkina et al., 1999). Stress fibres are loose 
bundles of actin filaments stretching across the cell, where they make contact with the 
plasma membrane forming an anchor structure (focal contact). Stress fibres are 
associated with myosin and the generation of contractile forces. Myosins are motor 
proteins capable of hydrolysing ATP upon association with actin filaments and this 
energy is used to move along the filaments in a minus to plus end orientation.
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l.B Rho GTPases
The Rho GTPase family, which consist of at least 23 members, are key regulators of the 
actin cytoskeleton, controlling migration, vesicle trafficking, cell polarity and neurite 
outgrowth but have also been implicated in microtubule rearrangements, cell adhesion, 
transcription regulation and reactive oxygen species production(Etienne-Manneville et 
al., 2002).
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These 20kDa proteins are capable of binding and hydrolysing GTP. Two functional 
loop regions (switch I and switch II) surround the y phosphate from the nucleotide and 
are conformationally altered upon GTP binding and hydrolysis (Milbum et al., 1990). 
GTPases are in effect molecular switches, “on” in their GTP bound forms and “o ff’ 
when GDP bound (Bourne et al., 1990). When “on”, they are capable of binding to and 
activating a diverse set of effector molecules, stimulating down stream signalling, which 
is self limited due to the protein’s intrinsic GTPase activity. The cycle of activation is 
regulated by three classes of proteins: Guanine nucleotide exchange factors (GEFs) 
stimulate the exchange of GTP for GDP, turning the switch on, GTPase activating 
proteins (GAPs) stimulate the intrinsic GTPase activity, turning the switch off and 
guanine nucleotide dissociation inhibitors (GDIs) inhibit the dissociation of GDP but
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also the hydrolysis of GTP therefore stabilising the switch. Rather than an on/off 
activity it is emerging cycling of the GTPases are crucial for dynamic functioning. The 
cycling of the Rho GTPases is tightly regulated with more than 60 GEFs and 
approximately 80 GAPs in the human genome.
These molecular switches must be spatially regulated as well as temporally. The 
C-terminal of most GTPases are post translational modified with the covalent 
attachment of a hydrophobic prenyl tail to a cysteine residue. The prenyl tail serves as a 
membrane anchor localising the GTPase activity to membranes (Hancock et al., 1989).
“ON”
Membrane
GDP
GEF
GTP
Rho
GAP
Effectors
GDI
Rho
GDP-------------
“OFF”
Fig 1.2 Rho GTPase cycle
l.B .l Guanine nucleotide exchange factors (GEFs)
Members of the Dbl family of GEFs catalyse the release of the tightly bound GDP from 
the GTPase, stimulating GTP uptake in response to upstream signalling. Like the Dbl 
oncoproteins, many GEFs have been implicated in cancers e.g. T-cell lymphoma 
invasion and metastisis (Tiaml), Lbc and Lsc (Van Aelst 1997). GEFs act in a dual 
manner, to destabilise the GDP bound form and stabilise the non nucleotide bound
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form, with the relative concentrations of cellular GTP/GDP driving the reaction. The 
DH (Dbl homology) domain is generally arranged in tandem with a 100 residue 
pleckstrin homology domain (PH), involved in membrane targeting, where the target 
prenylated Rho GTPases are located. In some cases the PH domain acts as negative 
regulator of the DH domain, which is relieved upon phosphoinositide association. As 
well as this catalytic 200-300 residue motif, a variety of other protein motifs connect 
GEFs to numerous signalling pathways.
Catalytic specificity varies amongst GEFs with Lbc and Lfc specific for Rho A, 
while Vav, is potentially active against RhoA, Rac 1 and Cdc42 (Olson et al., 1996). 
Trio is a Ser/Thr kinase with two distinct DH domains, displaying exchange activity 
towards Racl and RhoA respectively (Bellanger et al., 1998). Tyrosine phosphorylation 
of GEFs may serve as a regulatory mechanism, with Vav exchange activity upregulated 
by tyrosine phosphorylation (Crespo et al., 1997).
1.B.2 GTPase activating proteins (GAPs)
The Rho GAP family is defined by a conserved GAP domain of approximately 150 
amino acids. Rho GAPs far out number their cellular substrates, implicating tight 
regulation of their activities and specific functioning. Their tertiary structure is very 
similar to that of Ras GAP (Bax et al., 1998), consisting of nine a  helices and a 
conserved arginine finger (Gamblin et al., 1998). The GAP domain interacts with GTP 
binding core of the Rho GTPase (switch I and II and the P loop) inserting the positively 
charged arginine finger into the negatively charged active site. This serves to stabilise 
charges formed during the transition state of GTP hydrolysis, lowering the energy 
barrier, while at the same time positioning the catalytic glutamine residue of the GTPase
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to coordinate the nucleophillic attacking water molecule. GAPs also serve to stabilise 
the switch regions, which is an essential feature of GAP activity (Fidyk et al., 2002).
Studies in general have only characterized Rho GAP activities against the most 
well defined Rho GTPase members (RhoA, Racl and Cdc42) in vitro. GAP activity 
varies from highly specialised to active against multiple members. ARHGAP6 is only 
active against RhoA (Prakash et al., 2000) while OPH1 is active against all three 
members (Billuart et al., 1998). CeGAP from Caenorhabditis elegans surprisingly acts 
on human Ras and Rab3A as well as several Rho family members (Chen et al., 1994). 
The presence of a Rho GAP domain in the regulatory subunit of PI3K, p85a and 
p85J3, permits the association with and activation by Rac 1/Cdc42, although no GAP 
activity has been detected (Zheng et al., 1994, Bokoch et al., 1996). Similarly inositol 
polyphosphate 5-phosphatase GAP domain is devoid of activity (Jefferson et al., 1995). 
In some cases the Rho GAP domain may thus serve as a Rho GTPase interactive motif 
rather than a true catalytic GAP.
l.B.2.1 Rho GAP regulation
From their sequences Rho GAPs, in general, are multi domain proteins with a variety of 
protein and lipid binding domains, implicating complex regulatory mechanisms.
1..B.2.1.1 Lipid association
Rho GTPases are active on membranes and thus lipid association is a crucial 
requirement of many Rho GAPs. Cysteine rich domains (Cl) have been found in several 
Rho GAPs including chimaerins (Ahmed et al., 1990), Gmip (Aresta et al., 2002), 
PARG1 (Saras et al., 1997) and MgcRacGAP (Toure et al., 1998). Lipid association
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regulates chimaerin Rac GAP activity (Ahmed et al., 1993, Caloca et al., 2003) while 
the functional significance of the Cl domains in other GAPs remains to be determined.
Pleckstrin homology (PH) domains are also widely distributed amongst Rho 
GAPs including GRAF (Hilderbrand et al., 1996), Oligophrenin-1 (OPHN1) and 
PSGAP (Ren et al., 2001) where they have been presumed to be or shown to be required 
for correct localization. The Sec 14 domain of p50RhoGAP is also believed to mediate 
phosphoinositide associations (Krugmann et al., 2002) while START (StAR-related 
lipid transfer) domains in pl22RhoGAP (Homma et al., 1995) and other RhoGAP genes 
serve as an alternative lipid binding domain.
It was recently reported phospholipids can also switch the substrate preference 
of GAPs where phospholipids inhibited pl90RhoGAP activity but stimulated Rac-GAP 
activity (Ligeti et al., 2004).
l.B.2.1.2 Protein interactions
As well as lipid binding domains, Rho GAPs have incorporated numerous protein 
binding motifs, linking the Rho GTPases with a variety of signalling pathways. The 
SH3 domain of GRAF mediates interactions with both Focal adhesion kinase 
(Hilderbrand et al., 1996) and the Rho effector kinase PKN{3 (Shibata et al., 2001). 
Similarly PSGAP interacts with FAK and FAK related PYK2 (Ren et al., 2001). WW 
domains are also found in ARHGAP9 (Furukawa et al., 2001) and ARHGAP912 
(Zhang et al., 2002).
Rho GAPs also posses proline rich regions themselves thus associating with a 
variety of SH3 containing protein. 3BP-1 associates with c-Abl (Cicchetti et al., 1992) 
while RICH-1 associates with CIP-4 SH3 domain (Richnau et al., 2001). PDZ (PSD- 
95/DlgA/ZOl like) domain is another protein binding motif found in ARHGAP10
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(Basseres et al., 2002). PARG1 has been shown to bind a PDZ domain in the protein 
tyrosine phosphatases PTPL1 (Saras et al., 1997) while Nadrin binds the PDZ of EBP50 
(Reczek et al., 2001). Putative SH2 domains have also been found in Rho GAPs, 
linking them to tyrosine kinase signalling pathways. a2 chimaerin was found capable 
of binding phosphotyrosine residues, despite modification of the invariant N-terminal 
marking tryptophan (Hall et al., 2001).
Protein interactions potentially target Rho GAP activity or serve as an adaptor 
function. The first evidence of a protein association directly regulating GAP activity 
came from studies on CdGAP. The endocytic protein intersectin (Cdc42 GEF) was 
found to interact with CdGAP, via its SH3 domain, inhibiting GAP activity (Jenna et 
al., 2002). Alternatively Rho GAPs may regulate their associated proteins and 
pl22RhoGAP was found to bind and activate PLC5 (Homma et al., 1995).
l.B.2.13 Phosphorylation
The association of numerous GAPs with kinases/phosphatases implicates 
phosphorylation as a further potential regulation point. Phosphorylation could serve to 
regulate Rho GAP activity, location or complex formation and tyrosine phosphorylation 
of numerous Rho GAPs have been observed. The Src kinase, Fyn phosphorylates 
pl90RhoGAP (Wolf et al., 2001) and p250RhoGAP (Taniguchi et al., 2003, Moon et 
al., 2003) during oligodendrocyte maturation. pl90RhoGAP is phosphorylated by Src 
kinases at residues close to the GAP domain (Roof et al., 1998) where upon tyrosine 
phosphorylation recruits pl20RasGAP which stimulates pl90RhoGAP activity. PSGAP 
also associates with both FAK and PKY2. Co-expression of PSGAP with PKY2, but 
not FAK, in cells leads to tyrosine phosphorylation and inhibition of Cdc42-GAP 
activity (Ren et al., 2001).
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Ser/Thr phosphorylation of Rho GAPs has also been observed and found 
regulatory. PKC has been shown to phosphorylate pl90RhoGAP inducing translocation 
to membrane ruffles (Brouns et al., 2000). GRAF was observed phosphorylated by 
Mitogen activated protein kinase (Taylor et al., 1998) and RICS (p250RhoGAP) 
phosphorylation by Ca2+/Calmodulin dependent protein kinase II directly inhibited GAP 
activity (Okabe et al., 2003). Interestingly Ser phosphorylation of MgcRacGAP by 
Aurora B, during cytokinesis, was found to regulate substrate specificity in vitro, 
switching from Rac to Rho (Minoshima et al., 2003).
l.B.2.2 Rho GAP effector functions
The lack of GAP activity of some Rho GAP domains has suggested this domain may 
function as a Rho GTPase binding motif for possible effector function. GAPs could also 
conceivably promote dynamic GTPase signalling through increased cycling rates in 
cooperation with a GEF. Evidence of GAPs potentiating GTPase signalling do exist. 
The isolated GAP domain of a l  chimaerin serves to inhibit Rac stimulated lamellipodia 
formation. Full length protein however, cooperates with Racl and Cdc42 to induce 
lamellipodia and filopodia structures, requiring Rac binding but not GAP activity, 
suggestive of an effector function (Kozma et al., 1996). TCGAP translocates to the 
plasma membrane upon insulin stimulation and interacts with Cdc42 and 
TCI Op (Chiang et al., 2003). GAP activity has only been demonstrated in vitro and is 
undetectable in cells implying possible effector function or masking of GAP activity in 
vivo.
A number of Rho GAP members also contain other catalytic domains for 
multiple functions including the kinase and Cdc42-GEF domains of BCR. ARAPS 
contain both Rho and Arf GAP domains and provide potential points of cross talk
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between Rho and Arf GTPase signalling pathways (Miura et al., 2002). RICH1B 
contains a domain with homology to endophilins (Richnau et al., 2001), in which it 
functions as an LPA acyl transferase causing invagination of the plasma membrane 
(Schmidt et al., 1999). The role of this domain in RICH IB is thus highly intriguing and 
may implicate a function in vesicle formation. OCRL1 (oculocerebrorenal syndrome of 
Lowe) is a Rho GAP but also a PI(4,5)P2 5 phosphatase, providing another crucial link 
between Rho GTPase and PI(4,5)P2 signalling (Faucherre et al., 2003).
1.B.3 Guanine nucleotide dissociation inhibitors (GDIs)
Unlike GEFs and GAPs, the Rho GDI family is extremely small in number. GDIs serve 
to maintain an inactive pool of the Rho GTPases in the cytosol, through detachment of 
the GTPases from the membrane by burying their prenyl tail and inhibition of 
nucleotide exchange. The ubiquitously expressed Rho GDI was the first identified, 
binding to Rho A and B (Fukumoto et al., 1990) and since found to associate with Rac 
and Cdc42. Weak association with the GTP forms of these Rho GTPases has also been 
demonstrated, inhibiting GTP hydrolysis (Hart et al., 1992 and Nomanbhoy et al., 
1996).
1.B.4 Alternative mechanisms of Rho GTPase regulation
As well as prenylation and interactions with regulatory proteins, it has been reported 
that a few Rho GTPases interact homophically, mediated by the C-terminal polybasic 
region (Zhang et al., 2001). This oligomerisation results in self stimulated GAP 
activity with Arg suggested to function as an arginine finger (Zhang et al., 1999). 
Racl in the oligomeric state remains responsive to GEFs but not to GAPs and 
potentiates PAK activation. Oligomer dissolution is promoted by GDI association.
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Phosphorylation of Rho GTPases has also been observed. PKA phosphorylation 
of RhoA and Cdc42 increased Rho GDI binding (Forget et al., 2002) with consequent
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extraction of Rho-GTP from membranes (Lang et al., 1996). Ser phosphorylation of 
RhoA by PKA was also shown to inhibit association with its effector ROK (Dong et al.,
1998). Phosphoinositide associations of Rac also regulate GDI binding (Chuang et al., 
1993, Missy et al., 1998).
l.C The Rho GTPases and the cvtoskeleton
The Rho GTPases exert their function through a diverse set of effector proteins, which 
bind the active GTP form. Over 60 effector proteins for Rho, Rac and Cdc42 alone have 
been identified, implicating Rho GTPases in the regulation of several signal 
transduction pathways (Etienne-Manneville et al., 2002).
l.C .l Actin Dynamics
The first identified function of the Rho GTPases was actin cytoskeletal regulation. 
Microinjection of Rho A into fibroblasts cells resulted in stress fibre and associated 
focal adhesion formation (Ridley et al., 1992). Rac 1 promoted lamellipodia formation 
(Ridley et al., 1992), while Cdc42 was found responsible for filopodia induction 
(Kozma et al., 1995, Nobes et al., 1995). These three members (Rho A, Racl and 
Cdc42) are the most well characterised of the Rho GTPase family and have been 
implicated in extracellular receptor stimulated actin reorganisation. Lysophosphatidic 
acid (LPA) activates Rho (Ridley et al., 1992), Platlet derived Growth factor (PDGF) 
activates Rac (Ridley et al., 1992) and Bradykinin activates Cdc42 (Kozma et al., 1995).
Rho kinase (ROK) (Leung et al., 1995) was the first identified effector with 
direct links to the actin cytoskeleton (Leung et al., 1996). ROK in association with
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Rho-GTP was found to phosphorylate and inhibit Myosin Light Chain (MLC) 
Phosphatase (Kimura et al., 1996) and phosphorylate MLC (Amano et al., 1996). 
Upregulation of MLC phosphorylation by ROK promotes myosin association with actin 
filaments leading to stress fibre formation and actin/myosin contraction. ROK was also 
found to phosphorylate and activate LIM kinase, which in turn, inactivates cofilin, 
thereby inhibiting actin depolymerisation (Ohashi et al., 2000). PI40 mDiaphanous, 
another Rho effector, is a formin related protein, capable of binding profilin and 
stimulating actin polymerisation (Watanabe et al., 1997).
The first identified effectors of Racl/Cdc42 were the Ser/Thr kinases, p65 PAKs 
(p21 activated kinase) (Manser et al., 1994). Rac 1 /Cdc42-GTP association induces a 
conformational change, relieving kinase autoinhibition, promoting autophosphorylation 
and phosphorylation of exogenous substrates (Chong et al., 2001). PAKs phosphorylate 
and inactivate MLC kinase (Sanders et al., 1999), thus down-regulating phosphorylation 
of MLC, affecting actin/myosin contraction. Phosphorylation and activation of LIM 
kinase by PAK has also been demonstrated (Edwards et al., 1999) which in turn alters 
cofilin activity. Another Cdc42 effector, myotonic dystrophy kinase-related Cdc42 
binding protein kinase (MRCK) also phosphorylates MLC affecting actomyosin 
contractility (Leung et al., 1998).
The WASP family of Cdc42 effector proteins provided another crucial link 
between the Rho GTPases and the cytoskeleton (Rohatgi et al., 1999). Members of this 
family are capable of binding and activating the Arp2/3 complex, stimulating actin 
polymerisation (see l.D.2.3). WASP proteins exist in an inactive conformation which is 
relieved upon GTP-Cdc42 and PI(4,5)P2 association (Rohatgi et al., 2000), stimulating 
actin polymerisation at the plasma membrane. Rac has also been implicated in Arp2/3 
activation by WAVE, via association through the adaptor IRSp53 (Miki et al., 2000).
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IRSp53 has two distinct Rho GTPase binding sites for Rac 1 and Cdc42 and may 
provide another point of cross talk between the Rho GTPases. PIP5kinase is also a 
target of Rac, stimulating PI(4,5)P2 production (Tolias et al., 1995). In platelets, this 
has a direct effect on actin dynamics leading to plus end uncapping and severing of 
actin filaments, stimulating actin polymerisation and lamellipodia formation.
1.C.2 Tubulin Dynamics
The microtubule and actin cytoskeleton are not isolated, but regulate each other. Thus 
Rho GTPases may modulate microtubule dynamics indirectly, through their effects on 
the actin cytoskeleton, but evidence also exists for a direct regulation. In vitro Rac 1 
binds directly to tubulin in a GTP dependent manner (Best et al., 1996). Through the 
actions of PAK, Cdc42/Rac inactivate the microtubule destabilising protein, stathmin 
(Daub et al., 2001) while Cdc42 has been shown to regulate the orientation of the 
microtubule organising centre (MTOC) (Palazzo et al., 2001). The Rac/Cdc42 effector, 
IQGAP, serves to target microtubules to the leading edge via associations with the 
microtubule plus end targeted protein CLIP-170 (Fukata et al., 2002). The Rho effector 
mDiaphanous has also been shown to stabilise microtubules (Palazzo et al., 2001). 
Several GEFs including pl90RhoGEF (van Horck et al., 2001) and Lfc (Glaven et al., 
1999) have been localised to microtubules while the Rac GAP, a2 chimaerin, appears to 
bind tubulin via it’s SH2 domain (Ferrari Thesis 1999). Collapsin response mediator 
protein (CRMP-2) binds tubulin heterodimers promoting microtubule polymerisation 
(Fukata et al., 2002) and is a substrate of ROK activity (Arimura et al., 2000). The Rac 
effector p35/Cdk5 also phosphorylates the microtubule binding proteins Tau and MAP- 
1B, regulating microtubule stabilisation (Baumann., et al 1993, Paglini., et al 1998).
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Microtubule dynamics also regulate the Rho GTPases with polymerisation 
activating Rac (Waterman-Storer et al., 1999) and depolymerisation Rho (Ren et al.,
1999). (GEF)-Hl is a Rho specific GEF which binds inactively to microtubules, but is 
released and activated upon microtubule depolymerisation (Krendel et al., 2002).
The Rho GTPase coordinate the cytoskelton to regulate dynamic biological 
processes such as cell migration, differentiation and vesicle trafficking, all of which are 
especially apparent in the nervous system.
1.D Central Nervous System (CNS) Development
The central nervous system (CNS) consists of highly specialised cells (neurones) and 
their supporting cells (glia). The billions of neurones of the human brain are 
interconnected, forming a complex network allowing for diverse signalling. Neurones 
are highly polarised cells adapted for receiving and transmitting signals. They have 
developed elongated process called axons and dendrites that extend over relatively long 
distances and connect to other neurones. Input signals are received by the dendrites, 
processed and the output transmitted through the axon. Signalling within the CNS 
consist of electrical impulses that flow across neurones, passing from one to the other 
via synaptic connections. Here neurotransmitters are released, which induces the firing 
of the connecting neurones, propagating the signal.
Neurones do not divide once differentiated and so are given a “birthday”, 
defined as the time of final mitosis which generated the neurone from the neuronal 
precursor cell. Immature neurones then migrate from their place of birth guided by 
various factors. In vertebrates, neurones settle into six neuronal laminae within the 
forebrain. This program of neurogenesis occurs in an “inside-out” manner with early
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generated neurones settling into the deepest layers and later neurones in the more 
superficial layers. Radial migration along glial fibres is the most prominent form of 
migration in the mammalian cortex. Once the neurone has reached its desired location 
it exits the radial glial track and differentiates. Differentiation occurs with the 
development of neurites, which elongate to form a single axon and multiple dendrites. 
The outgrowth of these neurite structures is tightly regulated, ensuring they extend to 
the correct locations. At the tips of these structures is the growth cone, which acts as a 
sensory structure, guiding and powering the movement. CNS development thus 
requires dramatic neuronal morphological adaptations to first migrate to their correct 
destinations and then extend out axons and dendrites.
1.D.1 Neuronal Migration
Cell Migration in general is regulated in part by the Rho GTPases (Raftopoulou et al., 
2004). Through their various effectors, Rac/Cdc42, induce actin and microtubule 
polymerisation at the celTs leading edge. This, combined with the establishment of 
focal contacts, converts the forces of polymerisation into membrane extension. 
Coordinated contraction occurs at the rear of the cell through active myosin motors 
accompanied by efficient release of rear attachments with Rho/ROK signalling 
implicated, allowing forward movement. In the nervous system Cdk5 activity has also 
been implicated in neuronal migration.
l.D.1.1 Cyclin dependent kinase 5 (Cdk5)
This 33kDa proline directed Ser/Thr kinase is ubiquitously expressed in mammalian 
tissues but whose kinase activity is largely restricted to postmitotic neurones (Tsai et al., 
1993, Lew et al., 1994). It is the restricted expression of its activators that determines
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selectivity of activity. P35, a 35kDa protein, was the first identified and most well 
characterised activator of Cdk5. In situ hybridisation revealed p35 mRNA expression 
initiates as neurones exit the cell cycle and begin their journey of migration (Dellale et 
al., 1997). In mice, after birth, p35 mRNA levels rapidly decrease while Cdk5 levels 
increase, but a strong p35 signal remains in the adult brain associated with regions of 
high plasticity (pyriform cortex and pyramidal layer of the hippocampus). In brain 
lysates three separate pools of Cdk5 exist (Lee et al., 1996): isolated inactive 
monomeric Cdk5, relatively inactive Cdk5/p35 heterodimer in association with a large 
protein complex of 600kDa and an active p25/Cdk5 dimer. p25 is the C-terminal 
proteolytic cleavage product of p35 generated by the Ca2+ activated protease calpain 
(Lee et al., 2000). Cdk5 _/" mice display major defects in the hippocampus and cerebral 
and cerebellar cortices, reminiscent of reeler'A mice, leading to perinatal death (Ohshima 
et al., 1996, Gilmore et al., 1998, Ohshima et al., 1999). These phenotypes have been 
mimicked by electroporation of a dominant negative Cdk5 into ventricular zone cells in 
the cerebral cortex (Kawauchi et al., 2003). P35'/_ mice display severe cortical
lamination defects of the cerebral cortex with a reversed layering of the cortical 
neurones in an “outside-in” pattern (Chae et al., 1997). This implies Cdk5 activity is 
essential for cortical neurones to migrate past their predecessors. The p35'/_ mouse 
phenotypes appears to be only a subset of the Cdk5_/' phenoptypes with only mild 
hippocampal and cerebella abnormalities. P39 is another identified brain activator of 
Cdk5 with high similarity to p35 (Tang et al., 1995). p39’A mice display no obvious
brain developmental defects, implicating compensatory mechanisms between activators. 
Double mutant mice p35'/*p39'/", exhibit identical phenotypes to Cdk5'A mice, further 
implying p35 and p39 as the principal activators of Cdk5 (Ko et al., 2001), although p67 
has also been identified as an activator (Shetty et al., 1995).
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A preferred basic residue at the +3 position provides the consensus sequence 
S/TPX(K/H/R for Cdk5 phosphorylation. There are numerous identified substrates, 
including neuronal cytoskeletal elements. The lack of neuronal migration in p35/Cdk5 
knockout mice could suggest there is an upregulation of neuronal adhesions, p-catenin 
was identified as a p35 interactor (Kwon et al., 2000) and p35/Cdk5 was shown to both 
phosphorylate p-catenin and interact with N-cadherin. Phosphorylation inhibits P- 
catenin-N-cadherin association, reducing cellular adhesion. The tyrosine kinase FAK is 
linked to focal adhesions in non neuronal cells and is crucial for migration (Parsons et 
al., 2000). Highest mammalian expression levels are found in the brain, where it is 
enriched in neurones in which typical focal adhesion structures are absent although 
analogous structures may be present (Contestabile et al., 2003). Cdk5 phosphorylation 
of FAK was shown to mediate microtubule reorganisation around the nucleus 
promoting nucleokinesis and neuronal migration (Xie et al., 2003). Cdk5 also mediates 
microtubule dynamics through phosphorylation of Tau and MAP2 proteins (Patrick et 
al., 1999, Berling et al., 1994).
1.D.2 Neurite outgrowth
During brain development, once the neuroblast has reached its destination, 
neuritogenesis occurs, which is believed to be mediated by the coordination of actin and 
microtubule cytoskeletons. Evidence indicates both cytoskeletons are dispensable for 
neuritogenesis as inhibition of microtubule polymerisation with nocodazole or of actin 
with cytochalasin B does not affect neurite formation (Smith et al., 1994, Marsh et al., 
1984). Forces generated from the actin cytoskeleton were believed to break the 
neuronal sphere symmetry to induce a bud which develops to form an initial neurite.
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Recent evidence implicates lamellipodia as the direct precursors to neurites (Dehmelt et 
al., 2003), which subsequently accumulate microtubules, forming the neurite shaft.
These minor neurites develop through the stabilisation of microtubules, 
redirection of membrane trafficking and interplay of gene transcriptional changes. One 
of the neurites develops into the axon while the remaining ones form dendrites inducing 
neuronal polarity, which is reproduced in culture on rat hippocampal cells (Barlett et al., 
1984).
Rho GTPase signalling has been implicated in neurite outgrowth with opposing 
roles for Cdc42/Rac and Rho. Rho/ROK signalling induces neurite retraction in 
response to LPA in both N1E-115 neuroblastoma cells and PC 12 cells (Jalink et al., 
1994) while Rac/Cdc42 signalling is believed to promote outgrowth. Serum withdrawal 
of N1E-115 neuroblastoma cells results in neurite outgrowth in a Rac and Cdc42 
dependent manner (Kozma et al., 1997). Over-expression of Cdc42/Rac effectors N- 
WASP (Edgeworth Thesis 2003), PAK5 (Dan et al., 2002) and IRSp53 (Govind et al., 
2001) is also sufficient to promote neuritogenesis in N1E-115 neuroblastoma cells while 
mutants of N-WASP inhibit outgrowth in PC 12 and hippocampal neurones (Banzai et 
al., 2000). Ras also promotes neurite outgrowth in N1E-115 cells, activating PI3K with 
down-stream Rac/Cdc42 activation (Samer et al., 2000). Upregulators of Rac/Cdc42, 
including the GEFs Tiam (Leeuwen et al., 1997), STEF (Matsuo et al., 2002) and Trio 
(Bateman et al., 2000) also induce outgrowth, while the RhoGEF, ephexin induces 
retraction (Shamah et al., 2001). Exceptions to this general rule of Cdc42/Rac 
promoting outgrowth with Rho antagonism are exemplified by Serna 3 A and Ephrin A2 
induced growth cone collapse of neurones, which is Rac dependent (Jin and Strittmatter 
1997, Jumey et al., 2002). RhoV14 expression in PC 12 cells after NGF priming was
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also found to increase neurite length while RhoN19 expression reduced neurite length 
(Sebok et al., 1999).
l.D.2.1 Rho GAPs
Evidence for the involvement of Rho GAPs in the nervous system came from the 
discovery of the Rho GAPs OPHN-1 and OCRL, which are associated with X-linked 
mental retardation (Billuart et al., 1998, Lin et al., 1997). Numerous Rho GAPs have 
been found to be brain specific or brain enriched including chimaerin (Ahmed., et al 
1990), ARHGAP4 (Foletta et al., 2002) and Nadrin (Neuronal associated 
developmentally regulated protein), which regulates Ca dependent exocytosis (Harada 
et al., 2000). SrGAPs (Slit Robo) are recently identified Rho GAPs involved in Cdc42 
regulation, downstream of SLIT signalling (Wong et al., 2001).
P190RhoGAP is a well characterised Rho GAP required for axon outgrowth and 
guidance, mediating Src dependent adhesion. Fyn phosphorylates pl90RhoGAP (Wolf 
et al., 2001) and p250RhoGAP (Taniguchi et al., 2003) during oligodendrocyte 
maturation and the transient over-expression of both pl90RhoGAP and p250RhoGAP 
induces neurites in neuroblastoma cells (Brouns et al., 2001 and Moon et al., 2003).
a  Chimaerins are phorbol ester receptors (Ahmed et al., 1990) with GTPase 
activity towards Rac (Diekeman et al., 1991, Manser et al., 1992). The Cl domain of a  
chimaerins is a Zn dependent structure (Ahmed et al., 1991) involved in phorbol ester 
association and membrane translocation (Caloca et al., 2001), with lipid association 
regulating GAP activity in vitro (Ahmed et al., 1993). Two N-terminal splice variants 
of a  chimaerin exist, a l  / a2 (Hall et al., 1990, Hall et al., 1993).
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- Cl — B F""""^Ap ffll  a  1 Chimaerin (35kDa)
—t  SH2~ GAP H| a2 Chimaerin (47kDa)
Fig.1.3 a  Chimaerin members
a l  chimaerin mRNA is abundant in the adult brain associated with areas of learning and 
memory while a2  chimaerin is predominantly expressed in postmitotic neurones of the 
foetal brain (Hall et al., 2001). a2 chimaerin SH2 domain appears to alter subcellular 
distribution, adopting a more cytosolic location compared with the predominantly 
insoluble a l  chimaerin. The SH2 domain has been shown capable of binding 
phosphotyrosine residues, although specificity and in vivo receptors remain elusive.
a l  chimaerin, (Kozma et al., 1996) unexpectedly cooperates with Rac/Cdc42 to 
induce lamellipodia and filopodia in neuritic growth cones of N1E-115 cells, indicative 
of Rac/Cdc42 effector functions. Permanent expression of a2 chimaerin also induces 
neuritogenesis in N1E-115 neuroblastoma cells (Hall et al., 2001). No binding partners 
for a  chimaerins have been identified for these possible adaptor functions or to 
anchor/target and regulate enzyme activity.
l.D.2.2 Collapsin response mediator protein (CRMP-2)
The neuronal specific CRMPs (1-5) are homologues of C.Elegans Unc33, mutants of 
which result in impairment of neural circuits and uncoordinated locomotion (Hedgecock 
et al., 1985). CRMP-2 is expressed immediately after neuronal birth and increases 
dramatically during cortical neurogenesis (Mintum et al., 1995). Expressed in neural 
cell bodies and neurites, it is also localised to filopodia and lamellipodia of growth 
cones (Mintum et al., 1995). Implicated in Sema3A growth cone collapse (Goshima et
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al., 1995), CRMP-2 has also been found to induce axons in hippocampal neurones 
(Inagaki et al., 2001). Evidence suggests an involvement in tubulin dynamics (Gu et al., 
2000 and Yuasa-Kawada et al., 2003) where CRMP-2 binds tubulin heterodimers to 
promote microtubule assembly (Fukata et al., 2002). CRMPs exist as both cytosolic 
and membranous bound forms with members localised to lipid rafts (Rosslenbroich et 
al., 2003), with the exception of CRMP-2, but CRMP-2 does associate with the plasma 
membrane oxidoreductase complex on synaptic vesicles and the synaptic plasma 
membrane (Buillard et al., 1997). Despite sequence similarity with 
dihydropyrimiinidase and heterotetramer formation (Deo et al., 2004), no enzyme 
activity has been detected (Wang et al., 1997). Only a few binding partners of CRMP-2 
have been identified. Associations with Numb mediates endocytosis of proteins such as 
LI (Nishimura et al., 2003) while the interaction with neuronal phospholipiase D2 
serves to inhibit PLD2 enzyme activity (Lee et al., 2002).
CRMP-2 is a highly phosphorylatable protein and is found hyperphosphorylated 
associated with neurofibrillary tangles in tissue from Alzheimers disease patients (Gu et 
al., 2000). It is a target of Fps/Fes tyrosine phosphorylation downstream of Serna 3A 
signalling (Mitsui et al., 2002). CRMP-2 is also phosphorylated by ROK during LPA 
induced growth cone collapse (Aimura et al., 2000). Recently N-terminal splice 
variants of each CRMP have been identified (Leung et al., 2002 and Yuasa-Kawada et 
al., 2003). The new splice variant CRMP-1 A was found to form hetero-oligomers with 
CRMP-2 and associate with and inhibit ROK kinase activity (Leung et al., 2002). 
Recent work with non tagged protein also contradicted previous results. CRMP-2 
reducedaxonal length and increased branching, which was abolished by co-expression 
of the novel, longer splice variant CRMP-2A (Yuasa-Kawada et al., 2003).
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l.D.2.3 Cyclin dependent kinase 5 (Cdk5)
As well as regulation of neuronal migration, Cdk5 activity and has been implicated in 
neurite outgrowth through dominant negative and antisense studies (Nikolic et al., 1996, 
Xiong et al., 1997)). Cdk5 redistributes from the cell body toward axon growth cones in 
cultured neurones, during process formation, where it associates with the actin rich 
peripheral regions (Pigino et al., 1997, Paglini et al., 1998 and Nikolic et al., 1996). The 
short half life of p35 implies tight regulation of expression. Laminin engagement of 
integrins has been shown to upregulate p35 transcription and protein levels during 
neurite outgrowth (Paglini et al., 1998, Li et al., 2000). NGF induced outgrowth of 
PC12 cells also induces p35 expression through the ERK pathway (Harada et al., 2001). 
Studies imply Cdk5 activity does not simply promote outgrowth but acts as a key 
modulator of outgrowth (Pigino et al., 1997, Paglini et al., 1998 and Connel-Crowley et 
al., 2000).
Cdks are regulated by phosphorylation (see l.A.2.1). Cdk activating kinase 
(CAKs) do not phosphorylate and activate Cdk5 (Qi et al., 1995) but Thr159 
phosphorylation has been demonstrated by casein kinase I, which in vitro upregulates 
activity (Sharma et al., 1999). In contrast to Cdk2, phosphorylation of Cdk5 Tyr15 has 
been shown to increase kinase activity. C-Ableson (c-Abl) phosphorylates Tyr15 which 
is enhanced by the association of the adaptor protein Cables (Zuckerberg et al., 2000). 
Knockout of Cables reduces axon length while expression of active Abl increased axon 
length.
Cdk5 can influence cytoskeletal dynamics with the formation of filopodia and 
lamellipodia when p35 (Nikolic et al., 1998) and p39 (Humbert et al., 2000) are 
expressed in fibroblasts. Identified as a Rac effector, p35/Cdk5 also induces 
phosphorylation of PAK1 in a Rac dependent manner, which results in down regulation
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of PAK1 kinase activity (Nikolic et al., 1998). Cdk5 also associates with the 
microtubule cytoskeleton (Sobue et al., 2000). Several microtubule binding proteins 
serve as substrates, including Tau (Baumann et al., 1993) and MAP1B (Paglini et al., 
1998). Tau phosphorylation by Cdk5 reduces its affinity for microtubules (Patrick et al., 
1999, Takahashi et al., 2003), inhibits microtubule assembly (Evans et al., 2000) and 
decreases microtubule nucleation ability (Wada et al., 1998). Influences of 
neurofilament dynamics are also observed with phosphorylation of the intermediate and 
heavy chains tail regions during outgrowth (Pant et al., 1997, Li et al., 2000, Grant et 
al., 2001), which can reduce axonal transport rates (Yabe et al., 2001, Ackerley et al., 
2003).
Cdk5 activity is linked to axonal transport with kinase inhibition decreasing 
anterograde transport in giant squid axons (Ratner et al., 1998). Nudel is a recently 
identified substrate of Cdk5 that associates with the retrograde motor protein dynein 
(Niethammer et al., 2001). Phosphorylation of Nudel appears to regulate dynein 
function. P35/Cdk5 is also found to be active in Golgi membranes (Paglini et al., 2001), 
since its inhibition blocks the formation of membrane vesicles from the Golgi apparatus.
Increased sensitivity of p35_/" mice to seizures indicates Cdk5 might be involved 
in synaptic function (Chae et al., 1997). Cdk5 phosphorylates the presynaptic proteins 
synapsin 1 (Matsubara et al., 1996), Munc 18 (Shuang et al., 1998), amphiphysin 1 
(Floyd et al., 2001) and Synaptojanin (Lee et al., 2004) in vitro all of which are involved 
in synaptic vesicle endocytosis. Phosphorylation of Munc 18 disassembles the 
Muncl8/Syntaxinl complex allowing Syntaxinl to interact with vesicle SNARE 
proteins. Dynamin is a large GTPase essential for synaptic vesicle fission (Marks et al.,
2001). Recently Dynamin 1 phosphorylation by Cdk5 (Tan et al., 2003) suggested an 
essential, in vivo, vesicle recycling role for Cdk5. However contradictory results
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showed co-phosphorylation of dynamin 1 and amphiphysin 1 by Cdk5 serves to inhibit 
endocytosis (Tomizawa et al., 2003). Cdk5 influences synapse formation at the 
neuromuscular junction (Fu et al., 2001). Neuregulin increases Cdk5 expression and 
activity, leading to phosphorylation and endocytosis of the neuregulin receptor, ErbB, 
and downstream MAP/ERK signalling increases AchR expression.
Phosphorylation of DARP32 has implicated Cdk5 activity in dopamine 
signalling. PKA phosphorylates DARP32, which makes it a potent inhibitor of protein 
phosphatase 1 (PP1) and thus potentiates dopamine-induced phosphorylation of PKA 
substrates. Cdk5 activity has been shown to convert DARP-32 into a PKA inhibitor 
thus reducing dopamine signalling (Bibb et al., 1999). PKA and Cdk5 also both 
phosphorylate protein phosphatase inhibitor 1 with antagonistic consequences (Bibb et 
al., 2001). PKA phosphorylation converts protein phosphatase inhibitor 1 into an 
inhibitor of PP1, while Cdk5 phosphorylation reduces the substrate affinity for PKA. 
Cocaine dopaminergic signalling and p35/Cdk5 expression is found to be induced in 
rats administered cocaine (Bibb et al., 2001).
1.D3 Axonal Guidance
In 1890 Ramon, J Cajal first observed the growth cone, at the tips of axons, which is 
now attributed the function of guiding and powering axon outgrowth. Growth cone 
motility and guidance is dependent on the dynamic actin and microtubule cytoskeletons. 
Actin dynamics is required for proper axon guidance although axon elongation can 
occur independent of actin assembly (Marsh et al., 1984 and Bentley et al., 1986). 
Engagement of the actin cytoskeleton with the ECM slows actin retrograde flow and 
utilises the forces of actin polymerisation to generate forward motion -  “clutch
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hypothesis” (Lin et al., 1995). Disruption of microtubule dynamics results in wandering 
growth cones with loss of persistent outgrowth (Tanaka et al., 1995)
Morphologically the growth cone consists of three regions, the peripheral region, 
the central region and the transition zone, consisting of actin bundles (actin arcs). The 
peripheral region consists of a radial array of actin bundled filopodia with an in between 
actin meshwork of lamellipodia. Microtubules are predominantly found within the 
central region although a subpopulation extend their plus ends into the F-actin rich 
peripheral region. Inhibition of actin assembly promotes microtubule advance into the 
peripheral region (Forscher et al., 1988) and it is now believed that microtubules grow 
along actin bundles and that actin retrograde flow exports microtubules out of the 
peripheral region (Schaefer et al., 2002). Microtubules that are exported often buckle 
and break within the transition zone and thus retrograde flow regulates microtubule 
turnover. Reorganisation of actin bundling induces growth cone steering and 
microtubule reorganisation (Zhou et al., 2002). Conversely promotion of microtubule 
polymerisation also appears to promote actin polymerisation inducing lamellipodia and 
growth cone turning (Buck et al., 2002). Microtubule and actin interactions are thus 
crucial for growth cone steering. The neuronal microtubule associated proteins Tau and 
MAP2 have been shown to crosslink microtubules with F-actin in vitro (Griffith et al., 
1982) and phosphorylation has been shown to switch interactions of MAP2c from the 
microtubule to the actin cytoskeleton (Ozer et al., 2000).
As neurites elongate they must be guided to make the precise, required 
connections. Dynamic filopodia and lamellipodia at the leading edge of the growth 
cone are believed to sense the local environment. Guidance cues maybe attractive or 
repulsive; long or short range and many also influence neuroblast migration. As axons
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migrate they must adapt and remain sensitive to the local guidance cue requiring both 
protein synthesis and degradation (Campbell et al., 2001, Ming et al., 2002).
Contact mediated guidance occurs through several families of cell surface 
adhesion molecules including N-CAM (neuronal adhesion molecule) and L I. Binding 
of ECM such as laminins and fibronectin to neuronal integrins promote outgrowth 
(McKenna et al., 1988). Signalling of membrane bound ephrins through Eph tyrosine 
kinase receptors, elicit both “forward” and “reverse” signalling pathways in receptor 
and ligand expressing cells.
Several families of secreted proteins have also been implicated in axon guidance 
(Netrins, Slits, neurotophins and Semaphorins). Whether these act as diffusible factors 
or factors bound to cell surface membranes and ECM is unclear:
l.D.3.1 Semaphorins
More than 30 Semaphorins (Sema) have been identified and divided into eight classes. 
These include transmembrane (clases 1, 4 and 6), GPI anchored (class 7) and secreted 
(2, 3 and V) proteins of which classes 1 and 2 are found in invertebrates, 3 to 7 in 
vertebrates and V in viruses.
Two families of transmembrane proteins serve as receptors for the semaphorins; 
the plexins (Tamagnone et al., 1999) and neuropilins (NPs). Association and activation 
of plexins is a characteristic of all members except the secreted class 3 Sernas, which 
bind either NP1 or NP2 (Takahashi et al., 1999) and promote NP/Plexin association, 
relieving Plexin autoinhibition (Takashiti et al., 2001). Combinations of Plexins and 
NPs could generate specific responses to class 3 Sernas with the possibility of additional 
molecules composing the Sema receptor complex. The cell adhesion molecule LI 
associates with NP1, and LI deficient axons fail to respond to Sema 3A (Castellin et al.,
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2000). Similarly the kinase inactive drosophila receptor tyrosine kinase off track (Otk) 
associates with Plexs and functions downstream of semaphorin signalling (Windburg et 
al., 2001).
Plexins posses no known catalytic activity but do share minimal sequence 
similarity to Ras GAPs (Rohm et al., 2000). Plex B1 has been found to associate with 
RhoA and GTP-Racl (Vikis et al., 2000) and it has been proposed Plex B1 serves to 
sequester active Rac from downstream effector PAK (Vikis et al., 2002). Rac activity 
has however been shown essential for Sema3A collapse (Jin and Strittmatter 1997, 
Kuhn et al., 1999, Vastik et al., 1999) where it is required for endocytosis of the growth 
cone plasma membrane and reorganisation of F-actin following Serna 3A treatment but 
not for depolymerisation of F-actin (Jumey et al., 2002). PlexB has also been shown to 
activate Rho signalling through the RhoGEFs, PDZ-Rho-GEF (Driessens et al., 2002) 
and LARG (Leukeaemia associated RhoGEF) (Swiercz et al., 2002). Plex Al binds 
Rndl causing collapse but association with RhoD inhibits collapse (Zanata et al., 2002).
Phosphorylation of cofilin by LIM kinase is essential for Sema3A collapse 
(Aizawa et al., 2001) which may be controlled by either a Rac or Rho pathway, 
although the significance of ROK activity in Sema 3A collapse is controversial 
(Arimura et al., 2000 and Dontchev et al., 2002). CRMP-2 was one of the first 
identified cytosolic proteins linking Sema collapse and the actin cytoskeleton, through 
antibody perturbation studies (Goshima et al., 1995). CRMP-2 lies downstream of 
ROK in LPA but not Sema 3A induced growth cone collapse (Aimura et al., 2000) but 
has been shown to switch Rho/Rac signalling in neuroblastoma cells (Hall et al., 2001). 
Evidence points to a role for CRMP-2 in dynamic regulation of the microtubule 
cytoskeleton (Gu et al., 2000 and Fukata et al., 2002). Fes/Fps tyrosine kinase was also
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found to phosphorylate PlexAl, CRMP-2 and CRAM upon Sema 3 A treatment (Mitsui 
et al., 2002).
Another tyrosine kinase implicated in Sema 3A collapse is Fyn (Sasaki et al.,
2002) which localises to neuronal growth cones (Bixby et al., 1993). Fyn associates 
with and phosphorylates PlexA2 and Cdk5. Tyr15 phosphorylation of Cdk5 is essential 
for Sema 3A collapse and enhances kinase activity, which potentially inhibits PAK 
signalling (Nikolic et al., 1998) or may regulate tubulin dynamics through Tau/MAP 
phosphorylation (Sasaki et al., 2002). Sema 3A has also been shown to activate a pool 
of glycogen synthase kinase (GSK-3P) at the leading edge of growth cones (Eickholt et 
al., 2002) which is also involved in Tau phosphorylation (Mandelkow et al., 1992). 
Inhibitor studies reveal the potential involvement of PKG and PI3K activity in Sema 3 A 
collapse (Dontchev et al., 2002).
l.D.3.2 Regulation of guidance cues
Guidance cues in general are bifunctional (attractant and repellent) and are classified 
into two groups depending on their regulation. Group 1 (BDNF, netrinl, acetylcholine, 
MAG) response is abolished by depleting extracellular Ca and regulated by levels of 
cAMP/activity of PKA (Song et al., 1997). Decreasing cAMP converts netrin-1, NGF, 
BDNF attraction into repulsion (Song et al., 1999) while raising levels results in 
attraction (Ming et al., 1997). Group 2 guidance cues, including Sema 3A and NT-3, 
are regulated by levels of cGMP/activity of PKG (Song et al., 1998) and inhibition of 
cGMP signalling converts NT-3 attraction into repulsion.
Guidance cue signals interact and growth cones raised in NGF/BDNF become 
resistant to Sema 3A treatment where PKA but not PI3K activity is involved (Dontchev 
et al., 2002). Cross desensitisation experiments also provide evidence of common
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signalling pathways by guidance cues (Ming et al., 1999) with group 1 members 
signalling through PLCy and PI3K dependent pathways.
1.D.4 Neurodegenera tive Diseases
Errors in signal transduction pathways can result in degenerative diseases. The 
presence of neurofibrillary tangles (NFTs) is a pathological hallmark of several 
neurodegenerative diseases including Alzheimers Disease, Down’s Syndrome, 
progressive supranuclear palsy and Parkinson’s disease. NFT compose primarily of 
paired helical filaments of hyperphosphorylated Tau (PHF-Tau) with 21 identified 
phosphorylation sites, ten of which are Ser/Thr-Pro motifs. CRMP-2 is also found 
hyperphosphorylated associated with NFT in AD although the responsible kinases are 
unknown (Gu et al., 2000).
Relatively few Tau kinases exist in situ including PKA, microtubule affinity 
regulating kinase, GSKp and Cdk5. Cdk5 was shown to associate with NFT in vivo 
(Pei et al., 1998) and phosphorylate Tau on five sites in PHF-Tau (Paudel et al., 1993). 
Tau does not appear to be a physiological substrate of p35/Cdk5 but is of the more 
active p25/Cdk5. The N-terminus of p35 contains a myristolation signal, required for 
correct membrane localisation at the cell periphery (Patrick et al., 1999); as well as a 
Cdk5 phosphorylation site that initiates ubiquitin mediated degradation, which results in 
the short p35 half life of 20-30 min (Patrick et al., 1998). Both these signals are lost 
upon calpain cleavage of p35, resulting in sustained mis-localisaed Cdk5 activity. 
Highly phosphorylated p35 is found in the foetal brain where Cdk5 phosphorylation of 
p35 leads to rapid degradation which serves to protect from calpain cleavage (Kerokoski 
et al., 2002, Saito et al., 2003). In the adult brain p35 is susceptible to calpain cleavage 
and p25 accumulation is noted in Alzheimer’s disease and amyotrophic lateral sclerosis
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(ALS) where it is implicated in pathological conditions (Patrick et al., 1999). 
Transgenic mice over-expressing p25 display hyperphosphorylated Tau and 
neurofilament, as well as cytoskeletal disruptions associated with AD (Ahalijanian et 
al., 2000, Noble et al., 2003). Amyloid plaques are another pathalogical hallmark of 
AD with extracellular deposits of the fibrillogenic amyloid-(3 (Ap) peptides derived 
from the amyloid precursor protein (APP). Treating primary neurones with Ap peptides 
induces calpain activation (Nakagawa et al., 2000) and cleavage of p35 to p25 (Lee et 
al., 2000) with subsequent hyperphosphorylation of Tau (Busciglio et al., 1995), while 
inhibition of Cdk5 diminishes Ap neurtoxicity (Alvarez et al., 1999). Cdk5 may thus 
link plaque deposition and NFT formation, although this model is disputed (Kerokoski 
et al., 2002, Tandon et al., 2003, Hallows et al., 2003). Cdk5 phosphorylates and 
activates p53 in vitro (Zhang et al., 2002) but conversely has also been implicated in 
neuronal survival, inhibiting JNK3 mediated apoptosis (Li et al., 2002) and activating 
PI3K/Akt signalling in a neuregulin dependent manner (Li et al., 2003).
The ubiquitous, constituitively active GSK-P, is brain enriched (Woodgett et al., 
1990) and inactivated by Ser9 phosphorylation. GSK3P is capable of phosphorylating 
Ser/Thr-Pro motifs although in most cases the substrate must be previously 
phosphorylated at a site 4 residues C-terminal of the target site, which primes for GSK3 
phosphorylation (SAT XXXpS/T) (Harwood et al., 2001). These sites are often found in 
proline rich regions of the substrate. GSK3P was found to co-purify with Tau and 
microtubules (Imahori et al., 1997). GSK3P phosphorylates Tau at both primed and 
unprimed sites (Ishiguro et al., 1993) and p25/Cdk5 activity has been shown stimulatory 
for GSK3P mediated phosphorylation of Tau at specific sites (Thr ), reducing 
microtubule affinity (Cho et al., 2003). Ap peptides activate GSK-3p in cell culture 
(Takashima et al., 1996) leading to Tau hyperphosphorylation (Takashima et al., 1998).
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Activation of GSK3P contributes to neuronal apoptosis which PI3K/Akt 
phosphorylation of Ser9 serves to inhibit (Hetman et al., 2000, Cross et al., 1998). 
GSK3P and Cdk5 activity are also implicated in APP protein phosphorylation, 
enhancing processing (Phiel et al., 2003, Liu et al., 2003).
1.E Aims
It was hypothesised that a2 chimaerin could play an important role in axonal outgrowth 
as a mediator of negative guidance cues via Rac GAP function, which may be regulated 
by protein/lipid interactions and phosphorylation. Having identified CRMP-2 and p35 
as potential in vitro binding partners of a2 chimaerin the aims of this research were to:
1. Further characterise in vivo interactions of a2 chimaerin using pull down assays.
2. Establish whether Cdk5 phosphorylates a2-chimaerin or its novel target proteins in 
vitro and whether cdk5 phosphorylation affects interactions between these proteins.
3. Establish whether interactions of a2 chimaerin can regulate GAP activity in vivo.
4. Investigate the morphological effects of a2 chimaerin over-expression in the N1 fi­
l l s  neuroblastoma cell model and the consequences of protein interactions.
This research could potentially shed some light on the signal transduction pathways 
governing neurite outgrowth/collapse during neuronal development
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2.A Materials
2.A.1 Laboratory Reagents
General Laboratory reagents were obtained from Sigma or BDH. PBS tablets were from 
Oxoid and water was purified in the lab using Elga Option 4 purification System (Deionised 
and purified by reverse osmosis before filtered and UV sterilised). Amersham supplied 
radioactive nucleotides
2.A.2 DNA Manipulation Reagents
Epicurian Coli XL1- Blue and BL-21 competent cells were obtained from Stratagene. DNA 
restriction enzymes were purchased from Boehringer Mannheim, Gibco-BRL and NEB and 
DNA modifying enzymes from Promega and Stratagene. The Wizard DNA purification 
mini-prep system from Promega and Qiagen’s midi preparative kits were used. Agarose, 
Haelll-digested <|>X174 and Hindlll-digested X7 DNA markers were purchased from Gibco- 
BRL and ampicillin was obtained from Sigma. Stratagene site directed mutagenesis kit was 
utilised
2. A3 Tissue Culture Reagents
Dulbecco’s Modified Eagle Medium (DMEM), foetal calf serum, antibiotic/antimycotic 
solution and lipofectamine were all obtained from Gibco-BRL. Trypsin and poly-L-lysine 
were purchased from Sigma
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2.A.4 Protein Work Reagents
Commasie Brilliant Blue-R protein stain, glutathione agarose and Thrombin were from 
Sigma. Enhanced chemiluminescent (ECL) reagent and Hyperfilm were from Amersham as 
was ATP. ICN supplied polyvinyl difluoride (PVDF) membranes. Amicon protein 
concentrators were used as was MedicelPs dialysis tubing. Biorad supplied TEMED and 
protein assay reagent to quantitate protein concentration. Acrylamide/bis acrylamide was 
purchased from Scotlab and NEB’s prestained protein markers were used. Recombinant 
p25/Cdk5 was a gift from Dr R. Qi, while recombinant GSK3P and purified p55 Fyn was 
purchased from Upstate cell signalling solutions.
2.A.5 Antibodies
The following antibodies were used. Rabbit polyclonal a2chimaerin lab antibody (Hall., et 
al 2001) and mouse monoclonal 3F4 (Gu., et al 2000). M2-FLAG-AC, Rabbit polyclonal 
FLAG and p Tubulin were obtained from Sigma. Rabbit polyclonal Cdk5 (C-8), Cdk5-AC, 
p35 (C-19) and GST (Z-5) were obtained from Santa Cruz Biotechnology. Other antibodies 
used include mouse monoclonal HA (Babco), mouse monoclonal GFP (Clonetech). 
Transduction Lab mouse monoclonal Rac (R56220) and phosphotyrosine-HRP (RC20) were 
also used, as was mouse monoclonal P-Thr-Pro-101 (Cell Signalling Technology).
Donkey anti mouse or rabbit conjugated to FITC, TRITC or Cy5 (Jackson 
Immunochemicals) were used for cell staining along with TRITC conjugated Phalloidin 
(Sigma). DAKO’s HRP conjugated pig anti rabbit, rabbit anti mouse and mouse anti rabbit 
were used for western blotting.
57
Materials and Methods
2.A.6 cDNA Constructs
Several cDNA constructs were used in this study. CMV2FLAG-p35, pXJ40HA-Cdk5, 
pXJ40HA-Cdk5N144, pcDNA3.1p35, pCl-neop35 were a generous gift from Dr Robert Qi 
(Dept Biochemistry, Hong Kong University of Science and Technology ) as was HA- 
GSK3P from Dr Eikaholt (Molecular Neurobiology Group, Kings College London). pXJ40 
HA/FLAG-CRMP-2/a2 Chimaerin constructs as well as pGEXGST-a2chimaerin were 
obtained from Dr Clinton Monfries, while pXJ40GST-CRMP-2 constructs were from 
Mathew Brown. GFP/HA-a2 Chimaerin SH2 mutants were as previously described (Hall et 
al 2001)
2.A.7 Oligomer Synthesis and cDNA Sequencing
Oligomers were synthesised by Genosys, Sigma. cDNA constructs sequenced by Cytomyx.
2.B Methods
2.B.1 DNA Manipulation
2.B.1.1 Competent bacterial transformation
20ul Epicuriart Coli XL1- Blue competent cells (Stratagene) were thawed on ice and 
incubated with P-mercaptoethanol (25mM) for lOmin. Approximately lOOng of the relevant 
DNA was added and the cells were incubated on ice for a further 30min. Cells were heat 
shocked at 42°C for 45secs before incubating on ice for 2 min. Cells were allowed to grow 
at 37°C in 1 ml L-Broth (2% (w/v) tryptone, 1% (w/v) yeast extract, 2% (w/v) NaCl) with 
vigorous shaking for lhr before plating out on the relevant antibiotic containing (100pg/ml
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ampicillin) agar plates (2% (w/v) tryptone, 1% (w/v) yeast extract, 2% (w/v) NaCl, 1.5% 
agar). Plates were placed inverted in a 37°C incubator for 16 hours to allow colonies to 
grow.
5ml antibiotic containing L-Broth were innoculated with a single colony, picked 
using a sterile toothpick. Cultures were grown for 16hrs in a 37°C incubator with vigorous 
shaking.
2.B.1.2 Plasmid DNA mini preparations
Promega Wizard Plus Miniprep DNA Purification System was utilised for small scale DNA 
preparations. 5ml cultures of the relevant bacterial cells were pelleted by centrifugation at 
3000g for 5 min. The resulting pellet was resuspended in 1.5ml PBS and transferred to a 
1.5ml microfuge tube, where the cells were repelleted. The cell pellet was thoroughly 
resuspended in 250pl cell resuspension solution (50mM Tris-Cl, pH8; lOmM EDTA, 
lOOpg/ml RNase A). 250pl cell lysis buffer (200mM NaOH, 1% SDS) was added, mixed by 
inversion and incubated at room temperature for 5min. lOpl alkaline protease solution was 
added, mixed by inversion and incubated at room temperature for a further 5 minutes. 
Finally 350pl of neutralising buffer (3m potassium acetate, pH5.5) was added and mixed by 
inversion. After removal of cell debris by centrifugation at 18,000g for 10 minutes, the 
lysates were transferred to mini prep columns, which were placed into 2ml collection tubes. 
The columns were centrifuged at 18,000g for 1 minute and the flow through was discarded. 
Columns were washed twice with 250pi of column wash solution (1M NaCl, 50mM MOPS, 
pH7; 15% isopropanol) which was passed through the columns by centrifugation at 18,000g 
for 2 minutes at room temperature. Columns were transfered to clean microfuge tube tubes
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and the plasmid DNA was eluted by die addition of lOOpl of nuclease free water onto the 
mini prep columns, followed by centrifugation at 18,000g for 1 minute.
2.B.1.3 Plasmid DNA midi preparations
For greater yields of plasmid DNA, Qiagen’s hispeed midi plasmid purification system was 
used. 250ml cultures of the relevant transformed XL-1 Blue were grown up in L-Broth, 
containing 50pg/ml ampicillin, with vigourous shaking at 37°C. Bacterial cells were pelleted 
by centrifugation at 3,000g for 15 minutes at 4°C in a Beckman J6-HC centrifuge. The 
pellets were washed by resuspending in 30ml PBS and repelleting by centrifugation. 
Bacterial pellets were thoroughly resuspended in 6ml buffer PI (50mM Tris-Cl, pH8; lOmM 
EDTA, lOOfig/ml RNase A) by vigorous pipetting. 6ml buffer P2 (200mM NaOH, 1% 
SDS) was added, mixed by inversion and incubated at room temperature for 5 minutes. 10ml 
of chilled buffer P3 (3M potassium acetate, pH5.5) was added to the lysed cells to neutralise 
the acid. Samples were mixed immediately by inversion and the lysate was poured into the 
barrel of a QIAfilter cartridge and incubated at room temperature for 10 minutes. A 
precipitate containing the genomic DNA, proteins and detergent forms and floats to the top 
of the solution in the cartridge. During this incuabtion period a HiSpeed Midi tip was 
equilibrated by the application of 4ml buffer QBT (750mM NaCl, 50mM MOPS, pH7; 15% 
isopropanol, 0.15% Triton X-100) which was allowed to pass through the tip by gravity. 
Using a plunger, the cell lysate was filtered through the QIAfilter directly into the 
equilibrated tip, where it was allowed to enter the resin by gravity. The tip was washed with 
20ml of buffer QC (1M NaCl, 50mM MOPS, pH 7; 15% isopropanol) and the DNA eluted 
with 5ml of buffer QF (1.25M NaCl, 50mM Tris, Tris-Cl, pH8.5; 15% isopropanol). The
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eluted DNA was precipitated by the addition and incubation of 3.5ml (0.7 volumes) 
isopropanol (5min room temperature). The precipitated DNA was poured into a 20ml 
syringe and forced through a QLAprecipitator. Air was then forced through the precipitator 
using the empty syringe and finally the plasmid DNA was eluted by passing 1ml of TE 
buffer (lOmM Tris-Cl, pH 8; ImM EDTA) through the precipitator from a 5ml syringe. The 
elutant was reapplied to the 5ml syringe and passed through the precipitator again, to ensure 
maximum recovery of the plasmid DNA.
2.B.1.4 Phenol/Chloroform extraction
1.5ml phase light tubes (Sigma) containing an organic solvent penetratable gel were 
prepared by centrifuging at 16,000g for 2 minutes. DNA samples were placed into the 
prepared tubes with an equal volume of phenol. Samples were inverted several times until a 
white emulsion was formed and then centrifuging at 16,000g for 2 minutes. The gel in the 
phase light tubes formed an interface between the aqueous DNA containing layer and the 
phenol/RNA and protein containing layer. The upper aqueous DNA containing layer was 
removed and placed into fresh prepared phase light tubes with an equal volume of water 
saturated chloroform. Chloroform clean up was carried out as per phenol. The upper 
aqueous DNA containing layer was removed and the DNA was recovered by ethanol 
precipitation.
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2.B.1.5 Ethanol precipitation
DNA samples were adjusted to pH5.2 with addition of 0.1 volumes of 3M sodium acetate 
pH 5.2 and two volumes of ice cold absolute ethanol before incubating at -20°C for 20min. 
Samples were centrifuged at 18,000g for 5 minutes to pellet the DNA. The supernatant 
was removed by pippeting and vacuum desiccating. DNA was finally dissolved in TE buffer 
(lOmM Tris-Cl, pH 8; ImM EDTA).
2.B.1.6 Quantitation of DNA
Quantity and quality of DNA preps were evaluated by measuring the optical density at 
260nm and 280nm wavelengths, using a deuterium lamp spectrophotometer. 5 pi of purified 
plasmid DNA was diluted in 995pi of TE buffer. The optical density of each sample was 
measured in an UV cuvette at wavelengths of 260nm and 280nm. Since lmg DNA gives an 
O.D of 50 at 260nm the concentration of DNA was evaluated using the following formula: 
[DNA] pg/pl = 50 x (Dilution Factor) x (1/1000) x A260mn
2.B.1.7 Restriction digestion of DNA
Various endonucleases were used to digest cDNA plasmid, for analysis. Restriction digests 
were typically carried out in 20pl reaction volumes, using the buffer of the relevant salt 
concentration provided by the manufacturer. Units of enzyme used in the reaction were 
determined by the amount of DNA present but “star activity” (non specific cutting) which 
results from glycerol present in the enzyme samples was avoided (>5% v/v contributes to 
star activity). Digests were carried out at 37°C for 1-2 hours. Reactions were quenched by 
heating to 65°C for 20 minutes
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2.B.1.8 Agarose gel electrophoresis
10ja,l of linearised DNA was mixed with 2jol of 6 x DNA loading buffer (0.25%bromophenol 
blue, 0.25% xylene cyanol FF, 30% glycerol in water) and loaded on a 1% agarose gel. 5pl 
of Hae III digested <(>X174 DNA (23.13kb to 125bp, 0.6pg/pl 6 x loading buffer) and Hind 
III digested A. DNA (1353bp to 72bp, 0.6pg/pl 6 x loading buffer) were also loaded and 
electrophoresed at a constant voltage of MOV for 45 minutes.
2.B.1.9 Visualisation of DNA with Ethidium Bromide
To visualise DNA bands, the gel was removed from the tank and soaked in distilled water 
containing 40pg/ml of ethidium bromide, for 15 minutes. Ethidium bromide is a DNA 
binding agent, which fluoresces when excited with ultra violet (UV) light (312nm 
wavelength). Thus after soaking in EtBr, DNA bands could be visualised by placing the gel 
on a UV transluminator and the data was recorded on polaroid film.
2.B.1.10 Site directed mutagenesis
To introduce point mutations in CRMP-2, Stratagene’s Quickchange site directed 
mutagenesis kit was used on the FLAG-CRMP-2 pXJ40 plasmid. The procedure uses two 
synthetic oligonucleotide primers containing the desired mutation and Pfu Turbo DNA 
polymerase, to extend the primers by thermocycling. A mutated plasmid containing 
staggered nicks is thus generated and treatment with Dpn 1 endonuclease (target sequence: 
5’ Gm6ATC-3’) digests the parental methylated DNA template. The vector DNA is then 
transformed into XL 10-Gold ultra competent cells.
63
Materials and Methods
Mutated primers design 
CRMP-2 T509A
5’-GAG GTG TCT GTG GCG CCC AAG ACG GTC-3’
3’-CTC CAC AGA CAC CGC GGG TTC TGC CAG- 5’
CRMP-2 T514A
5’- CCC AAG ACG GTC GCT CCG GCC TCA TC-3’
3’- GGG TTC TGC CAG CGA GGC CGG AGT AG- 5’
CRMP-2 S518A
5’- C ACT CCG GCC TCA GCA GCT AAG ACA TCC-3’
3’- G TGA GGC CGG AGT CGT CGA TTC TGT AGG- 5’
CRMP-2 S522A
5’- CA GCT AAG ACA GCC CCT GCC AAG CAG-3’
3’- GT CGA TTC TGT CGG GGA CGG TTC GTC-5’
CRMP-2 T514E
5’- G ACG CCC AAG ACG GTC GAG CCG GCC TCA TCA GCT AAG-3’
3’- C TGC GGG TTC TGC CAG CTC GGC CGG AGT AGT CGA TTC- 5’
CRMP-2 S518E
5’- G ACG GTC ACT CCG GCC TCA GAG GCT AAG ACA TCC CCT GCC-3’ 
3’- C TGC CAG TGA GGC CGG AGT CTC CGA TTC TGT AGG GGA CGG-5’
CRMP-2 S522E
5’-GCC TCA TCA GCT AAG ACA GAG CCT GCC AAG CAG CAG GCG-‘3 
3’-CGG AGT AGT CGA TTC TGT CTC GGA CGG TTC GTC GTC CGC-5’
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The PCR reaction was set up as follows:
5 pi lOx reaction buffer
lOng of ds DNA template (FLAG-CRMP-2)
125ng mutant primers(5’-> 3’ + 3’->5’) 
lpldNTP mix 
3 pi Quik solution
ddH20 to final reaction volume of 50pl 
lpl Pfu Turbo DNA polymerase (2.5 U/pl)
Tubes were placed into a Perkin Elmer PCR machine for the following cycles:
95°C for 30sec to denature template DNA.
95°C for 30 seconds to denature template DNA in later amplification cycles 
X°C for 1 minute to allow annealing of mutated oligomers to template DNA 
68°C for 13 min to allow extension of oligomers
This part of the cycle was repeated 16 times in order to amplify the required section of the 
template DNA.
68°C for 7 minutes to allow final extensions of oligomers
The value of X is based upon the Tm value of the oligonucleotides used in the reaction.
Tm = 81.5 + 0.41(%GC) -675/N -% mismatch 
where N is primer length
lpl of Dpn 1 restriction enzyme (lOU/pl) was added directly to each reaction and incubated 
for lhr at 37°C. XL-1 Blue competent cells were transformed and plated out as described.
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2.B.1.11 Identification of positive mutant clones
To identify positive mutant clones one of the mutated oligos used in the clone syntheses was 
labelled and used as a probe to screen the colonies. N-Hybond filter lifts of the plate were 
taken using ink stabs to determine orientation. The master plate was allowed to recover 
again at 37°C for 4hrs while the filter lifts were placed back inverted on a fresh agar plate 
and allowed to grow up at 37°C for 2hrs. Filters were chilled at 4°C for 30min before 
placing colony side up on presoaked 3mm Whatman paper in the following sequence:
3min in 10% SDS, to lyse colonies
7min Denaturation buffer (1.5M NaCl, 0.5M NaCl)
3min Neutralising buffer (1M Tris/HCL pH7.4, 1.5MNaCl)
3min 2xSSC (20xSSC= 3MNaCl, 0.3M NaCitrate)
Filters were air dryed and exposed to UV for lOmin to fix the DNA. Cell debris was 
removed by wiping with 2xSSC/0.1%SDS and the filters were then incubated at 65°C for 
lhr in 20ml prehybridisation solution (6xSSC, 0.1%SDS 5xDenhardt’s solution’s (50 x 
stock 5g Ficoll, 5g polyvinylpyrolidone, 5g BSA in 500ml dd H2O filter steralised, aliquoted 
and stored at -20°C).
lpg of the mutated oligo was labelled with 33P by T4 kinase in a 20pl reaction 
volume with, 2pl xlO reaction buffer, 4pl 32P yATP (lOpCi/pl) and lpl of enzyme for lhr at 
37°C. The labelled probe was then added to 20ml of hybridisation solution (6xSSC, 5 x 
5xDenhardt’s solution’s) and incubated with the filter for several hours at 10°C below the 
Tm of the probe (Tm-10°C). Filters were finally washed in 6XSSC (3x 30min, 150ml 
washes) before exposing to film.
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2.B.2 Cell Culture
Cell cultures were grown in a Hereus Cell incubator at 37°C in a humid environment and 5% 
CO2. Cultures were grown in Dulbecco’s Modified Eagle Medium with 0.1 lg/1 sodium 
pyruvate with pyridoxine (DMEM) containing 10% foetal calf serum (FCS) and 1% 
antibiotic/ antimycotic solution (penicillin, streptomycin and amphotericin) in 90mm tissue 
culture dishes (Nunc). N1E-115 neuroblastoma cell cultures were passaged every 2-3 days 
by aspirating the media and then physically detaching the cells by repeated pippetting of 
10ml fresh media over the dish. The cell suspension was pelleted by centrifugation at lOOOg 
(Beckman GP) for 5 min. The cell pellet was resuspended in fresh media before seeding 
the cells in fresh dishes. With the use of more adhesive cell lines (Cos-7, Swiss -3T3 
fibroblasts and a 2.10 chimaerin cell lines), trypsinisation was required to detach cells.
2.B.2.1 Cell stocks
Cell stocks were maintained in liquid nitrogen. Stocks were brought up by thawing the cells 
rapidly in a 37°C water bath and resuspending in 10ml 10% FCS containing media. After 
pelleting in a Beckman GP centrifuge (lOOOg, 5 min) the cells were resuspended in fresh 
media and seeded out at relevant densities. Cell stocks were constantly replenished:
The plate of cells to be stocked was harvested and pelleted, before resuspending in the 
freeze stock mixture (90%FCS /10% DMSO). This suspension was then placed in a 
polystyrene box and placed at -20°C for several hours before placing at -70°C for 16-24-hrs 
and finally in liquid nitrogen.
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2.B.3 Morphological Analysis 
2.B.3.1 Coverslip preparation
For morphological analysis, cells were seeded on coverslips:
Glass coverslips (22mm x 22mm) were cleaned with a 30 min wash in 60% Ethanol/40% 
HC1 solution. After washing in copious amount of water, coverslips were dried and heat 
sterilised (4 hours at 121°C). Glass coverslips could be used ‘bare’ or coated with poly(L) 
Lysine. A solution of poly-L-lysine (5pg/ml) was used to coat the coverslips for 30min at 
room temperature before excess protein was washed away with ddFLO. Prepared coverslips 
were placed in 30mm dishes and cells were seeded onto them (1.3xl05), in 2ml of 10% FCS 
containing media.
2.B.3.2 Transfections on coverslips
To examine the morphological effect of over expression of proteins, cells were transiently 
transfected with relevant cDNAs. Cells were serum starved for lhr in 1ml DMEM media, 
while the transfection mix was prepared. The relevant cDNAs (lug), lipofectamine 2000 
(6ul) and 200pl DMEM were mixed and incubated at room temperature for 45min. This 
mix was then added to the cells and after 5hrs the media was replaced with fresh FCS and 
antibiotic containing media. Proteins were allowed to express for 16hrs.
2.B.3.3 Immunostaining
Cells, on coverslips were washed briefly in PBS before fixing in 4% paraformaldehyde/PBS 
solution for lOmin. A lOmin wash in PBS was carried out before quenching residual PFA in 
lOOmM Glycine/PBS for lOmin. Cells were then permeabilised with 0.2% Triton-x-
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100/PBS for lOmin and blocked in 3% BSA/PBS for a further lOmin. Incubation with the 
relevant antibodies in 1% BSA/PBS solution was carried out in a humid container for l-2hrs 
at 37°C. Excess antibody was washed away with 3 x 5min PBS washes before incubation 
with the relevant FITC/TRITC/Cy5 conjugated secondary antibodies/phalloidin for lhr at 
37°C. Again 3 x 5min washes in PBS were carried out and finally the coverslips were air 
dryed before mounting on glass slides with a drop of immuno fluorescent mountant. Slides 
were left to air dry at room temperature and then stored at 4 °C in the dark.
2.B.3.4 Fixed cell imaging and characterisation
Slides were examined using a Zeiss axioplan microscope. 300 transfected cells per 
experiment were counted for various phenotypes and three separate experiments performed 
for each experiment. The student t test was performed to determine statistical significance. 
Cell images were taken using a Zeiss LSM 4.10 Confocal microscope.
2.B.3.5 Live cell imaging
For live cell fluorescent imaging, cells were transfected on glass bottom dishes (World 
Precision Instruments) before imaging in a heated humid chamber with a Zeiss axiovert 135 
microscope and Cool SNAP camera (Photometries).
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2.B.4 Protein Work
2.B.4.1 Recombinant protein production
Recombinant proteins were expressed and isolated in BL-21 cells which are deficient in a 
number of proteases, allowing greater yields of protein production. pGEXcDNAs were used, 
containing an inducible promoter, allowing the production of GST fused proteins. BL-21s 
were transformed and grown up as per XL-1 Blue cells. 500ml cultures were inoculated 
from overnight cultures (1/20) and grown at 32°C with vigorous shaking. When the O.D5 9 5  
of the culture reached 0.5-1, protein expression was induced with the addition of IPTG 
(0.2mM). Expression was continued for 2hrs at 32°C before the cells were harvested by 
centrifugation, washed in PBS, repelleted and frozen at -70°C.
Temperatures were kept at a minimum (on ice) throughout the isolation procedure to 
reduce the action of proteases. Cells were thawed and resuspended in 20ml of lysis buffer 
(Tris/HCL pH8, l%Triton-X-100. ImM PMSF + Complete protease inhibitors). Lysate was 
sonicated (level 6, 20s pulses) until clear (~2min) and incubated on ice for 20min. Cell 
lysate was cleared by centrifugation at 20Kg for 20min and to the supernatant 100jxl/l 00ml 
culture of prewased 4B beads (3x 40ml PBS) were added and incubated at 4°C for ~2hrs on 
a spiral mixer. The beads were washed 3 x 30min in 40ml lysis buffer, pelleting each time 
by centrifugation (5min, 3000g).
The following steps in the isolation procedure depends on the desired recombinant 
protein:
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2.B.4.1.1 GST fused protein
Beads were washed in 50mM Tris/HCL pH 8 before incubating at room temperature for 
15min with 15ml elution buffer (lOmM Glutatione/50mM Tris/HCL pH8). Beads were 
removed by passing the slurry through a column and the elutant was dialysed in PBS (3x 
2L) at 4°C.
2.B.4.1.2 Non tagged protein:
For a pure protein, cleavage from the GST moiety using thrombin was carried out. Beads 
were washed in Thrombin Cleavage buffer (50mM Tris/HCl pH7.5, 150mM NaCl, 3mM 
CaCL) before incubating with 5 units of thrombin per expected mg protein o/n at 4°C in 
10ml Thrombin Cleavage buffer. The slurry was passed through a column where the filtrate 
was incubated with 0.5ml Benzamidine for 15min at 4°C to remove the thrombin. After 
passing through another column, the isolated protein could be concentrated using Amicon’s 
Centriprep centrifugal filter devices.
2.B.4.2 Mammalian cell 90mm plate transfection
For in vivo analysis and the isolation of mammalian expressed proteins, cells were 
transiently transfected with the relevant cDNAs. Sub confluent (-70%) mammalian cells in 
90mm dishes were serum starved for lhr in 5ml DMEM. The transfection mix was prepared 
during serum withdrawal by mixing the relevant cDNAs (5pg) with 20pl lipofectamine in 
1.3ml DMEM. This transfection prep was incubated at room temperature for 45min before 
adding to the cells. 5hr after addition, the media was replaced with fresh 10% FCS, 1% 
antibiotic containing media and proteins were allowed to express for 16-48 hrs.
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2.B.4.3 Cell treatment
Numerous in vivo treatments were carried out before protein isolation and analysis 
2.B.4.3.1 Pervanadate (peroxides of vanadate)
A powerful inhibitor of tyrosine phosphatases, pervanadate is a useful tool to investigate 
phosphotyrosine signalling (Kadota., et al 1987). Pervandate was prepared by mixing 60pl 
sodium orthovanadate (Na3VC>4 200mM), 539pl PBS and lpl 30% w/w H2O2 and incubating 
at room temperature for 5 min. Excess H2O2 was removed by the addition of 200ug/ml 
catalase (0.6pl 20mg/ml stock) and incubating at room temperature for a further 5 min. 
Peroxide treated pervanadate was used immediately treating as x200 stock (lOOpM final) in 
DMEM for 20 min at 37°C.
2.B.4.3.2 Phorbol 12-myristate 13-acetate (PMA)
PMA (Sigma) is a mimic of DAG and was used to study the phorbol ester receptor a2 
chimaerin. PMA was made up in DMSO (1M) and cells were treated at the relevant 
concentration for lhr at 37°C in relevant media.
2.B.4.4 Cell lysis
Mammalian cells, in 90mm culture plates and expressing the relevant plasmids or treated 
with the relevant conditions, were washed in PBS and then lysed on the dish with 500pl 
lysis buffer (Tris-HCL pH7.5,0.3M NaCl, 1% Triton-x-100, 1mm NaVC>4, 5mm DTT, ImM 
PMSF) on ice for 5 min. Cells lysate was collected by scraping and this was solubilised
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with sonication at level 6 for 1 min (20sec pulses/5sec rest) and incubating on ice for 30min. 
The cell lysate was cleared by centrifugation at 20Kg for 20min.
2.B.4.5 Immunoprecipitation/GST pulldown
GST pulldowns, using sepharose 4B beads, and agarose conjucated antibody 
immunoprecipitations (Sigma FLAG-M2, Cdk5-AC) were carried out as follows.
450ul of the cleared lysate was added to 20pl of pre-washed agarose conjugated/ 4B beads 
(washed 2x 1ml Lysis buffer) while the remaining lysate was kept for analysis of protein 
expression. The beads were incubated at 4°C for 2-3hrs on a rotor, before washing with 
repeated cycles of pelleting/resuspending (centrifugation at 1kg for lmin/ resuspending in 
lml of lysis buffer for 2-3min). After washes, the captured proteins were eluted by heating 
to 95°C for 5 min in 30ul 2x sample buffer.
With non agarose conjugated antibodies, immunoprecipitations were carried out in a 
similar manner: 5pg of antibody was added to 450ul of the cleared lysate. After lhr 
incubation at 4°C on a rotor, 30pl of rehydrated/washed Protein A-beads (0.05g in lml LfeO, 
wash 3x lml H2O) was added to capture the antibody. Incubation at 4°C was carried out for 
a further 2hrs before washing and eluting as before.
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2.B.4.6 Rac-GTP assay
To determine the amount of active Rac (GTP bound) in a cell, PAK’s CRIB (Cdc42 and Rac 
interactive binding) domain was utilised, which only associates with GTP bound p21s. 
Recombinant CRIB was grown up and isolated as described but left attached to 4B beads.
Cells were washed with ice cold PBS + ImM MgCfe + 0.5mM CaCb before quickly 
harvesting on ice with 0.5ml Lysis buffer (Tris-HCL pH7.5, 0.3M NaCl, 1.5% Triton-x-100, 
1mm NaVC>4, 5mm DTT, ImM PMSF). Lysate was rapidly cleared with 2min 20,000xg 
spin down before 450ml of cleared lysate was added to relevant amount of bound GST- 
PAK CRIB. The beads were incubated at 4°C for l-2hrs on a rotor, before washing with 
repeated cycles of pelleting/resuspending (centrifugation at lOOOxg for lmin/ resuspending 
in lml of lysis buffer for 2-3min). After washes, the captured proteins were eluted by 
heating to 95°C for 5 min in 30ul 2xlamelli sample buffer.
2.B.4.7 Cell fractionation
For analysis of <x2 chimaerin’s subcellular distribution, a2.10 Cells were plated out on 
50mm dishes (4 xlO5) in 10%FCS containing media and cultured overnight. Cells were 
washed in PBS before lysing and harvesting in 200pl Hypotonic buffer (Tris/HCL pH7.5 
2mM PMSF) off the plate. The cell lysate was completely suspended by sonication at level 
6 for 1.5 min (20sec pulses/5sec rest) and then cleared by centrifugation at 49Kg for lhr at 
4°C(Beckman TL-100). The supernatant (Cytosolic fraction) was collected and stored and 
the pellet was washed twice with 200pl hypotonic buffer. The pellet was then resuspended 
in 200pl 1% Triton buffer (1% Triton-x-100, Tris/HCL pH7.5, 2mM PMSF) and again 
completely resuspended by sonication at level 6 for 3 min (20sec pulses/5sec rest). After
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incubation on ice for 15min the cell lysate was centrifuged at 18,000g, for 20min, at 4°C in a 
benchtop centrifuge. The supernatant (Triton soluble fraction) was again removed and 
stored and the pellet was washed twice with 200pl l%Triton buffer. This final pellet was 
resuspended in 50pl 2x Lammelli sample buffer (Triton insoluble fraction) by extensive 
sonication (level 9) and freeze thaw cycles.
2.B.4.8 In vitro kinase assays
In-vitro kinase assays were carried out on recombinant protein substrates or 
immunprecipitated proteins. 2-5 pg substrate protein was suspended in the relevant kinase 
buffer in a 30pl reaction volume. The required amount of kinase plus ATP (lOOpM final 
concentration) and 0.37MBq of 32P yATP (lllTBq/mMole) was added and the reaction 
incubated at 30°C for 30min, before quenching with 15pi of Laemmli Sample Buffer and 
heating to 95°C for 5min.
2.B.5 Protein Analysis
2.B.5.1 Protein quantification
The amount of protein in a sample was evaluated using Biorad protein reagent. 200pl 
Biorad reagent, a relevant amount of the sample (l-5pl) and ddl^O to a final volume of 1ml 
were mixed together and incubated at room temperature for 15min. The O.D at 595nm 
wavelength was recorded and by comparison to BSA standards the amount of protein 
evaluated.
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2.B.5.2 SDS-poIyacrylamide gel electrophoresis
SDS polyacrylamide gel electrophoresis was used to separate proteins based on their 
molecular weight. The acrylamide concentration in the resolving gel is determined by the 
molecular weight of the proteins to be resolved. Typically 10% acrylamide resolving gels 
were used for the separation of proteins 16kDa to 68kDa KD:
3.15ml 30% acrylamide/bis-acrylamide, 1.25ml 1.5M Tris/HCl pH8.8, 1.25ml 80% 
Glycerol, 4ml H20, lOOpl 10% (w/v) SDS, 50pl 10% APS, 5pi TEMED.
7.5mls of the gel solution was pipetted into a mini gel apparatus (Biorad) and 
overlayed with ddH20, to prevent any oxidation. The gels were left to polymerise at room 
temperature for 45 minutes after which the ddH20  was poured off and a stacking gel mixture 
was prepared:
1.67ml 30% acrylamide/bis-acrylamide, 1.25ml 0.5M Tris/HCl pH6.8, 7ml ddH2O,100pl 
10% (w/v) SDS, 50pl 10% APS, 12pl TEMED
The stacking gel was pipetted on top of the polymerised resolving gel, into which a 
teflon comb was inserted. The stacking gel was left to polymerise at room temperature for 
30 minutes before removing the comb.
Samples were mixed with 5 x SDS Laemmli gel loading buffer (2% (v/v) SDS, 10% 
(v/v) glycerol, 62.5mM Tris/HCl pH 7-8, 5% (v/v) p-mercaptoethanol, bromophenol blue) 
and heat denatured at 95°C for 5 minutes before loading onto the denaturing SDS 
polyacrylamide gels. To determine the molecular weight of proteins separated on the 
acrylamide gels, protein markers of known size were also run. Proteins were separated 
using a Biorad vertical gel discontinuous buffer system. Gels were run at 170V for 1 hour in 
1 x electrode buffer (10 x electrode buffer: 0.25mM Tris, 0.5M Glycine, 1% SDS).
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Proteins could be either transferred onto PVDF membranes (western transfer) or visualised 
by Commasie blue staining:
2.B.5.3 Commasie blue staining
To stain for proteins in gels the gels were soaked for several hours in Commasie blue 
solution (40% Methanol, 10% glacial acetic acid, 0.005% Commasie brilliant blue). Excess 
Commasie blue was removed (destained) by soaking in 40% Methanol, 10% glacial acetic 
acid solution until background levels were negligible.
2.B.5.4 Western transfer (semi-dry blotting)
Proteins separated by electrophoresis were transferred onto PVDF membranes for antibody 
probing. The SDS-gels were equilibrated in 1 x transfer buffer (100ml of 10 x stock (25mM 
Tris, 192mM glycine) 20% (v/v) methanol made up to 1 litre with ddFkO), along with a 
piece of PVDF membrane (PVDF was pre-soaked in methanol and washed in ddtkO before 
equilibration) and two pieces of extra thick and 3mm Biorad filter paper. A sandwich was 
prepared on a Biorad Transfer-Blot SD semi-dry transfer machine, ensuring no air bubbles 
were trapped: Bottom-Top: Thick Biorad filter paper, Whatman filter paper, PVDF 
membrane, SDS-acrylamide gel, Whatman filter paper and thick Biorad filter paper. 
Proteins were transferred overnight at a constant voltage of 8 volts.
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2.B.5.5 Immunoblotting
After western transfer, the PVDF was allowed to air dry at room temperature to ensure 
maximal protein immobilisation. The membranes were then stained/destained with 
Commmasie blue to visualise the immobilised proteins (also reduces background of 
immunoblotting). After ddFfeO washes the membranes were incubated in blocking solution 
(5% marvel milk, 0.1% tween-20/PBS) for lhr at room temperature. Membranes were 
incubated with the required antibodies at the relevant concentration in 1% marvel, 0.1% 
tween-20/PBS for l-2hrs at room temperature. Excess antibody was washed away with 5 x 
5min, 10ml 0.1% tween-20/PBS washes. The primary antibody could then be detected using 
a secondary horseradish peroxidase (HRP) conjugated antibody (Dako) raised against the Fc 
portion of the IgGs from the species of the primary antibody. A 1/2000 dilution in 1% 
marvel, 0.1% tween-20/PBS was used for lhr at room temperature. Again excess antibody 
was washed away with 0.1% tween-20/PBS washes. Bound secondary antibody was 
detected by enhanced chemi imunofluorescence (ECL Amersham). Equal volumes of 
reagents 1 and 2 were mixed and washed over the membranes for lmin. Excess fluid was 
removed with tissue paper and the membranes were exposed to ECL film for developing.
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3 al Chimaerin: GAP Regulation and Neuronal Morphology
The Rho GTPases have been implicated in numerous cell responses and their cycling 
activity is crucial for function. The C-terminus of a  chimaerins contain a GAP domain, 
which is selective towards Rac 1 (Diekeman et al., 1991, Manser et al., 1992). 
a  Chimaerins thus down regulate Rac 1 activity but could also promote Rac signalling 
(Kozma., et al 1996) possibly via coordinating with a GEF to increase cycling or via an 
effector function.
Two a  chimaerin isoforms exist, a l  (Hall et al., 1990) and alternatively spliced 
a2 (Hall et al., 1993), containing a SH2 domain at its N-terminus. A cysteine rich 
domain (Cl) and GAP domain are also common to both isoforms (see 1 .G.2.1). The Cl 
domain is homologous to the Cl region of PKCs and is required for phospholipid- 
dependent phorbol ester binding (Ahmed et al., 1990). Phospholipid association has 
been shown to regulate a  chimaerin GAP activity in vitro (Ahmed et al., 1993).
As well as differences in developmental expression patterns, a  chimaerin 
isoforms differ in their subcellular distribution, with a 2 chimaerin adopting a more 
cytosolic distribution compared with the predominant membranous/cytoskeletal 
association of a  1 chimaerin (Hall et al., 2001). This different cellular distribution of a2 
chimaerin has been presumed to be due to the SH2 domain, suggested by a 
“translocating” mutation within the SH2 domain (N94H), which results in an 
a l  chimaerin-like distribution and morphology in N1E-115 neuroblastoma cells.
It can thus be hypothesised that signalling events altering a l  chimaerin 
location/lipid association would in turn regulate GAP activity and the effect of this on 
neuronal cell morphology is of interest.
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3A. al Chimaerin Location
3.A.1 Mutations in the SH2 and GAP domains of a l  chimaerin alter subcellular 
distribution
Modelling a l  chimaerin SH2 domain on Grb2 SH2 domain structure indicated the 
N94H mutation could potentially locally alter surface charges in the region adjacent to 
the phosphotyrosine binding pocket, without directly effecting phosphotyrosine binding. 
It is not clear whether this mutation affects interactions with target proteins or 
intramolecular interactions. It was of interest to determine if mutations in other regions 
of a l  chimaerin might result in altered distribution. The sub-cellular distribution of a l  
chimaerin mutants was examined in Cos-7 cells transiently transfected with GFP fused 
a l  chimaerin cDNA constructs (Fig. 3.1).
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Fig. 3.1 a2 chimaerin mutant expression in Cos-7 cells.
Cos-7 cells were transiently transfected on glass coverslips, with indicated GFP tagged a2 
chimaerin cDNA constructs (green) and cultured in 10% FCS containing media for 16 hrs before 
fixing and staining with TRITC-phalloidin (red).
In Cos-7 cells, the transient expression of the Rac GAP, a2 chimaerin, surprisingly had 
little effect on cell morphology, as Rac-dependent, lamellipodial structures were still 
present. a2 chimaerin was uniformly distributed throughout the cytosol and extended to 
peripheral structures (Fig. 3.1 Top row). However deletion of three residues in the GAP 
domain of a2 chimaerin (A303-305) (Fig. 3.1 4th row), resulted in a more particulate
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distribution with the mutated protein concentrating around the nucleus, similar to that 
seen with a2 chimaerin N94H (Fig. 3.1 2nd row). This distribution indicates 
insolubility of the mutant proteins through membrane association or possibly through 
protein aggregation. The deletion of A303-305 in a l  chimaerin, eliminates GAP 
activity but maintains Rac binding (Ahmed et al., 1994). Arginine 304 constitutes a 
highly conserved residue in the GAP domain, whose mutation has been shown to 
abolish GAP activity (Nassar et al., 1998). a2 chimaerin R304G maintained normal a2 
chimaerin distribution implying this difference between A303-305 and R304G is 
independent of GAP activity. Similar results were obtained when these mutants were 
expressed in N1E-115 neuroblastoma cells (see Fig 3.8). The association with internal 
membranes and not the plasma membrane, by the translocating mutants, is consistent 
with p2-chimaerin distribution in Cos-1 cells, where Golgi localisation was observed 
(Caloca et al., 2001).
The altered distribution of the mutants could result from conformational 
alterations in a 2 chimaerin. a 2 chimaerin may adopt a closed conformational structure, 
in which Cl domain mediated membrane insertion is inhibited, maintaining a2 
chimaerin in the cytosol. It is tempting to speculate the closed conformational could be 
a result of an intramolecular interaction between SH2 and GAP domains with a key Tyr 
residue, Tyr303. This however remains to be determined by mutational analysis.
3.A.2 PMA translocates a2 chimaerin
The Cl domain of chimaerin is responsible for DAG/phorbol ester binding (Ahmed et 
al., 1990). Phorbol ester treatment has been shown to translocate PKC to membranes, 
with the accepted view that ligand binding to the Cl domain caps a hydrophilic site at 
the top of the structure; providing a contiguous hydrophobic surface, promoting
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insertion into the lipid bilayer (Zhang et al., 1995). It has been demonstrated that 
a l ,  pi and p2 chimaerin are all translocated to membranous/cytoskeletal compartments 
upon phorbol ester treatment in Cos-1 cells (Caloca et al., 1997). In this study the 
functional consequence of phorbol ester treatment on a2 chimaerin was investigated in 
relevant cell types.
a  chimaerins are neuronally expressed proteins (Hall et al., 1990, Hall et al., 
1993), thus to evaluate in vivo functions of a2 chimaerin, a permanent N1E-115 
neuroblastoma cell line over-expressing a2 chimaerin was utilised, a2.10 line (Hall et 
al., 2001). These cells adopt a more flattened phenotype with prominent lamellipodia, 
compared with parental N1E-115 cells. A proportion of these cells also form neurites in 
10% serum containing media and they are more adhesive, requiring trypsinisation 
during culturing. a2.10 cells were treated with the phorbol ester, PMA, and fractionated 
(A) or fixed and stained with a2 chimaerin antibody (B).
A
Fig. 3.2 PMA translocates a2 chimaerin in neuroblastoma cells.
a2.10 neuroblastoma cells were treated with PMA in 10% FCS containing media for 1 hr. Cells 
were fractionated and 25 |ig of cytosolic, 1% Triton soluble proteins, and 10 pi of 1% Triton 
insoluble fraction were analysed by SDS gel electrophoresis and immunoblotting with a2 
chimaerin antibody (A).
Cytosolic
1 2 3 4 5 6
1% Triton Soluble — ---------------------- -
1% Triton Insoluble — —  -  - -
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Fig. 3.2B PMA translocates a2 chimaerin in neuroblastoma cells.
a2.10 neuroblastoma cells were treated with 10 gM PMA, or vector, in 10% FCS containing 
media for 1 hr. Cells were fixed and stained with TRITC phalloidin (red) and a2 chimaerin 
antibody (green)
From cell fractionation and immunoblotting, a clear translocation of a2 chimaerin from 
the cytosol to 1% Triton soluble and insoluble fractions was found to occur, upon PMA 
treatment, with concentrations as low as 10 nM being effective (Fig. 3.2A lane 3). Cell 
staining of a2.10 neuroblastoma cells showed a2 chimaerin adopts a roughly uniform 
distribution throughout the cytosol, extending to peripheral structures such as 
lamellipodia, where a2 chimaerin stains the actin rich leading edge (Fig. 3.2B). PMA 
induced translocation results in a particulate accumulation concentrating near the cell 
periphery. This implies possible translocations to membranes and cytoskeletal 
components as well as lipid rafts upon PMA treatment. A dramatic change in 
neuroblastoma cell morphology was also observed upon PMA treatment. The flattened, 
spread cells (indicative of Rac activity) became contracted with loss of lamellipodia and 
the appearance of microspikes, consistent with down regulation of Rac activity.
85
Results I
3.B a2 Chimaerin GAP Activity and Neuroblastoma Cell Morphology
3.B.1 PMA causes retraction of a2.10 neuroblastoma cells accompanied by a 
decrease in Rac-GTP
It appeared after fixing and staining that a2.10 neuroblastoma cells had responded to 
PMA treatment with altered morphology; this was therefore monitored with live cell 
imaging.
Fig. 3.3 PMA induced retraction of a2.10 neuroblastoma cells
a2.10 neuroblastoma cells, seeded on poly-L-lysine in 10% FCS containing media, were treated 
with 10 pM PMA and monitored by phase contrast microscopy with images recorded over the 
indicated time intervals.
5nun
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Neuroblastoma cells permanently over-expressing a2  chimaerin (a2.10) generate 
neurites in the presence of 10% FCS (Hall et al., 2001). Live cell imaging phase 
contrast analysis showed these cells were morphologically very dynamic, exhibiting 
fluctuating lamellipodia (arrows -7.5 and -2.5 min prior to PMA treatment), indicative 
of dynamic Rac activity (Fig. 3.3). This is consistent with results obtained by 
microinjection of a recombinant a l  chimaerin protein into neuroblastoma cells where 
dynamic Rac/Cdc42 effector functions were apparent (Kozma et al., 1996). Upon PMA 
treatment of a2.10 neuroblastoma cells, rapid retraction/col lapse was observed. The 
microspikes observed in fixed neuroblastoma cell staining (Fig. 3.2B) were therefore 
likely to be retraction fibres rather than filopodia formation.
In Swiss 3T3 fibroblast cells, PMA treatment has been shown to induce 
prominent lamellipodia, indicating activation of Rac signalling (Ridley et al., 1992). 
The lack of this response to PMA in the a2.10 neuroblastoma cell line was thus 
intriguing. The Rac activity in these cells in response to PMA was determined using a 
GST recombinant PAK CRIB domain fusion protein, immobilised on Sepharose beads 
to pull out Rac-GTP.
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Fig. 3.4 a2.10 neuroblastoma cell Rac signalling, in response to PMA.
a2 .1 0  neuroblastoma cells in 10% FCS containing media were treated with indicated 
concentrations of PMA for 1 hr before harvesting and extracting Rac-GTP with GST-PAK CRIB 
domain pull downs. Western blots of total and pulled out (GTP) Rac were densitometry 
analysed and Rac-GTP levels as a percentage of the control (no PMA) were evaluated (error 
bars indicate SDs for three separate experiments).
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There was a decrease in Rac-GTP levels in these neuroblastoma cells permanently 
expressing a2 chimaerin with increasing concentration of PMA treatment (Fig. 3.4). 
This decrease in Rac-GTP is consistent with activation of a2 chimaerin GAP activity.
3.B.2 PMA causes retraction of N1E-115 neuroblastoma cells which can be 
inhibited by the expression of GAP inactive a2 chimaerin
The lack of N1E-115 neuroblastoma cell ruffling in response to PMA has previously 
been reported (Kozma et al., 1997). N1E-115 neuroblastoma cells endogenously
express a2 chimaerin and thus it was of interest to determine if there was a similar 
morphological response in parental cells to PMA treatment, which could be attributed to 
a2 chimaerin GAP activity. GAP inactive a l  chimaerin mutants, which maintain Rac 
binding, can act as dominant negative constructs in vitro (Ahmed et al., 1994). N1E- 
115 neuroblastoma cells deprived of serum undergo Rac dependent morphological 
differentiation and neuritogenesis (Kozma et al., 1997) providing an in vivo system to 
examine a l  chimaerin Rac GAP activity.
N1E-115 neuroblastoma cells were plated onto poly-L-lysine and transiently 
transfected with GFP-a2 chimaerin constructs, before inducing differentiation by 
culturing in low serum containing media. Cells were then treated with PMA, for up to 
30min, fixed, stained and the number of transfected cells bearing neurites counted.
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Fig. 3.5 Inhibition of PMA induced retraction of neuroblastoma cells by expression of a2 
chimaerin GAP inactive mutants. N1E-115 neuroblastoma cells were transiently transfected 
with GFP, GFP-a2 chimaerin, GFP-a2 chimaerin R304G or GFP-a2 chimaerin A303-305 
constructs and grown in 1% serum media for 16 hrs. Cells were treated with 1 PMA for 
indicated times, before fixing and staining with TRITC-phalloidin. Cells with processes > 2 cell 
body diameters were counted as neurite bearing cells.
Culturing N1E-115 neuroblastoma cells in media containing low serum (1% FCS) 
induces Rac/Cdc42 dependent neurite formation (Kozma et al., 1997) with -25%  cells 
bearing neurites. Subsequent PMA treatment caused obvious neurite retraction of both 
GFP and GFP-a2 chimaerin over-expressing neuroblastoma cells within 15 min (Fig. 
3.5). This PMA induced retraction was significantly reduced in cells expressing the 
GAP inactive mutants ,GFP-a2 chimaerin R304G and A303-305.
These GAP inactive mutants are capable o f Rac association and thus potentially 
act as dominant negative constructs, inhibiting endogenous a2 chimaerin GAP activity 
through competition of Rac and DAG associations (Ahmed et al., 1994). Lack of 
complete effectiveness implicates incomplete inhibition by the transfected proteins or 
possibly alternative signalling pathways, potentially PKC mediated. To examine a
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possible role for PKC in this PMA induced response, cells were pre-treated with the 
PKC (a,Pu,pi,y,5 and e) kinase inhibitor GF109203X.
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Fig. 3.6 PKC involvement in PMA induced neuroblastoma cell retraction.
N1E-115 neuroblastoma cells were transiently transfected with indicated GFP tagged constructs 
and grown in 1% serum media for 16hrs. Cells were pre-treated +/- PKC inhibitor (5 pM 
GF109203X) for 30 min, before 15min incubation in +/- 1pM PMA. Cells were fixed and stained 
with TRITC-phalloidin and cells possessing processes > 2 cell body diameters were counted as 
neurite bearing cells (error bars indicate SDs for three separate experiments)
None of the GFP fused a2 chimaerin constructs significantly altered the basal level of 
neurite formation upon serum withdrawal, with no observed increase in neurite length. 
Thus none of these constructs inhibited Rac dependent outgrowth, either through 
possible sequestration or down regulation of Rac. This suggests an inactive state of the 
expressed wild type a2  chimaerin. Treatment with the PKC kinase inhibitor, 
GF109203X, caused dramatic filopodia formation with significantly increased 
neuritogenesis compared with control cells (p<0.05), within the short period of
90
Results I
treatment (45min). Thus it appears PKC kinase activity serves to inhibit filopodia and 
neurite formation in N1E-115 neuroblastoma cells.
Over-expression of a2 chimaerin did not significantly enhance the retraction of 
neurites upon PMA treatment but expression of both GAP inactive a2 chimaerin 
mutants, A303-305 and R304G, did reduce collapse (37% and 40 % collapse compared 
to control GFP collapse of 82%). No significant retraction was observed in cells 
expressing GFP a2 chimaerin A303-305 upon PMA treatment (p>0.1) and although 
cells expressing a2 chimaerin R304G did significantly retract in response to PMA this 
response was small compared to GFP and GFPa2 chimaerin expressing cells. PMA in 
the presence of GF109203X also did not cause significant collapse (p>0.05, 37% 
collapse). However GF109203X treatment induced significant neuritogenesis compared 
with GFP expressing cells alone (p<0.05). Thus inhibition of both a2 chimaerin and 
PKC activities separately can reduce PMA induced retraction of neurites to some 
degree, implicating both these proteins in this PMA induced response. Of interest is the 
similar degree of inhibition produced by PKC inhibitor and GAP inactive constructs, 
which might implicate both proteins in the same signalling pathway. To investigate this 
further cells transfected with GAP inactive a2 chimaerin constructs, treated with PMA 
in the presence of GF109203X would need to be evaluated.
These results obtained by expression of GAP inactive constructs imply a2 
chimaerin GAP activity is not required for neurite outgrowth stimulated by serum 
withdrawal, but is implicated in PMA induced neurite retraction of N1E-115 
neuroblastoma cells. PKC also appears involved in this morphological response to PMA 
and inhibition of PKC kinase activity causes increased neuritogenesis (at least as a short 
term response). However caution must be taken regarding the specificity of inhibitors. 
GF109203X is a potent inhibitor of GSK3 (Hers et al., 1999), as well as PKC and
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therefore GSK3 and other potential kinase activities can not be excluded from the 
observed results.
3.B.3 a2 chimaerin GAP activity inhibits neuritogenesis of N1E-115 
neuroblastoma cells when membrane targeted
PMA treatment appears to activate a l  chimaerin GAP activity and induce neurite 
retraction. To further investigate the effect of a l  chimaerin GAP activity on neurite 
morphology, N1E-115 neuroblastoma cells on poly-L-lysine were transiently 
transfected with GFP fused a l  chimaerin constructs and cultured in low serum media 
before fixing and staining cells.
E) Neurites 
■  Round
GFP GFP-a2 GFP-a2 GFP-a2 GFP-a2 GFP- a2
Chimaerin Chimaerin Chimaerin Chimaerin Chimaerin N94H + 
N94H A303-305 R304G A303-305
Fig. 3.7 a2 chimaerin GAP activity inhibits neuritogenesis of N1E-115 neuroblastoma 
cells. N1E-115 neuroblastoma cells on poly-L-lysine were transfected with the relevant GFP 
constructs and cultured in 1% FCS containing media for 16hrs before fixing and staining with 
TRITC- phalloidin (B). Transfected cells with processes >2 cell body diameters (neurite 
bearing) and cells possessing no visible processes (round) were counted (A) (error bars 
indicate SDs for three separate experiments).
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Fig. 3.7B a2 chimaerin GAP activity inhibits neuritogenesis of N1E-115 neuroblastoma 
cells.
Serum withdrawal of neuroblastoma cells results in neuritogenesis with approximately 
20% of GFP expressing control cells bearing neurites under these low serum conditions 
(Fig. 3.7A). The over-expression of wild type a2  chimaerin and GAP inactive mutants 
(R304G and A303-305) did not significantly affect this process of neurite formation 
compared with control GFP transfected cells (p>0.1), implying a2 chimaerin GAP 
activity is not required for neurite outgrowth of N1E-115 neuroblastoma cells. 
However, expression of a2 chimaerin N94H, which adopts a membranous localisation, 
almost completely inhibits neurite formation compared with control GFP cells (p<0.01), 
causing cells to round up (p<0.001). This inhibition of neurite outgrowth is a direct 
result of GAP activity as the use of the double mutant (a2chimaerin N94H A303-305) 
restored normal neurite formation (Fig. 3.7 A +  B).
From the cell staining, a2  chimaerin is found uniformly throughout the 
cytoplasm extending along neurites and even to filopodia structures (Fig.3.7B). The 
double mutant a2 chimaerin N94H A303-305 displays a more particulate, punctate
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appearance, concentrating around the nucleus but which also extends along the neurite 
structures absent in a2 chimaerin N94H transfection.
The lack of morphological effect from over-expression of wild type a2 
chimaerin on neuritogenesis in these cells (Fig 3.7A) is again consistent with lack of 
Rac GAP activity. There was however a small but significant increase in the number of 
round cells expressing GFP-a2 chimaerin compared with GAP inactive GFP-a2 
chimaerin expressing cells (p<0.05), potentially implying partial GAP activity of the 
expressed wild type ct2 chimaerin.
3.B.4 GAP inactive a2 chimaerin expression induces neurite outgrowth in N1E- 
115 neuroblastoma cells
a2 chimaerin GAP activity inhibits outgrowth and induces collapse of neuroblastoma 
cell neurites. It was thus intriguing if inhibition of endogenous a2 chimaerin is 
sufficient to induce neurite outgrowth in these cells. To investigate this, a2 chimaerin 
GAP inactive cDNAs were transfected, which could act as dominant negative constructs 
in vitro (Ahmed et al., 1994). N1E-115 neuroblastoma cells were transfected with GFP 
fused constructs, cultured in 5% FCS containing media and morphologically examined.
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Fig. 3.8 GAP inactive a2 chimaerin expression induces neuritogenesis of N1E-115 
neuroblastoma cells. N1E-115 neuroblastoma cells, on poly-L-Lysine, were transiently 
transfected with GFP fused a2 chimaerin constructs, cultured in 5% FCS containing media for 
16hrs and fixed/stained with TRITC-phalloidin. Transfected cells with processes >2 cell body 
diameters were counted as neurite bearing (error bars indicate SDs for three separate 
experiments)
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Neurite formation in N1E-115 cells is a Rac/Cdc42 dependent phenomenon, which the 
Rho acting antagonistically serves to inhibit Culturing cells in 5% FCS containing 
media inhibits neurite formation, with less than 10% neuroblastoma cells bearing 
neurites (Fig. 3.8). Over-expression of a2 chimaerin did not significantly alter this 
(p>0.1), again consistent with an inactive state. However the expression of GAP 
inactive a2 chimaerin constructs lead to significant neurite formation (p<0.01), with 
greater than 20% cells bearing neurites. The expression of the GFP-a2 chimaerin 
A303-305 mutant tended towards aggregated protein distribution, similar to that seen in 
Cos-7 cells (Fig. 3.1). These mutant constructs potentially act by competitive inhibition 
of endogenous a2 chimaerin GAP activity. These results therefore possibly imply 
serum containing factors serve to inhibit neuritogenesis of N1E-115 neuroblastoma 
cells, in part through inactivation of Rac signalling, via activation of a2 chimaerin GAP 
activity.
However GAP proteins, including a l  chimaerin, have been shown to promote 
Rac/Cdc42 effector morphology independent of their GAP activity (Kozma et al., 
1996). Thus the observed neurite outgrowth could be an effector/adaptor function of a2 
chimaerin. It is of interest to note the two a2 chimaerin GAP inactive mutants induce 
neurite formation to similar extents despite quite different subcellular distributions (Fig.
3.1).
3.C PMA Activates a2 Chimaerin GAP Activity
3.C.1 PMA alters a2 chimaerin distribution in Cos-7 cells
The translocation of a2 chimaerin in neuroblastoma cells, in response to PMA was 
difficult to visualise due to the fast retraction/collapse response of these cells. In live 
cell fluorescence imaging, the associated technical problems with these cells are
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increased. Therefore the Cos-7 cell line was used for live fluorescent imaging of a2 
chimaerin, as the more adhesive, flattened nature of these cells made imaging easier.
(i) GFP a l  Chimaerin
(ii) GFP
Ominl 40m in
Fig. 3.9 PMA translocates a2 chimaerin in Cos-7 cells.
Cos-7 cells seeded onto glass dishes were transiently transfected with GFP-a2 chimaerin (i) or 
GFP (ii) constructs and cultured in 10% serum containing media. Live cell fluorescence was 
monitored for 15min, before treating with 10 gM PMA at time 0 and continued thereafter.
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High fluorescence was observed in the cell body due to cell shape, saturating detection 
and making observations surrounding the nucleus difficult. PMA treatment had very 
little effect on the distribution of GFP (Fig. 3.9ii), while GFPa2 chimaerin distribution 
was significantly altered (Fig. 3.9i). GFP a2 chimaerin was uniform throughout the 
cytoplasm with diffuse fluorescence. Within a few minutes of PMA treatment, GFP <x2 
chimaerin was shown to aggregate within the cytoplasm with a punctate accumulation, 
while no plasma membrane localisation was observed. This could represent a 
redistribution to inner membranes and vesicles in response to PMA in Cos-7 cells.
Imaging using UV radiation caused considerable retraction of GFP expressing 
cells in the presence or absence of PMA, but interestingly not of GFP-a2 chimaerin 
expressing cells. However in non-monitored cells PMA induced dramatic collapse of 
Cos-7 cells expressing GFP-a2 chimaerin but not those expressing GFP (data not 
shown). The mechanisms of this remain unclear but for morphological analysis, fixed 
cell studies were carried out.
3.C.2 a2 chimaerin inhibits PMA induced lamellipodia in Cos-7 cells 
PMA treatment of Swiss 3T3 fibroblasts has been shown to induce lamellipodia, a Rac 
dependent phenomenon (Ridley et al., 1992), and PMA treatment translocates a2 
chimaerin (Fig. 3.9). To investigate the phenotypic effects of PMA on a2 chimaerin 
expressing Cos-7 cells, cells seeded on glass coverslips were transiently transfected 
with GFP-a2 chimaerin (WT) and GAP inactive GFP-a2 chimaerin A303-305 and 
treated with a concentration gradient of PMA for lhr before fixing and staining the 
cells. Morphological analysis was then undertaken.
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Fig. 3.10 a2 chimaerin Inhibits PMA Induced lamellipodia in Cos-7 cells.
Cos-7 cells seeded on glass coverslips were transfected with wild type chimaerin (circles)or 
GAP inactive a2-chimaerin (triangles) and cultured in 10% serum containing media. After 
treatment with PMA for 1 hr, cells were fixed and stained with TRITC phalloidin. Cells with 
prominent lamellipodia (blue) or having collapsed (red) were counted (A) (error bars indicate +/- 
SDs from three separate experiments) and imaged (B)
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PMA induced prominent lamellipodia in non transfected Cos-7 cells and cell expressing 
GAP inactive a2 chimaerin A303-305 (Fig. 3.10 A+B). This phenotype was inhibited 
by the exogenous expression of wild type a2 chimaerin, where PMA induced 
significant cellular collapse. The inhibition of lamellipodia formation and collapse of 
cells expressing a2 chimaerin upon PMA treatment is thus a direct result of GAP 
activity. PMA has been shown to translocate a2 chimaerin to lipid environments (Fig.
3.2) and this appears to stimulate GAP activity resulting in a global loss of Rac activity, 
which under these conditions, results in cellular collapse. Cells were cultured in the 
presence of 10% FCS which has been shown to activate Rho signalling, thus the 
removal of the antagonistic Rac could lead to increased actin/myosin contraction. 
These results again imply a2 chimaerin exists in an inactive state in the cytosol, 
requiring lipid association for GAP activation, which results in cell collapse.
In a minority number of cells a particulate accumulation of a2 chimaerin was 
observed in the absence of collapse which was also apparent during live cell imaging 
(Fig.3.9). This particulate appearance of a2 chimaerin may be through vesicle 
association or it could be a result of aggregation/insolubilisation of a2 chimaerin, 
potentially through oligomerisation, which may result in inactive complexes.
3.D Summary of Results I
Phorbol ester treatment has now been shown to translocate a2 chimaerin to membrane 
and cytoskeletal fractions. Phorbol ester/DAG binding to the Cl domain in some way 
promotes lipid interactions, whether, like PKC it allows a contiguous hydrophobic 
surface for insertion, or whether it is a drastic conformational change remains unclear. 
The target membrane translocation appear cell specific. Lipid binding results in
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activation of <x2 chimaerin GAP activity which is under the control of the Cl domain 
via DAG association.
As in neuronal growth cones, PMA treatment causes neurite collapse/retraction 
of N1E-115 neuroblastoma cells, which can now in part be attributed to a l  chimaerin as 
well as PKC. a2 chimaerin GAP activity appears to inhibit neuritogenesis and cause 
neurite retraction in these cells. A mutant disrupting the inactive conformation (N94H), 
allowing lipid association and GAP activation, inhibits neurite formation while the 
expression of a GAP inactive cx2 chimaerin constructs is sufficient to stimulate neurite 
formation, through potential inhibition of endogenous a2 chimaerin activity. In Cos-7 
fibroblasts, treatment with PMA causes lamellipodia formation but with the exogenous 
expression of a2 chimaerin, results in cellular collapse in response to PMA.
The differences between a l  and ct2 chimaerin subcellular distribution have been 
attributed to an N-terminal variance, including an SH2 domain in a2 chimaerin (Hall et 
al., 2001). Influences of the SH2 domain presumably inhibit lipid interactions in some 
manner, resulting in the cytosolic localisation of a2 chimaerin. N94H mutation in the 
SH2 domain results in membrane association and GAP activation. These results led to 
the postulation of a model for a2 chimaerin activation. a2 chimaerin exists in an auto­
inhibited state in the cytosol, possibly through association of the SH2 domain with the 
GAP domain. This closed conformation inhibits lipid interactions as well as GAP 
activity. This potential intramolecular interaction is likely to be phosphotyrosine 
independent as mutations in the SH2 domain, which knock out phosphotyrosine binding 
(R56L and R73L), do not affect cellular distribution (Hall et al., 2001).
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4. a2 Chimaerin and p35/Cdk5
The proposed model of an auto inhibited conformation of a l  chimaerin out-lined in 
Results I would allow for tight regulation of GAP activity. Phorbol ester association 
and subsequent lipid interactions have been proposed to increase a l  chimaerin GAP 
activity in vivo. DAGs are themselves tightly regulated and it is likely specific DAGs, 
would vary in affinity for the Cl domains of chimaerins, enhancing targeting of GAP 
activity (Caloca et al., 2001). Specificity in phospholipid binding is also observed with 
acidic phospholipids such as phosphatidylserine preferred (Ahmed et al., 1993).
Protein-protein interactions could also conceivably serve to regulate GAP 
activity and location. As with PKC, it is likely proteins exist that interact with the active 
state, the inactive state or that serve as substrates for a l  chimaerin. Rac binding and 
GAP activity are distinguishable properties (Ahmed et al., 1994) leading to the 
postulation that chimaerins could also serve as Rho GTPase effectors, through adaptor 
functions. Hence protein interactions of a l  chimaerin are of great interest.
In an attempt to identify novel interactors for the neuronal specific activator of 
Cdk5, p35, Dr Robert Qi undertook a yeast two hybrid screen and isolated a  chimaerin 
as a possible candidate (Qi et al., 2004).
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4.A.1 P35 interacts with a2 chimaerin C-terminus
The yeast two hybrid screen identified the C-terminal 98 residues of a  chimaerin 
responsible for the interaction with p35 (Qi et al., 2004). Because of their similar 
developmental patterns of expression, a2 chimaerin may be the more likely in vivo 
interacting isoform. To confirm an in vivo interaction in mammalian cells and identify 
the region of a2  chimaerin involved, immunoprecipitations from Cos-7 cells over- 
expressing fragments of a2  chimaerin and full length p35 were carried out.
IP: anti-FLAG
(a2  chimaerin) (kDa)
WB: anti-p35
anti-FLAG 
(a 2 chimaerin)
Lysate: anti-p35 
FLAG-a2 chimaerin - w t  i9f*4S9 268-459
Fig. 4.1 P35 interacts with a2 chimaerin C-terminus in transfected Cos-7 cells.
Cos-7 cells were transiently transfected with p35 +/- FLAG-a2 chimaerin constructs. After 16 
hrs expression, cells were lysed and immunoprecipitated with anti-FLAG antibody. Samples 
were analysed by SDS gel electrophoresis and western blotted with indicated antibodies.
These immunoprecipitations (Fig.4.1) confirm an association of p35 with a2 chimaerin 
in vivo, and the C-terminus of a2 chimaerin (residues 268-459), encompassing the GAP 
domain was sufficient for interaction (Fig.4.1 lane 4). Thus both a l  and a2 chimaerin 
isoforms are potential in vivo binding partners of p35. There was an increase in 
association of p35 with N-terminal deleted fragments of a2  chimaerin (Fig.4.1). This is 
consistent with a restricted conformation of a2 chimaerin involving the N-terminus.
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4.A.2 a2 Chimaerin is not an in vitro p25/Cdk5 substrate
Cdk5 is a neuronal kinase, thus the association of a  chimaerins with p35 implicates a 
possible substrate role of a  chimaerins for Cdk5 activity. Cdk5 is a proline directed 
Ser/Thr kinase and both a  chimaerin isoforms possess a minimal Cdk5 consensus site 
(S/TP) within their C-terminus (SPEL see Fig. 4.13), with an additional site unique to 
a l  chimaerin N-terminus (39SPKS). To test whether a  chimaerin isoforms could serve 
as potential substrates for Cdk5 activity, in vitro kinase assays were undertaken with 
recombinant p25/Cdk5 and a  chimaerin proteins. p25 is an N-terminal truncated form 
of p35 (Patrick et al., 1999), which still binds a  chimaerin (Qi et al., 2004).
(kDa)
-83
-6 2
-47.5
_32 5 Kinase Reaction 
1 = p25/Cdk5 
~25 2 = p25/Cdk5 + a2 Chimaerin
-16.5  3  = p25/Cdk5 +  a l  Chimaerin
4 = p25/Cdk5 + C-term a  Chimaerin
5 = p25/Cdk5 + Myelin Basic Protein
6 = p25/Cdk5 + GST
-83  ^
-62
-47.5
-32.5
-25
-16.5
Fig 4.2 p25/Cdk5 in vitro kinase assay with recombinant a  chimaerin.
5pg of recombinant substrate protein was mixed with 2pl recombinant p25/Cdk5 in a 30 pi 
Reaction Volume (5pCi 32PyATP, 100 pM ATP, 20 mM MOPS pH 7.4, 5 mM MgCI2) and 
incubated at 30 °C for 30min. Samples were analysed by SDS gel electrophoresis and exposed 
to film.
Commasie 
Blue Stain
Radiograph
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In vitro kinase assays with recombinant p25/Cdk5 showed that neither a l  or a2 
chimaerin served as a substrate for Cdk5 activity under the conditions tested (Fig. 4.2 
lane 2 and 3), despite phosphorylation of myelin basic protein (MBP lane 5). To 
eliminate the possibility of a  chimaerin conformational hindrance, a cleaved 
recombinant peptide fragment comprising a  chimaerin C-terminal GAP domain was 
also utilised, but which remained unphosphorylated (Fig. 4.2 lane 4). Experiments 
using heat denatured GST-a2 chimaerin also yielded no phosphorylation (data not 
shown). The favoured consensus for Cdk5 phosphorylation includes a highly basic 
residue at the +3 position (S/TPXK/R) which is not apparent in either a  chimaerin 
isoform. In vivo P25/Cdk5 displays higher activity and reduced specificity compared 
with p35/Cdk5 (Patrick et al., 1999), therefore this lack of in vitro phosphorylation 
suggests a l  and a2 chimaerins are unlikely to serve as substrates for p35/Cdk5 activity 
in vivo.
These results are in disagreement with Qi et al., 2004, where direct 
phosphorylation of a l  chimaerin by p25/Cdk5 was observed. This discrepancy is a 
possible result of the state of recombinant chimaerin proteins used. Recombinant 
proteins could be treated with phosphatases to investigate whether proteins have been 
prephosphorylated on any potential Cdk5 site during synthesis and purification.
4.A3 a2 Chimaerin interacts separately with p35 and Cdk5, but not with the 
active p35/Cdk5 complex
In vivo, p35 interacts with Cdk5, which it activates. To investigate the relationship of 
a2 chimaerin with the p35/Cdk5 complex, immunoprecipitation studies from Cos-7 
cells over-expressing combinations of these proteins, were carried out.
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IP: anti-FLAG (p35) (kDa)
-83
WB: anti- a2 Chimaerin
f , " . '
anti-Cdk5 • ' 4 M M f e ' 325
anti-p35 - - •  -32.5
Transfection 1 2 3 4 5 6
GFP-a2 chimaerin - - + + - +
HA-Cdk5 - + + N I4 4  N144
FLAG-p35 + + + + + +
Fig. 4.3 FLAG-p35 immunoprecipitations from transfected Cos-7 cells.
Cos-7 cells were transfected with indicated plasmids and cultured for 16 hrs in 10% FCS 
containing media before lysis and immunoprecipitation with anti-FLAG antibody. Samples were 
analysed by SDS gel elecreophoresis and western blotted with indicated antibodies.
FLAG-p35 was immunoprecipitated from Cos-7 cells expressing combinations of p35, 
Cdk5 and a2 chimaerin. As expected Cdk5 associated with p35 when both proteins are 
co-expressed (Fig. 4.3 lane 2). a2  chimaerin was also found to associate with p35, 
when both proteins are expressed in Cos-7 cells (Fig. 4.3 lane 3). When all three 
proteins were co-expressed in Cos-7 cells, immunoprecipitation of p35 only co­
precipitated Cdk5, with no observable a2  chimaerin association (Fig. 4.3 lane 4), 
implying that there was competitive binding, with much higher binding affinities of p35 
for Cdk5 than a2 chimaerin. However a2  chimaerin was co-precipitated with p35 in the 
presence of the inactive kinase mutant Cdk5N144 (Fig. 4.3 lane 6). In cells Cdk5N144 
forms a more stable complex with p35 (Nikolic et al., 1996) as ubiquitin mediated 
degradation of p35 is initiated by Cdk5 phosphorylation. Since p35/Cdk5 activity has 
also been found to be detrimental to some cells, in that it induces apoptosis, it is 
possible that a2 chimaerin may only associate in a hetero-trimer with the inactive and 
more stable p35/Cdk5N144. Alternatively, this result implies a role for Cdk5 activity in
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down regulating a2 chimaerin association with p35. Since a2 chimaerin is not a 
substrate for Cdk5 (at least under the conditions tested), phosphorylation of p35 by 
Cdk5 may be responsible for the loss of interaction with a2  chimaerin. It is also 
possible two separate complexes may be eo-precipitated with p35 when the inactive 
kinase is present (p35/Cdk5N144 and p35/a2 chimaerin).
To further investigate the protein complexes of a2 chimaerin/p35 and Cdk5, 
immunoprecipitation experiments were also carried out by pulling down either Cdk5 
(Fig. 4.4) or a2 chimaerin (Fig. 4.5) with antibody and investigating associated proteins.
IP: anti-Cdk5 (kDa)
WB: anti-GFP • m -83
(a2 chimaerin)
anti-p35 1 S ' •  -32.5
anti-Cdk5 • • • -
•
Tranfection 1 2 3 4 5 6
GFPa2 chimaerin + + + +
FLAG-p35 + + +
HA-Cdk5 + + + + N144 N144
Fig. 4.4 Cdk5 immunoprecipitations from transfected Cos-7 cells.
Cos-7 cells were transfected with indicated plasmids and cultured for 16 hrs before harvesting 
and immunoprecipitation with agarose conjugated anti-Cdk5 antibody. Samples were analysed 
by SDS gel electrophoresis and western blotted with indicated antibodies.
Immunoprecipitation of Cdk5 from Cos-7 cells expressing both Cdk5 and p35 resulted 
in expected p35 pull down (Fig. 4.4 lane 2). Immunoprecipitation of Cdk5 (WT or 
N144) was also sufficient to co-precipitate a2  chimaerin when co-expressed (Fig. 4.4 
lane 3 and 5), suggesting it too interacts directly with a2  chimaerin, although an indirect 
association cannot be ruled out. However, in the presence of p35, a2 chimaerin 
association with Cdk5 was abolished (Fig. 4.4 lane 4). With Cdk5
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immunoprecipitation, no observable potential trimeric protein complex was evident 
when a2 chimaerin, p35 and Cdk5N144 or Cdk5 were all over-expressed (Fig. 4.4 lane 
4 and6), implying p35 and a2 chimaerin compete for the same binding site on Cdk5.
IP: anti-FLAG
(a2 chimaerin) (kDa)
WB: anti-p35 -32.5
a„ti-Cdk5 ' 32'5
anti-FLAG 
(a2 chimaerin) *'*' '
Transfection 1 2 3 4 5 6 7
p35 - + + - - +  +
HA-Cdk5 -  +  -  +  N 144 +  N 144
FLAG-a2 chimaerin + - + + + + +
Fig. 4.5 FLAG-a2 chimaerin immunoprecipitation from transfected Cos-7 cells.
Cos-7 cells were transfected with indicated plasmids and cultured for 16 hrs in 10% FCS 
containing media before harvesting and immunoprecipitation with anti-FLAG antibody. Samples 
were analysed by SDS gel electrophoresis and western blotted with indicated antibodies.
Immunoprecipitation of FLAG-a2 chimaerin confirmed its association with both p35 
and Cdk5 separately (Fig. 4.5 lane 3 and 4). Again when all three proteins were over 
expressed little or no p35/Cdk5 was co-precipitated with a2 chimaerin, nor was inactive 
p35/Cdk5N144 (Fig. 4.5 lanes 6 and 7) co-precipitaed with a2  chimaerin.
4.A.4 a2 chimaerin does not regulate p35/Cdk5 in vitro
The association of a2  chimaerin with p35 and Cdk5, but its lack of phosphorylation is 
suggestive of a regulatory role for a2  chimaerin on p35/Cdk5 kinase activity. This was 
tested with in vitro kinase assays, however recombinant GST a2 chimaerin failed to 
show any significant effect on recombinant p25/Cdk5 kinase activity using MBP as a
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control substrate (data not shown). The experiment was repeated using p35/Cdk5 
immunoprecipitated from transfected Cos-7 cells as the source of kinase.
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>
o 
<0 60  0)(0 cs
3? 40
20 
0
0  0  2  0  4  0  6  0  8  1 1.2 1 4
GST-a2Chimaerin mg/ml
Fig. 4.6 In vitro p35/Cdk5 kinase assay in the presence of increasing concentrations of 
GST a2  chimaerin. Immunoprecipitated Cdk5 from Cos-7 cells expressing FLAG-p35 plus HA- 
Cdk5 was used in an in vitro kinase assay with MBP as a substrate in the increasing presence 
of recombinant GST-a2 Chimaerin. Activity was expressed as a percentage of the control. A 
separate experiment gave similar results.
Recombinant GST a2 Chimaerin failed to show any significant effect on p35/Cdk5 
kinase activity (Fig. 4.6). However this involved a pre-associated p35/Cdk5 complex 
and it is quite possible that in vivo a2  chimaerin can interfere with the formation of the 
complex. a2 chimaerin potentially competes for p35 and Cdk5 binding with Cdk5 and 
p35 respectively, albeit with much lower affinities. Kinase regulation through this 
mechanism or possibly via down regulation of Rac, a Cdk5 activating protein (Nikolic., 
et al 1998) is thus still feasible under the appropriate conditions in vivo. This lack of in 
vitro regulation of Cdk5 kinase activity by a2 chimaerin is consistent with results of Qi 
et al., 2004.
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4.A.5 PMA promotes a2 chimaerin binding with p35
Because p35 associates with a  chimaerin C-terminal GAP domain, p35 could regulate a  
chimaerin GAP activity. Phorbol ester binding to the Cl domain of a l  chimaerin has 
been shown to promote lipid association and increase GAP activity, potentially through 
a conformational change. The relationship between phorbol ester binding and p35 
association in vivo was therefore investigated. Cos-7 cells were transiently transfected 
with p35 and a l  chimaerin and treated with PMA before FLAG immunoprecipitations 
were carried out.
1 2  3 4  5 (kDa)
• d ^ - 4 7 . 5
IP: anti-FLAG (p35)
WB: anti-a2chimaerin
PMA/|iM 10 0 0.001 0.1 10
FLAG-p35 - + + + +
Fig. 4.7 PMA increases in vivo binding of p35 and a2 chimaerin.
Cos-7 were transfected with HA-a2 chimaerin +/- FLAG-p35 and cultured for 16 hrs, after which 
cells were treated with the specified concentration of PMA for 1 hr before lysis and 
immunoprecipitation with anti-FLAG antibody. Samples were analysed by SDS gel 
electrophoresis and western blotted with indicated antibodies.
The results clearly showed a concentration dependent increase in the association of a l  
chimaerin with p35 in response to PMA (Fig. 4.7). Immunoprecipitations were also 
carried out with the translocating mutants of a l  chimaerin (Fig. 4.8).
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IP: anti-FLAG (p35) (kDa)
WB: anti-a2 chimaerin — •
-83
anti-FLAG (p35) -32.5
1 2 3 4 5
-83
Lysate: anti-a2 chimaerin mm —
W T N 9 4 H R 304G A 303-305
Fig. 4.8 FLAG-p35 immunoprecipitations with a2 chimaerin mutants.
Cos-7 cells were transfected with FLAG-p35 +/- GFP-a2chimaerin or a2chimaerin mutant cDNA 
constructs and cultured for 16 hrs in 10% FCS containing media before lysing cells and 
immunoprecipitation with anti-FLAG antibody. Samples were analysed by SDS gel 
electrophoresis and western blotted with indicated antibodies.
Mutations a2 chimaerin N94H and A303-305 showed increased binding to p35 (Fig. 4.8 
lane 3 and 5). As with PMA treatment, both these mutations result in translocation of 
a2  chimaerin from the cytosol to membranous and cytoskeletal fractions (Fig.3.1). P35 
is a membrane protein, possessing a myristolation signal at its N-terminus (Patrick et 
al., 1999). Thus this increase in binding could be a result of increased a2  chimaerin 
association with membranes, where p35 is localised, or alternatively, these mutations or 
PMA treatment may alter the conformation of a2  chimaerin, exposing the p35 binding 
region.
4.A.6 a.2 Chimaerin C-terminal GAP domain is sufficient for Cdk5 association
Immunoprecipitation experiments indicated an association of Cdk5 with a2 chimaerin. 
To determine the region of interaction, FLAG immunoprecipitations from transfected 
Cos-7 cells were carried out with N-terminal deleted constructs of FLAG-a2 chimaerin 
(Fig. 4.9).
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IP: anti-FLAG
(a2 chimaerin) (kDa)
WB: anti-Cdk5 •  ^  *  ~32'5
-47.5
anti-FLAG 
(a2 chimaerin)
-32
-25
2 3 4 5 6
Lysate: anti-Cdk5 -32.5
FLAG-a2 c h i m a e r i n  -  W T W T 39-459196-459 268-459
Fig. 4.9 Cdk5 interacts with a2 chimaerin C-terminus in transfected Cos-7 cells.
Cos-7 cells were transfected with HA-Cdk5 (lanel), FLAG-a2 chimaerin (lane 2) or HA-Cdk5 in 
combination with FLAG-a2 chimaerin constructs as specified (lanes 3-6). 16 hrs post
transfection, immunoprecipitations with anti-FLAG antibody were carried out. Samples were 
analysed by SDS gel electrophoresis and western blotted with indicated antibodies.
The C-terminal GAP domain of a2 chimaerin (residues 268-459) is sufficient for 
association with Cdk5 (Fig. 4.9 lane 6), as with p35.
To investigate the effect of phorbol ester association on the interaction between 
Cdk5 and a2-chimaerin, immunoprecipitations of FLAG-a2 chimaerin were carried out 
after treatment of cells with PMA. Cos-7 cells were transiently transfected and treated 
with PMA and the association of Cdk5 with FLAG a l  chimaerin analysed (results 
shown in Fig. 4.10).
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IP: anti-FLAG 
(a2  chimaerin)
I 2 3 4 5
(kDa)
WB: anti-Cdk5 - •  -  4  -32’5
anti-FLAG
(a2 chimaerin) ‘m a tm m  mm  -47.5
PMA/(iM 10 0 0.001 0.1 10
-  -- n c
Lysate: anti-Cdk5
FLAG-a2 chimaerin - + + + +
Fig. 4.10 PMA increases a2 chimaerin binding with Cdk5 in vivo.
Cos-7 cells were transfected with HA-Cdk5 +/- FLAG-cc2 chimaerin. 16 hrs post transfection, 
cells were treated with indicated PMA concentrations for 1 hr before immunoprecipitation with 
FLAG antibody. Samples were subjected to SDS gel electrophoresis analysis and western 
blotting with indicated antibodies.
PMA increases the binding of Cdk5 to a2 chimaerin, as with p35 (fig. 4.10). Unlike p35 
however, Cdk5 is a cytosolic protein, implying that a conformational change in a2 
chimaerin upon PMA binding, and not membrane translocation, is most likely 
responsible for the increased binding.
4.A.7 PMA increases binding of a2 chimaerin with p35/Cdk5
Since PMA substantially increases the association of a2 chimaerin with p35 and Cdk5 
separately (Fig.4.7 and 4.10), it was important to re-evaluate the potential for a trimeric 
complex of p35/Cdk5 and a2 chimaerin in the presence of PMA.
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IP: anti-FLAG (p35)
1 2 3 4 (kDa)
WB: anti-a2 chimaerin -  w  -47.5
anti-cdk.5 •  • • •  -32-5
anti-p35 — — '-32.5
PMA/pM 0 0.1 1 10
Lysate: anti-a2 Chimaerin _  —  —  _  -47.5
Fig. 4.11 a2 Chimaerin associates with p35/Cdk5 in the presence of PMA.
Cos-7 cells were transfected with FLAG-p35 + HA-Cdk5 + HA-a2 chimaerin cDNAs and cells 
incubated for 16 hrs to allow protein expression. Cells were treated with indicated PMA 
concentrations for 1 hr before immunoprecipitation with agarose conjugated anti-FLAG 
antibody. Samples were analysed by SDS gel electrophoresis and western blotting using the 
indicated antibodies.
Cos-7 cells were transiently transfected with p35/Cdk5 and a2  chimaerin and 
subsequently treated with PMA for lhr and then FLAG-p35 was immunoprecipitated. 
After treatment with higher concentrations of PMA, a2 chimaerin can associate with 
p35 in the presence of Cdk5 (Fig. 4.1 llane 3 and 4). It is unclear whether a trimeric 
complex or two separate protein complexes (i.e p35/Cdk5 and p35/a2Chimaerin) are 
being pulled down. However since the presence of a2  chimaerin in the 
immunoprecipitate does not appear to alter the level of Cdk5 co-precipiated, it is 
possible that a trimeric complex can be formed.
In view of this potential trimeric association of p35/Cdk5 kinase complex with 
a2  chimaerin in the presence of PMA the potential for kinase regulation by a2 
chimaerin or for phosphorylation of a2  chimaerin was re-evaluated. To test 
phosphorylation of a2 chimaerin in vitro kinase assays with recombinant p25/Cdk5 and 
FLAG immunoprecipitated a2  chimaerin and chimaerin fragments from transfected 
Cos-7 cells, in the presence of PMA, were undertaken (Fig. 4.12).
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Autorad
W B : anti-FLAG
FLAG-a2 Chimaerin 
P25/Cdk5 
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- 47.5
-25
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Fig. 4.12 p25/Cdk5 in vitro kinase assay with immunoprecipitated FLAG-a2 chimaerin 
proteins. Cos 7 cells were transiently transfected with various FLAGa2 chimaerin domain 
constructs and allowed to express for 16 hrs before immunoprecipitations were carried out with 
FLAG antibody to isolate the sample proteins. Isolated proteins including recombinant MBP 
(lane 2), were re-suspended in kinase buffer (20 mM MOPS pH7.4, 5 mM MgCI2) with or without 
PMA for 30 min. In vitro kinase assays were then undertaken on these samples, incubating 
with recombinant p25/Cdk5 30 °C for 30 min in the presence of 32PyATP.
a2  chimaerin conformation appears crucial for activity. Recombinant proteins isolated 
from prokaryotic cells potentially lack native conformation and thus isolated 
mammalian cell expressed proteins are advantageous. The lack of phosphorylation of 
the various FLAG-a2 chimaerin proteins in the presence or absence of PMA by 
p25/Cdk5 further suggests a non substrate role of a2  chimaerin for p35/Cdk5 activity 
(Fig. 4.12).
It was of interest to note a clear 22kDa (-200 residues) protein in the 
immunoprecipitate containing the FLAG epitope. It is highly likely this represents an 
N-terminal proteolytic cleavage product of full length a2  chimaerin which was 
immunoprecipitated using FLAG antibodies (Fig.4.12 lane 4 and 5). A single 
proteoytic cleavage at this site could possibly release a C-terminal cleavage product
116
Results II
encompassing the Cl-GAP domains and could implicate proteolytic cleavage of a2 
chimaerin as a further regulatory mechanism.
1 maltlfdtde yrppvwksyl yqlqqeaphp rritctceve nrpkyygref hgmisreaad
61 qllivaegsy liresqrqpg tytlalrfgs qtrnfrlyyd gkhfvgekrf esihdlvtdg
121 litlyietka aeyiakmtin piyehvgytt lnrepaykkh mpvlkethde rdstgqdgvs
181 ekrltslvrr atlkeneqip kyekihnfkv htfrgphwce ycanfmwgli aqgvkcadcg
241 lnvhkqcskm vpndckpdlk hvkkvyscdl ttlvkahttk rpmvvdmcir eiesrglnse
301 glyrvsgfsd liedvkmafd rdgekadisv nmyediniit galklyfrdl piplityday
361 pkfiesakim dpdeqletlh ealkllppah cetlrylmah lkrvtlheke nlmnaenlgi
421 vfgptlmrsp eldamaalnd iryqrlvvel liknedilf
RED = SH2
BLUE = CRD
GREEN= GAP BLOCKs CONSTITUTING GAP DOMAIN
Fig. 4.13 a2 chimaerin peptide sequence
An alternative approach to investigate a2  chimaerin function with p35/Cdk5 was to 
transfect p35/Cdk5 and a2 chimaerin into Cos-7 Cells, treat with PMA and isolate the 
active complex by immunoprecipitation. The addition of 32PyATP could then be used to 
test for the phosphorylation of a2  chimaerin or the kinase activity of the Cdk5 complex.
IP: anti-FLAG
(a2 chimaerin) (kDa)
Radiograph • • -47.5
W B: anti-a2 chimaerin -47.5
anti-p35
■■ m0 -32.5
anti-Cdk5 A -32.5
PMA + - + +
Transfection: I 2 3 4 5
FLAG-a2-chimaerin + + + + +
p35 - - + + +
Cdk5 - + + N144
Fig. 4.14 In vitro kinase assay with immunoprecipitated FLAG-a2 chimaerin proteins.
Cos-7 cells were transiently transfected with FLAG-a2 chimaerin + p35 + HA-Cdk5 and allowed 
to express for 16 hrs before treating +/-PMA lysing and immunoprecipitating with anti-FLAG 
antibody to isolate the sample proteins. Isolated proteins were re-suspended in kinase buffer 
(20 mM MOPS pH7.4, 5 mM MgCI2) and incubating at 30 °C for 30 min in the presence of 
32PyATP.
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Transfecting Cos-7 cells with FLAG-a2chimaerin and immunoprecipitating with FLAG 
antibody followed by addition of 32PyATP resulted in no clear phosphorylation of a2 
chimaerin or any other proteins (Fig. 4.14 lane 1). However treatment with PMA before 
FLAG immunoprecipitation did result in phosphorylation of a2 chimaerin upon 
addition of labelled ATP, but no detection of associated phosphorylated proteins. This 
suggests the association of a2 chimaerin with a kinase upon PMA treatment, leading to 
phosphorylation with the addition of ATP. Alternatively PMA activates an associated 
kinase leading to phosphorylation. The co-expression of p35/Cdk5 with FLAG-a2 
chimaerin and treatment with PMA did not increase phosphorylation of a2 chimaerin 
(lane 4) despite the presence of p35/Cdk5 in the immunoprecipitate. This suggests a2 
chimaerin does not serve as a significant downstream target of Cdk5 activity. However 
the co-expression of p35/Cdk5N144 with FLAG-a2-chimaerin did reduce 
phosphorylation upon PMA treatment suggesting Cdk5 activity may in some way 
regulate phosphorylation of a2 chimaerin directly or indirectly.
Repeating this experiment but immunoprecipitating with anti-Cdk5 antibody and 
monitoring phosphorylation of p35 and exogenously added MBP also indicated that the 
presence of a2 chimaerin did not appear to regulate p35/Cdk5 activity in vitro (data not 
shown)
4.A.8 p35 or CRMP-2 co-expression does not regulate a2 chimaerin induced
morphology
Lipid association stimulates a  chimaerin GAP activity and it was of interest to 
determine whether protein interactions of a2 chimaerin could regulate this. Collapsin 
Response Mediator Protein-2 (CRMP-2) was purified from rat brain extract (Teo Thesis
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1994) and is shown here (Results III) to be an in vivo interactor of a2 chimaerin SH2 
domain. CRMP-2 and p25/Cdk5 did not regulate a2  chimaerin GAP activity in vitro 
(Teo Thesis 1994, Qi et al., 2004) and so an in vivo assay was used to investigate 
functional correlates of the interaction in cells.
a2  chimaerin N94H appears to be a GAP-active mutant of a2  chimaerin, which 
inhibits neurite induction of N1E-115 neuroblastoma cells, upon serum withdrawal 
(Fig.3.7) and interacts strongly with both p35 and CRMP-2 (Fig. 4.8 and Fig. 5.3). This 
active mutant of a2  chimaerin was therefore used to investigate whether protein 
interactions with either p35 or CRMP2 could alter a2  chimaerin GAP regulated 
neuroblastoma cell morphology.
G FP- a 2  G FP- o 2  G FP + G FP + G FP- ot2 G F P -a 2
C him aerin Chim aerin FL A G -p35 F L A G -C R M P -2 C him aerin N 94H  C him aerin  N 9 4 H
N 94H  N 9 4 H + A 3 0 3 -3 0 5  + F L A G -p 3 5  +  F L A G -C R M P -2
Fig. 4.15 Co-expression of CRMP-2 or p35 with a2 chimaerin N94H in N1E-115 
neuroblastoma cells. N1E-115 neuroblastoma cells on poly-L-Lysine were transiently 
transfected with indicated plasmids before culturing for 16hrs with 1% FCS containing media. 
Cells were then fixed and stained with TRITC- phalloidin and the number of transfected cells 
bearing processes>2 cell body diameters were counted as neurite bearing (blue columns) and 
round cells (red columns) were also counted (error bars indicate SDs from three separate 
experiments)
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Culturing N1E-115 neuroblastoma cells in low serum containing media results in 
neuritogenesis, which a l  chimaerin GAP activity was found to inhibit (Fig. 3.7). Over- 
expression of CRMP-2 alone had no effect on neuritogenesis under low serum 
conditions (Fig. 4.15). Over expression of p35 did appear to reduce neuritogenesis, but 
this was not statistically significantly (p>0.1) (Fig. 4.15). a2 chimaerin N94H inhibits 
neuritogenesis and interacts strongly with p35 and CRMP-2. The co-expression of 
either p35 or CRMP-2 with a2 chimaerin N94H did not affect inhibition of neurite 
formation suggesting GAP activity was unaffected.
In Cos-7 cells a l  chimaerin inhibited PMA induced lamellipodia formation (Fig. 
3.10), and PMA also increased a2 chimaerin association with p35 and with CRMP-2 
(Fig.4.7.and Fig.5.2). Co-expression in Cos-7 cells of a2 chimaerin with either p35 or 
CRMP-2 and subsequent PMA treatment stimulates both a2 chimaerin GAP activity 
and target protein interactions and therefore provides a system for analysis of the effect 
of partner proteins on a l  chimaerin biological activity.
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Fig. 4.16 PMA treatment of Cos-7 cells co-expressing CRMP-2 or p35 with a2 chimaerin.
Cos-7 cells were transfected with GFP-a2-chimaerin plus FLAG-p35 or FLAG-CRMP-2 and 
proteins allowed to express for 16 hrs. Cells were then treated with 100 nM PMA for 1hr before 
fixing and staining with TRITC phalloidin. The number of transfected cells possessing 
prominent lamellipodia (blue columns) or having undergone collapse (red columns) were 
counted. Error bars indicate SDs from three separate experiments.
Cos-7 cells expressing a2  chimaerin do not form lamellipodia upon PMA treatment as a 
direct result of a2  chimaerin GAP activity (Fig.3.10). There was no significant change 
in the number of cells possessing lamellipodia or having collapsed in cells co­
expressing CRMP-2 and a2 chimaerin (Fig. 4.16). Thus the interaction of CRMP-2 
with a2 chimaerin does not appear to inhibit PMA-induced a2 chimaerin GAP 
activation. The co-expression of p35 with a2  chimaerin also had no significant 
morphological effect on PMA stimulated Cos-7 cells compared with a2  chimaerin 
expressing cells (Fig.4.16 ) , indicating p35 association with a2 chimaerin also does not 
inhibit GAP activity. However these results can not rule out that p35 and CRMP-2 
protein interactions regulate a2 chimaerin GAP activity in permissive cell types.
□  Lamellipodia ■  C ollapsed j
GFP-a2Chimaerin GFP-a2Chimaerin GFP-a2Chimaerin
+ FLAG + FLAG-p35 + FLAG-CRMP-2
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4.A.9 p35 expression in neuroblastoma cells disassociates a2 chimaerin from the
membrane fraction
The above studies did not detect any significant regulation of a2  chimaerin activity by 
association with CRMP-2 or p35. Since a2  chimaerin is active when translocated to 
membranes, the effect of p35 association on a2 chimaerin localisation was evaluated. 
a2.10 neuroblastoma cells, permanently expressing a2  chimaerin, were transiently 
transfected with FLAG-p35 and incubated for increasing time periods to allow p35 
accumulation. Cells were then harvested and fractionated and the levels of a2 chimaerin 
in the membrane fraction (1% Triton soluble) examined (Fig. 4.17).
WB: anti a 2 chimaerin
1 2 3 4 5 (kDa)
-47.5
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anti-p35 -32.5
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-25
p35 Expression Time/hrs 0 2 4 20 27
Fig. 4.17 a2.10 neuroblastoma cells 1% Triton soluble fraction with p35 expression.
a2.10 neurobastoma cells were transiently transfected with FLAG-p35 and allowed to express 
proteins for indicated hours. Cells were fractionated and 25 pg of 1% Triton-x-100 soluble 
fraction was analysed by SDS gel electrophoresis and western blotted with indicated antibodies.
P35 was detectable 4 hrs post transfection and showed increased accumulation in the 
membrane fraction with time, up to 27hours (later time not shown) upon transient 
transfection (Fig. 4.17). At the same time the levels of a2  chimaerin in this fraction 
appeared to decrease, while endogenous Rac protein levels remained constant. Thus it 
would appear p35 expression in these cells removes a2  chimaerin from the 1% Triton 
soluble fraction. This fraction largely represents membranes and thus p35 binding to
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a2  chimaerin potentially disassociates a2  chimaerin from the lipid membranes, 
although an indirect consequence of p35 signalling can not be ruled out. A 
corresponding increase in a2 chimaerin levels in the other fraction could not be detected 
(data not shown). This may be due to the abundance of a2  chimaerin in the cytosol or 
alternatively p35 expression could lead to a2 chimaerin degradation
4.A.10 Cdk5 kinase activity is not required for neuritogenesis of N1E-115 
neuroblastoma cells
Cdk5 has been implicated in both neurite outgrowth and growth cone collapse. In 
human SH-SY5Y neuroblastoma cells, p35 expression is enhanced upon laminin 
engagement and neuronal differentiation, promoting outgrowth with associated NF-H 
chain phosphorylation (Li et al., 2002). N1E-115 neuroblastoma cells differentiate 
upon serum withdrawal and this is enhanced upon laminin engagement. To examine 
endogenous proteins levels during N1E-115 neuroblastoma cell differentiation, cells 
were seeded on to laminin and cultured in 10% serum or serum free containing media 
for 16 hrs before western blotting.
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«■» ___ -32.5
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p35 Cdk5 pY 15-Cdk5
Fig. 4.18 Endogenous proteins of N1E-115 neuroblastoma cells.
N1E-115 neuroblastoma cells on laminin were cultured in the presence or absence of 10% FCS 
containing media for 16hrs before harvesting. Western blotting of whole cell lysates (40 p.g 
protein) with indicated antibodies was carried out.
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Cdk5 was easily detectable in N1E-115 cells and its levels were unaffected by serum 
starvation and differentiation (Fig. 4.18 lanes 3 + 4). Endogenous p35 protein was 
undetectable in N1E-115 cells with numerous commercial antibodies, even upon 
differentiation (Fig. 4.18 lanes 1 + 2). Tyr15 phosphorylation of Cdk5 has been shown 
to promote kinase activity and is thus a further indicator of activity. No Tyrl:> 
phosphorylation of Cdk5 was detected using the phosphospecific pY15 antibody. These 
results imply a lack of p35 expression in N1E-115 neuroblastoma cells and thus a lack 
of involvement of p35/Cdk5 activity in early differentiation and neuritogenesis.
To further investigate a role of Cdk5 kinase in N1E-115 neuroblastoma cell 
differentiation, cells were transiently transfected with inactive Cdk5N144 and cultured 
in low serum (Fig. 4.18).
□  Neurites ■  Round
FLAG-p35 HA-Cdk5 H A-Cdk5N 144 FLAG-p35+
HA-Cdk5
FLAG-p35+
HA-Cdk5N144
Fig. 4.19 Cdk5 activity in differentiating N1E-115 neuroblastoma cells.
N1E-115 neuroblastoma cells on Poly(L)lysine were transfected with indicated constructs and 
cultured in low serum (1% FCS) containing media for 16 hrs, before fixing and staining. 
Transfected cell morphology was then analysed. Error bars indicate SDs for 3 separate 
experiments.
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Over-expression of either Cdk5 or Cdk5N144 had no effect on neurite outgrowth with 
-20% of cells bearing neurites as with non transfected cells (Fig. 4.19 and Fig 3.6). 
Cdk5N144 is a kinase inactive mutant and binds p35 with 2-3x the affinity of native 
protein, acting as a dominant negative construct. These results imply Cdk5 kinase 
activity is not required for serum withdrawal induced neuritogenesis of N1E-115 
neuroblastoma cells. Over-expression of these proteins also did not lead to any 
significant neuritogenesis when cells were cultured in 5% serum (data not shown). 
However, co-expression of p35 and Cdk5 inhibited N1E-115 neuritogenesis induced by 
low serum, with resulting round neuroblastoma cells (Fig.4.19). This is a direct affect 
of Cdk5 kinase activity as shown by the transfection of p35 + Cdk5N144, which was 
without effect Cdk5 activity has been linked to neuronal death which has not been 
excluded here.
4.B Summary of Results II
a2 chimaerin can associate with both lipids and proteins. Protein interactions could be 
undertaken for adaptor function, or may serve to regulate localisation or GAP activity. 
Here a2 chimaerin was found to interact with the activator of Cdk5, p35 and also with 
Cdk5 itself. The GAP domain of a2 chimaerin was sufficient for these interactions, 
with the presence of phorbol ester increasing binding. Mutants of a2 chimaerin which 
showed increased lipid association also displayed increased binding to p35, suggesting a 
proposed closed conformation of a2 chimaerin inhibits p35 and Cdk5 interactions as 
well as lipid associations and GAP activity. A complex relationship between a2 
chimaerin and p35/Cdk5 may exist with potential competitive binding and 
phosphorylation regulated interactions.
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a2 chimaerin did not appear to serve as a substrate for, or regulate p35/Cdk5 
activity under the conditions tested. Neither did the interactions of p35 and CRMP-2 
appear to alter stimulated GAP activity of a2 chimaerin. However results suggest p35 
association with a2 chimaerin may inhibit lipid membrane association and possibly 
inhibit GAP activation to some degree. Proteolytic cleavage of a2 chimaerin was also 
observed in a cellular system, which may serve as a further regulatory mechanism, 
although not investigated here.
Cdk5 activity was found not to be required for neuritogenesis of N1E-115 
neuroblastoma cells, and excess activity resulting from co-expression of p35 and Cdk5 
was sufficient to inhibit neurite formation.
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5. cc2 Chimaerin SH2 Domain and Associated Phosphorylation 
Pathways
The N-terminus of a2 chimaerin, encompassing the putative SH2 domain, appears to be 
responsible for its predominant cytosolic localisation, where a2 chimaerin may reside in 
an autoinhibited conformation. DAG binding to the Cl domain, promotes lipid 
insertion and GAP activation, although the precise mechanisms remain unclear. The 
SH2 domain of a2 chimaerin could play a part in targeting of GAP activity. Relief of 
the autoinhibited structure, upon DAG association, could allow intermolecular 
interactions regulated by tyrosine phosphorylation, locally regulating a2 chimaerin 
distribution on the membrane. A high affinity receptor for the SH2 domain may 
alternatively be sufficient to “open up” the a2 chimaerin structure, recruiting to target 
membrane/non membrane receptors.
a  chimaerins have also been shown to display possible effector functions 
(Kozma et al., 1996). The SH2 domain may be vital for any adaptor function, recruiting 
a2 chimaerin to tyrosine kinase signalling events. Thus targets of the SH2 domain are 
of considerable interest. Previous work to identify such targets utilised a labelled a2 
chimaerin SH2 domain to probe rat brain extract, and resulted in the isolation of a 
neuronal phosphoprotein subsequently identified as CRMP-2 (Teo Thesis 1994, 
Mintum et al., 1995 ).
Phosphorylation is the most well characterised post translational modification of 
proteins, responsible for dynamic regulation and forms the basis for transient protein 
interactions. Phosphorylation of GAP proteins has been found to regulate activity and 
possibly even alter specificity (Minoshima et al., 2003) whilst phosphorylation of 
microtubule binding protein alters their affinities for microtubules, with
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hyperphosphorylation of Tau and CRMP-2 associated with neurodegenerative diseases 
(see 1.G.4).
5.A. Phosphotyrosine binding is not required for GAP inactive a2 chimaerin
induction of neurites
a2  chimaerin has been shown to display possible effector/adaptor functions independent 
of its GAP activity, promoting neurite formation in N1E-115 neuroblastoma cells 
(Fig.3.7). If this represents an adaptor function, the role of the SH2 domain and 
phosphotyrosine association may be of importance. To investigate this a double mutant 
eliminating phosphotyrosine binding capability and GAP activity (a2chimaerin R73L- 
R304G) was utilised.
GFP GFP-a2
Chimaerin
GFP-oc2
Chimaerin
R73L
GFP-a2
Chimaerin
R304G
GFP a2  Chimaerin 
R73L-R304G
Fig. 5.1 Expression of a2 chimaerin phosphotyrosine binding mutants in neuroblastoma 
cells. N1E-115 neuroblastoma cells were transiently transfected with GFP constructs and 
cultured in 5% FCS containing media. 16hrs post transfection, cells were fixed and stained and 
the number of transfected cells bearing neurites were counted. Error bars indicate SDs for 
three separate experiments.
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Over-expression of a2 chimaerin, or a2 chimaerin R73L, with eliminated 
phosphotyrosine binding capability, does not induce any significant neuritogenesis of 
N1E-115 neuroblastoma cells, in 5% serum containing media. GAP inactive a2 
chimaerin R304G, does induce significant neurite formation which appears to be 
independent of phosphotyrosine binding as shown by the double mutant a2chimaerin 
R73L-R304G. The question of whether this neurite induction is an effector function of 
a2 chimaerin or whether it is a result of inhibition of endogenous a  chimaerins remains 
unclear. However the absence of an a2 chimaerin R73L effect in serum does not 
preclude a receptor mediated response to other specific signals.
5.B al Chimaerin and CRMP-2
5.B.1 PMA increases CRMP-2 association with a2 chimaerin in vivo 
Since CRMP-2 is a potential novel interactor of the a2 chimaerin SH2 domain, which 
has been shown to interact in vitro assays (Teo Thesis 1994), it was sought to determine 
if these proteins could interact in vivo in a cellular system. Previous 
immunoprecipitation studies of a2 chimaerin yielded minimal association of CRMP-2 
with a2 chimaerin (Caan Thesis 2000). In view of the effects of a2 chimaerin 
mutations and PMA it was of interest to determine if this lack of association was due to 
the proposed closed conformation of a2 chimaerin. PMA activates a2 chimaerin and 
immunoprecipitations were therefore undertaken in the presence of PMA. Cos-7 cells 
were transiently transfected with FLAG-CRMP-2 and HA-a2 chimaerin, treated with a 
range of PMA concentrations and immunoprecipitated with FLAG antibodies. Controls 
were also set up to confirm PMA was not causing trapping of a2 chimaerin to agarose 
conjugated FLAG antibodies.
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Fig. 5.2 PMA increases in vivo binding of CRMP-2 with a2 chimaerin.
Cos 7 cells were transfected with HA-a2 chimaerin alone (lanes 1-4) or in combination with 
FLAG-CRMP-2 (lanes 5-8). 16hrs post transfection, cells were treated with increasing PMA 
concentrations for 1 hr before lysis and immunoprecipitation with anti-FLAG antibodies. 
Samples were analyses by SDS gel electrophoresis and western blotted with indicated 
antibodies.
When FLAG-CRMP-2 was immunoprecipitated from over expressing Cos-7 cells a 
clear dependence on PMA for the association of a2  chimaerin and CRMP-2 was shown 
(Fig. 5.2). In the absence of PMA there was little a2  chimaerin association with FLAG- 
CRMP-2 (Fig. 5.2 lane 5) but in the presence of PMA above 100 nM concentrations, the 
association was drastically increased (Fig. 5.2 lane 8). Of interest to note is, in this 
instance, at high PMA concentrations (10 pM) an approximate 90 kDa band was 
detected by the a2  chimaerin antibody. This could represent a dimer of a2  chimaerin 
which has not been completely denatured in the SDS gels. This dimerisation event may 
be explained by the conversion of a potential intramolecular bond to an intermolecular 
one: In response to PMA, a2 chimaerin is translocated/opened up, and at high
concentration when over expressed, a2 chimaerin molecules could dimerise through 
potential SH2 and GAP domain interactions.
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To further investigate a l  chimaerin association with CRMP-2, immunoprecipitations 
with the translocating a2 chimaerin N94H mutant were also undertaken.
IP: anti-FLAG (CRMP-2) (kDa)
1 -83
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Fig. 5.3 FLAG-CRMP-2 immunoprecipitates with a2 chimaerin N94H mutant.
Cos-7 cells were transfected with FLAG-CRMP-2 +/- GFP-a2chimaerin or GFP-a2chimaerin 
N94H and cultured for 16 hrs in 10% FCS containing media before lysis and 
immunoprecipitation with anti-FLAG antibodies. Samples were analysed by SDS gel 
electrophoresis and western blotted with indicated antibodies
No significant co-precipitation of wild type a2 chimaerin was observed with 
immunoprecipitated FLAG-CRMP-2 (Fig. 5.3 lane 2). However, a l  chimaerin N94H 
was able to co-precipitate with CRMP-2 (Fig. 5.3 lane 3). Thus as with p35, an 
increased association of a l  chimaerin with CRMP-2 was observed with a l  Chimaerin 
N94H mutant (Fig. 4.8 and 5.3)
5.B.2 a l  chimaerin N-terminal region is required for CRMP-2 association
The detection of CRMP-2 from brain extract using labelled GST-a2 chimaerin SH2 
domain (Teo Thesis 1994), indicated a direct interaction with this domain. To confirm 
this interaction in vivo with a l  chimaerin, immunoprecipitates of amino-terminal 
deleted constructs of a l  chimaerin were carried out in the presence/absence of PMA 
and tested for the presence of CRMP-2 by western blotting.
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Fig. 5.4 CRMP-2 associates with a2 chimaerin N-terminus.
Cos-7 cells were transfected with HA-CRMP-2 (all lanes) +/- FLAG-a2 chimaerin cDNA 
constructs (WT, 196-459 and 268-459) and treated with +/- 10 pM PMA for 1 hr before lysis and 
immunoprecipitation with anti-FLAG antibody. Samples were analysed by SDS gel 
electrophoresiss and western blotted with indicated antibodies.
When FLAG-a2 chimaerin and CRMP-2 were co-expressed in Cos-7 cells, on 
immunoprecipitation with FLAG-a2 chimaerin there was no detectable pull down of 
CRMP-2 in the absence of PMA (Fig. 5.4 lane2). However in the presence of PMA, 
full length a2  chimaerin coprecipitated CRMP-2 (Fig. 5.4 lane 6) and the presence of 
the N-terminus (1-196) of a2 chimaerin, containing the putative SH2 domain was 
required for association with CRMP-2.
5.B.3 a2 chimaerin potentially interacts with multiple regions of CRMP-2
To determine the region of CRMP-2 responsible for a2  chimaerin interaction, Cos-7 
cells were transiently transfected with HA-a2 chimaerin and GST fused CRMP-2 
constructs and treated with PMA before pulling out GST constructs with Glutathione 
agarose.
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Fig 5.5 GST-CRMP-2 pulldowns from transfected Cos-7 cells.
Cos-7 cells were transiently transfected with HA-a2 Chimaerin and various GST-CRMP-2 
constructs. Cells were treated with 1 |iM PMA for 1 hr before carrying out GST pulldowns. 
Samples were analysed by SDS gel electrophoresis and western blotted with indicated 
antibodies.
In the presence of PMA, a2 chimaerin can associate with both N- and C-terminal halves 
of CRMP-2 (Fig. 5.5 lane 2 and 3) and various N-terminal fragments, indicating 
possible multiple regions of association. To examine this further, immunoprecipitations 
from cells expressing these and other C-terminal CRMP-2 constructs and the isolated 
SH2 domain of a2 chimaerin should be carried out in the absence of PMA.
5.B.4 CRMP-2 association with a2 chimaerin is independent of phosphotyrosine, 
in the presence of PMA
Having identified the N-terminal of a2  chimaerin, encompassing the SH2 domain, as 
responsible for its in vivo interaction with CRMP-2 it was of interest to determine if  this 
interaction could be phosphotyrosine regulated. To accomplish this, a2  chimaerin 
mutants possessing SH2 mutations R56L and R73L which have been shown to
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eliminate phosphotyrosine binding in vitro (Hall et al., 2001) were used in 
immunoprecipitation studies of FLAG-CRMP-2, in Cos-7 cells in the presence of PMA.
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Fig. 5.6 FLAG-CRMP-2 co-immunoprecipitation of SH2 mutated a2 chimaerin.
Cos-7 cells were transfected with HA-a2 chimaerin constructs (lanes 1 and 3-6) and FLAG- 
CRMP-2 (lanes 2-6) and treated with 10 ^M PMA for 1 hr before lysis and immunoprecipitation 
with anti-FLAG antibody. Samples were analysed by SDS gel electrophoresis and western 
blotted with indicated antibodies.
Co-expression of CRMP-2 and a l  chimaerin in Cos-7 cells, followed by PMA 
treatment promotes the association of these two proteins. In the presence of PMA the 
association of a l  chimaerin and CRMP-2 does not require tyrosine phosphorylation as 
a l  chimaerin mutated proteins, R56L and R73L, which are incapable of 
phosphotyrosine interactions in vitro, were still able to associate with CRMP-2 (Fig. 5.6 
lane 5 and 6).
5.B.5 Pervanadate treatment enhances a2 chimaerin association with CRMP-2 in 
N1E-115 neuroblastoma cells
The previous result indicated CRMP-2 and a l  chimaerin can associate, with impaired 
SH2 function, in the presence of PMA. To further investigate whether tyrosine 
phosphorylation plays a part the association of these two molecules, 
immunoprecipitations from Cos-7 cells over expressing FLAG-CRMP2 and HA-a2
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chimaerin were carried out, following treatment with the tyrosine phosphatase inhibitor 
pervanadate (peroxides of vanadate; Kadota et al., 1987).
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Fig. 5.7 Pervanadate treatment does not effect co-precipitation of a2 chimaerin with 
FLAG-CRMP-2 in Cos-7 cells. Cos-7 cells were transfected with FLAG-CRMP-2 alone (lanes 
1+2) or co-transfected with HA-a2 Chimaerin (lane 3 and 4) and after 16hr expression were 
treated with 100 pervanadate (lane 2 and 4) or H20 2 control (lane 1 and 3) for 20min before 
harvesting, lysis and immunoprecipitation with anti-FLAG antibody. Samples were analysed by 
SDS gel electrophoresis and western blotted with indicated antibodies.
Pervanadate treatment of Cos-7 cells substantially increased tyrosine phosphorylation of 
CRMP-2 (Fig. 5.7 lane 2 and 4) and a2 chimaerin (data not shown). Thus in Cos-7 cells 
endogenous tyrosine kinases are capable of phosphorylating both CRMP-2 and a2 
chimaerin. Pervanadate treatment however had no effect on the association of CRMP-2 
and a2 chimaerin which remained negligible (lane 3 and 4). This finding is consistent 
with the previous result where mutations of the SH2 domain demonstrated interactions 
between these two proteins are independent of tyrosine phosphorylation (Fig. 5.6). 
However the consequence of tyrosine phosphorylation of a2 chimaerin remains unclear. 
To further investigate whether tyrosine phosphorylation of CRMP-2 can promote a2 
chimaerin interaction in a neuronal environment, these studies were repeated in N1E- 
115 neuroblastoma cells.
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Fig. 5.8 Pervanadate treatment enhances co-precipitation of a2 Chimaerin with FLAG- 
CRMP-2 in neuroblastoma cells. N1E-115 neuroblastoma cells were transfected with HA-a2 
chimaerin (Lanes1,3, 4 + 5) and FLAG-CRMP-2 (lanes 2-5) and after 16 hrs expression were 
treated with 100 pM pervanadate (lane 4) or Catalase/H20 2 control (lane 5) for 20 min before 
lysis and immunoprecipitation with anti-FLAG antibody. Samples were analysed by SDS gel 
electrophoresis and western blotted with indicated antibodies.
N1E-115 neuroblastoma cells in serum were transiently transfected with CRMP-2 and 
a2  chimaerin. Co-immunoprecipitation of a2 chimaerin with FLAG-CRMP-2 was 
negligible under unstimulated conditions (Fig. 5.7 lane3 and 5). Treating N1E-115 
neuroblastoma cells with lOOpM pervanadate increased the association of over­
expressed CRMP-2 and a2 chimaerin (Fig.5.7 lane4). The phosphotyrosine blot of the 
immunoprecipitate, showed potential tyrosine phosphorylation of CRMP-2 is slightly 
increased upon pervanadate treatment and there are at least two associated tyrosine 
phosphorylated proteins. Thus in neuroblastoma cells, CRMP-2 exists in a dynamic 
state of tyrosine phosphorylation/dephosphorylation and treatment with pervanadate 
shifts the equilibrium to the phosphorylated state and at the same time enhances a2  
chimaerin association.
137
Results III
It is possible the associated tyrosine phosphorylated protein which co-migrates 
with a l  chimaerin (47kDa) is a2 chimaerin in a phosphorylated state but the ~80kDa 
protein remains elusive. This could potentially represent one of the recently identified 
CRMP isoforms, as CRMPs have been shown to exist as heterotetramers (Wang et al., 
1997, Leung et al., 2002) and splice variant isoforms of all CRMP members (1-5) have 
been found of ~80kDa (Leung et al., 2002, Yuasa-Kawada et al., 2003).
The increase in association of CRMP-2 with a2 chimaerin could be explained 
by classical SH2/phosphotyrosine association. However a2 chimaerin appears itself 
tyrosine phosphorylated and the consequences of this is unknown. Alternatively 
tyrosine kinase signalling events, upregulated by pervanadate treatment, may increase 
CRMP-2 and a2 chimaerin association independent of direct tyrosine phosphorylation 
e.g by recruitment and activation of PLCy, leading to DAG production and subsequent 
chimaerin activation. It was of interest to note N1E-115 neuroblastoma cells collapsed 
upon pervanadate treatment and therefore potential neurite collapsing signals may 
promote CRMP-2/a2 chimaerin interaction. An alternative possibility would be tyrosine 
phosphorylation signalling induces the interaction of CRMP-2 with a l  chimaerin, 
which subsequently promotes collapse.
The different result between cell lines are indicative of neuronal specificity, 
potentially a neuronal specific tyrosine kinase is required to phosphorylate CRMP-2 to 
increase a2 chimaerin association. No co-precipitation of any tyrosine phosphorylated 
proteins was observed with immunorecipitated CRMP-2 from Cos-7 cells (Fig 5.7), 
highlighting the difference in signalling and binding partners between the two cell 
types. Pervanadate treatment of N1E-115 neuroblastoma cells causes neurite retraction, 
while in Cos-7 cells it lead to dramatic cell ruffling and endocytosis (data not shown). 
These cell specific responses are also generated by PMA treatment and could possibly,
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in part, be attributed to the presence of endogenous levels of a2  chimaerins in the 
neuroblastoma cells. Further immunoprecipitations following expression of the isolated 
SH2 domain of a2 chimaerin and CRMP-2 constructs in pervanadate treated 
neuroblastoma cells could possibly map any region of phosphotyrosine regulated 
interaction.
In an attempt to determine whether this was a direct pY CRMP-2 and a2 
chimaerin SH2 interaction, immunoprecipitationss were carried out from N1E-115 
neuroblastoma cells expressing CRMP-2 and the mutant a2 chimaerin R73L, with 
eliminated phosphotyrosine binding ability, after treatment with pervanadate.
IP: anti-FLAG
(CRMP-2) 1 2 3 (kDa)
W B: anti-a2 chimaerin " *+ o  -47.5 
• - *  \
anti-FLAG
(CRMP-2) «H
Lysate: anti a 2-chimaerin -47.5
R73L
Fig. 5.9 a l  Chimaerin R73L was not co-precipitated with FLAG-CRMP-2 in pervanadate 
treated neuroblastoma cells. N1E-115 neuroblastoma cells were transfected with HA-a2 
chimaerin and FLAG-CRMP-2 and after 16 hrs expression were treated with 100 pM 
pervanadate for 20 min before lysis and immunoprecipitation with anti-FLAG antibody. Samples 
were analysed by SDS gel electrophoresis and western blotted with indicated antibodies.
Treating neuroblastoma cells with pervanadate enhanced the association of over­
expressed CRMP-2 and a2 chimaerin (Fig. 5.8 and 5.9 lane 1 and 2). Mutant a2 
chimaerin R73L did not bind CRMP-2 in pervanadate treated neuroblastoma cells 
suggesting tyrosine phosphorylation binding of a2  chimaerin may be responsible for 
this increased association, presumably directly to CRMP-2.
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5.C Tyrosine Phosphorylation of a2 Chimaerin
5.C.1 a2 chimaerin is tyrosine phosphorylated and associates with tyrosine 
phosphorylated proteins in vivo
From the previous experiment involving pervanadate treatment, it appears a2 chimaerin 
is itself a target of endogenous tyrosine kinases in both Cos-7 and N1E-115 
neuroblastoma cells (data not shown and Fig.5.8). To substantiate this and to 
investigate phosphotyrosine associations of a2  chimaerin, a cell line permanently 
expressing a2  chimaerin (a2.13) was treated with combinations of PMA and 
pervanadate.
IP: anti-a2 Chimaerin (kDa)
-175
W B: anti pY
1 -83 
= « :-62-4 7 .?
-32.5
1 2 3 4 5
a2chimaerin IgG + + + +
Pervanadate + _ +
l(iM PMA - - - + +
Fig. 5.10 a2 chimaerin is tyrosine phosphorylated in vivo.
a2.13 neuroblastoma cell lines were treated with +/- pervanadate for 20 min +/- 1 pM PMA for 
1 hr before lysis and immunoprecipitation with anti-a2 chimaerin antibody. Western blots were 
then probed with anti-phosphotyrosine antibody.
Immunoprecipitation of a l  chimaerin from a2.13 neuroblastoma cell lines resulted in 
no detectable association of any tyrosine phosphorylated proteins and minimal tyrosine 
phosphorylation of a2  chimaerin itself (Fig. 5.9 lane 2). Treatment with pervanadate 
increased tyrosine phosphorylation of a band corresponding to a2 chimaerin and 
allowed the detection of two associated tyrosine phosphorylated proteins (~55kDa and 
~80kDa) (Fig. 5.9 lane3). PMA treatment alone also resulted in the slight detection of a
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~55kDa tyrosine phosphorylated protein but no increase in tyrosine phosphorylation of 
a l  chimaerin (Fig. 5.9 lane 4). A combination of PMA plus pervanadate led to a 
considerable increase in tyrosine phosphorylation of a2 chimaerin and an increase in 
association/phosphorylation of the -55kDa protein (Fig. 5.9 lane 5 arrow). No 
significant increase association/phosphorylation of the 80kDa protein, compared with 
pervanadate treatment alone, was apparent, but minor -62 kDa and ~100kDa bands 
were also observed under these conditions. The 62kDa band was not CRMP-2 as 
determined by western blotting (data not shown).
These increases in phosphotyrosine bands could represent an increase in 
association of a phosphotyrosine containing protein (potentially via the SH2 domain) or 
alternatively an increase in phosphorylation of an associated protein. Tyrosine 
phosphorylation of a2 chimaerin itself could also recruit other SH2/PTB containing 
proteins, which may themselves be substrates for tyrosine kinases. It is also highly 
possible none of these associated proteins are directly bound to a2 chimaerin but are 
members of a complex.
The increase in tyrosine phosphorylation of a band corresponding to a l  
chimaerin with pervanadate, and its further increase with PMA plus pervandate, 
indicates the potential association of a l  chimaerin with a tyrosine kinase which is 
promoted by PMA, or the activation of tyrosine kinases by PMA treatment. The lack of 
a l  chimaerin tyrosine phosphorylation upon PMA treatment alone would however 
therefore argue for rapid phosphatase activity associated with a l  chimaerin. The 
~80kDa protein associated with a l  chimaerin upon pervanadate treatment is unaffected 
by further phorbol ester treatment. This result could imply not all protein interactions of 
a l  chimaerin are increased by phorbol ester treatment although whether this represents 
a direct association is unclear. It was of interest to determine if the 55kDa protein was p
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tubulin (55kDa), which has previously been found to associate with a l  chimaerin SH2 
domain in vitro (Ferrari Thesis 1999). Western blotting did not detect any associated 
{3 tubulin (data not shown). It is tempting to speculate the 55kDa protein represents a 
tyrosine kinase/phosphatase.
Tyrosine phosphorylation of a2 chimaerin and associated proteins was also 
investigated in transiently transfected N1E-115 neuroblastoma cells expressing both full 
length and various FLAG-N-terminal deleted fragments of a l  chimaerin. These were 
treated with pervanadate and immunoprecipitated with FLAG antibody to determine 
regions of a2chimaerin involved in binding.
IP: anti-FLAG 
(a2 Chimaerin)
W B: anti-pY
Pervanadate
anti-FLAG
FLAG-a2 Chimaerin
(kDa)
-83
-63
-47.5
-32.5
-25
^
a2 39-459 196-459 268^59
Fig. 5.11 Associated tyrosine phosphorylated proteins of a2 chimaerin from 
neuroblastoma cell immunoprecipitations.
N1E-115 neuroblastoma cells were transiently transfected with FLAG a2 chimaerin constructs 
and treated with +/- pervanadate before immunoprecipitation with anti-FLAG antibody. Samples 
were analysed by SDS gel electrophoresis and western blotted with indicated antibodies. 
Immunoprecipitation of full length FLAG-a2 chimaerin from transiently transfected
N1E-115 neuroblastoma cells, and probing with a phosphotyrosine antibody showed the
presence of a weakly tyrosine phosphorylated band corresponding in mobility to a l
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chimaerin (Fig. 5.10 lane 1 arrow). Treatment with pervandate prior to FLAG 
immunoprecipitation of full length FLAG-a2 chimaerin only slightly increased tyrosine 
phosphorylation of this band (a2 chimaerin) but significantly increased the detection of 
associated tyrosine phosphorylated proteins, namely a ~ 65 kDa protein (Fig. 5.10 lane 
2). Interestingly the population of a2 chimaerin associated phosphotyrosine proteins 
recovered from transiently transfected cells differed from those of permanent a2 
chimaerin cell line, a2.13 (Fig.5.9).
Deletion of the N-terminal 38 residues of a2 chimaerin also had profound 
effects on a2 chimaerin phosphotyrosine associations and enhanced tyrosine 
phosphorylation of a2 chimaerin upon pervanadate treatment (Fig. 5.10 lane 4). This 
result could implicate these N-terminal residues in a native inhibited conformation of 
a2 chimaerin. The ~65 kDa major phosphoprotein, which bound to full length a2 
chimaerin, was also lost with removal of N-terminal 38 residues, implicating these 
residues in protein associations. Thus the -65 kDa protein could perhaps represent an 
anchoring protein which associates with inhibited conformation of a2 chimaerin.
Removal of the N-terminal 195 residues, including the SH2 domain, abolished 
all tyrosine phosphorylation of a l  chimaerin, upon pervanadate treatment, and also 
resulted in the loss of the majority of associated tyrosine phosphorylated proteins. Thus 
a2 chimaerin N-terminal 195 residues most likely encompasses the target sites for 
tyrosine kinases as well as residues (SH2 domain) for the interaction with several 
tyrosine phosphorylated proteins. However these differences may also be a result of 
altered conformation of these fragment proteins. Due to background bands it was also 
impossible to determine the phosphorylation state of the isolated GAP domain (268-459 
Fig. 5.10 lane8), although increased detection of a ~55 kDa phosphotyrosine protein 
was observed upon pervanadate treatment, which may represent a specific cytosolic
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GAP domain associating phosphoprotein. Again these associations may well be 
indirect.
5.C.2 Fyn phosphorylates a l  chimaerin in vitro
Fyn non receptor tyrosine kinases are members of the Src family and one isoform (59 
kDa) is highly enriched in the brain where it is neurone specific and localised to axonal 
tracts and growth cones (Bare et al., 1993, Bixby et al., 1993). NCAM dependent 
neurite outgrowth is inhibited in Fyn -/- mice (Beggs et al., 1994) and it is believed 
NCAM, FAK and Fyn form a functional adhesion signalling complex modulating 
growth cone motility (Beggs et al., 1997). Fyn has been shown to interact with and 
phosphorylate Tau (Lee et al., 1998) and was recently implicated in Serna 3A induced 
growth cone collapse where it tyrosine phosphorylates (Y15) and activates Cdk5 
(Sasaki et al., 2002). pl90RhoGAP and p250RhoGAP are also target of Fyn during 
oligodendrocyte differentiation (Wolf et al., 2001, Taniguchi et al.,). It is therefore 
possible that Fyn kinase might be responsible for tyrosine phosphorylation of a2 
chimaerin. To test this in vitro kinase assays with purified Fyn (Upstate) and FLAG 
immunoprecipitated a l  chimaerin proteins from Cos-7 cells were undertaken.
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Radiograph
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-32.5-
C.ST C .S T a2W T  39-459 196-459 268-459
F L A G -a 2  ch im aerin
W T  39-459 196-459 268-459
2 3 4 5 6
F L A G -a 2  ch im aerin
WB: anti-FLAG
-62
-47.5
-32.5
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Fig. 5.12 Fyn in vitro kinase assay with immunoprecipitated a2 chimaerin proteins.
Cos 7 cells were transiently transfected with FLAG constructs and allowed to express for 16hr 
before immunoprecipitations with anti-FLAG antibody were carried out. Isolated substrate 
proteins were re-suspended in kinase buffer (5pCi 32PyATP, 100 pM ATP, 25 mM Tris-HCI 
pH7.2, 31.25 mM MgCI2, 6.25 mM MgCI2M 0.5 mM EGTA). In vitro kinase assays were then 
undertaken on these samples and recombinant GST proteins (5pg), using purified Fyn (2 units) 
and incubated at 30 °C for 30 min. Samples were analysed by SDS gel electrophoresis, and 
exposed to film before western blotting with indicated antibodies.
Immunoprecipitation of FLAG-a2 chimaerin proteins, from Cos-7 cells followed by in 
vitro kinase assays demonstrated Fyn was not capable of phosphorylating full length a2 
chimaerin (Fig. 5.11 lane 2). However deletion of the N-terminal 38 residues of a2 
chimaerin resulted in clear phosphorylation by Fyn (Fig. 5.11 lane 3). This implies that 
the N-terminal 38 residues masks Fyn kinase sites and is consistent with a closed 
conformation of a2 chimaerin. It was of interest to note there was minimal 
phosphorylation of bacterial recombinant GST a2 chimaerin (Fig. 5.11 lane 8). Further 
deletion of the N-terminal 195 residues completely abolished phosphorylation by Fyn 
(Fig. 5.11 lane 4) indicating that phosphorylation target sites are likely to reside within
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residues 39-196, although further conformational hindrances are possible. This region 
contains the SH2 domain and several tyrosine residues which are candidates for 
phosphorylation (Fig. 5.12). Although no phosphorylation by endogenous associated 
Cos-7 cell kinases occurred, it is possible the addition of purified Fyn protein could 
activate any associated kinases with misleading results. However some direct 
phosphorylation of recombinant GST-a2 chimaerin was demonstrated (last lane).
a2 chimaerin (1-240)
1 maltlfdtde yrppvwksyl yqlqqeaphp rritctceve nxpkyygref hgmisreaad
61 qllivaegsy liresqrqpg tytlalrfgs qtmfrlyyd gkhfvgekrf esihdlvtdg
121 litlyietka aeyiakmtin piyehvgytt lnrepaykkh mpvlkethde rdstgqdgvs
181 ekrltslvrr atlkeneqip kyekihnfkv htfrgphwce ycanfmwgli aqgvkcadcg
XXX= 39-196 
RED = SH2 Domain
y = potential tyrosine phosphorylation site 
Fig. 5.13 a2 chimaerin N-terminal (1-240) peptide sequence
5.D CRMP-2 Phosphorylation
5.D.1 CRMP-2 tyrosine phosphorylation
When expressed in either neuroblastoma cells or Cos-7 cells treated with pervanadate, 
tyrosine phosphorylation of CRMP-2 was observed (Fig. 5.7 and 5.8). CRMP-2 is a 
highly expressed neuronal phosphoprotein which has been implicated in Serna 3A 
collapse (Goshima et al., 1995), a pathway involving Fyn activity (Sasaki et al., 2002). 
CRMP-2 has been shown tyrosine phosphorylated during Serna 3A induced collapse by 
Fps/Fes tyrosine kinase (Mitsui et al., 2002). It was of interest to determine whether Fyn 
could phosphorylate CRMP-2. From the in vitro kinase assay it appears Fyn is not 
capable of phosphorylating full length CRMP-2 synthesised in Cos-7 cells (Fig 5.12 
lane 6), although this does not preclude in vivo phosphorylation.
146
Results III
5.D.2 CRMP-2 is phosphorylated on Ser"'22 in vitro by Cdk5 (p25/Cdk5)
CRMP-2 is highly Ser/Thr phosphorylated in vivo (Gu et al., 2000) and ROK has been 
identified as a kinase responsible, phosphorylating Thr555 during LPA, but not Sema 3A 
induced growth cone collapse (Aimura et al., 2000), although CRMP-2 has also been 
implicated in Sema 3A collapse. Cdk5 activity has also recently been implicated in 
Sema 3A collapse (Sasaki et al., 2002) and since both these proteins have been 
identified as a2  chimaerin interactors the possibility that CRMP-2 could serve as a 
substrate for Cdk5 activity was investigated.
(kDa)
-83 
-62 
-47.5
-32 5 Commmasie Stain
-25 
-16.5
1 2 3 4 5
-83
-62
-47.5
Radiograph
-32.5
-25
-16.5
1. p25/Cdk5 + Myelin Basic Protein
2. p25/Cdk5 + GST
3. "Purified” CRMP-2
4. p25/Cdk5+ "Purified CRMP-2"
_______ 5. p25/Cdk5 + GST-CRMP-2__________________________________
Fig. 5.14 p25/Cdk5 in vitro kinase assay with CRMP-2.
5 fig of recombinant protein or purified rat brain protein was mixed with 2 pi recombinant 
p25/Cdk5 in a 30pl Reaction (5 pCi 32PyATP, 100 pM ATP, 20 mM MOPS pH 7.4, 5 mM MgCI2) 
and incubated at 30 °C for 30 min. Samples were analysed by SDS gel electrophoresis and 
exposed to film.
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In vitro kinase assay revealed the “purified” CRMP-2 from rat brain extract had 
associated kinase activity (Fig. 5.14 lane 3) but phosphorylation was still enhanced 
upon the addition of recombinant p25/Cdk5 (Fig. 5.14 lane 4). p25/Cdk5 was also 
capable of phosphorylating recombinant GST-CRMP-2 (Fig. 5.14 lane5) thus 
identifying it as a potential novel substrate for Cdk5 activity. Kinase assays were 
however extremely variable with different recombinant GST-CRMP-2 preparations. 
This could be because post translational modifications serve to regulate Cdk5 
phosphorylation of CRMP-2, such as phosphorylation by other kinases, which is the 
case for Tau phosphorylation (Sengupta et al., 1997)
CRMP-2 contains seven minimal Cdk5 consensus sites (S/TP) with S522PAK 
matching the preferred consensus sequence S/TPXK/R (Fig. 5.15). CRMP-2 is
rn n  r  i o
phosphorylated on Thr , Ser and Ser in association with Neurofibrillary tangles 
(NFT) in tissue from Alzheimer disease patients (Gu et al., 2000); where p25/Cdk5 
accumulation has also been noted (Patrick et al., 1999). It was therefore sought to 
determine whether any of these in vivo sites were Cdk5 phosphorylation sites, by using 
site directed mutagenesis to change Ser/Thr to non phosphorylatable residues.
1 msyqgkknip ritsdrllik ggkivnddqs fyadiymedg likqigenli vpggvktiea
61 hsrmvipggi dvhtrfqmpd qgmtsaddff qgtkaalagg ttmiidhvvp epgtsllaaf
121 dqwrewadsk sccdyslhvd itewhkgiqe emealvkdhg vnsflvymaf kdrfqltdsq
181 iyevlsvird igaiaqvhae ngdiiaeeqq rildlgitgp eghvlsrpee veaeavnrsi
241 tianqtncpl yvtkvmsksa aeviaqarkk gtvvygepit aslgtdgshy wsknwakaaa
301 fvtspplspd pttpdflnsl lscgdlqvtg sahctfntaq kavgkdnftl ipegtngtee
361 rmsviwdkav vtgkmdenqf vavtstnaak vfnlyprkgr isvgsdadlv iwdpdsvkti
421 sakthnsale ynifegmecr gsplvvisqg kivledgtlh vtegsgryip rkpfpdfvyk
481 rikarsrlae lrgvprglyd gpvcevsvtp ktvtpassak tspakqqapp vrnlhqsgfs
541 lsgaqiddni prrttqriva ppggranits lg
s/tp = minimal cdk5 consensus
s/t = phosphorylated in Alzheimer's Disease (509,518,522)
Fig. 5.15 CRMP-2 Peptide Sequence with Highlighted Phosphorylation Sites
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To map the potential sites of phosphorylation, site directed mutagenesis of FLAG- 
CRMP-2 was undertaken to produce the mutants T509A and S522A (see methods). 
These constructs were expressed in Cos-7 cells and the FLAG immmunoprecipitated 
proteins were used in an in vitro kinase assay with recombinant p25/Cdk5 (Fig. 5.16).
+p25/Cdk5 -p25/Cdk5
(kDa)
. -83-
-62-
-32.5-
f
-25-
MBP 1 2  3 4 4 5
WB: anti-FLAG (CRMP)
-83
-62
-32.5
1 =  em pty beads
2 = FLAG CRMP-2
3 = FLAG-CRMP-2 T509A
4 = FLAG-CRMP-2 S522A
5 -  FLAG-CRMP-2 T555A
6 = FLAG-CRMP-1A
Fig. 5.16 p25/Cdk5 in vitro kinase assay with immunoprecipitated CRMP-2 proteins.
Cos-7 cells were transiently transfected with FLAG constructs and allowed to express for 16hr 
before immunoprecipitations with anti-FLAG antibody were carried out to isolate the substrate 
proteins which were re-suspended in kinase buffer (5pCi 32PyATP, 100 pM ATP, 20 mM MOPS 
pH7.4, 5 mM MgCI2l). In vitro kinase assays were undertaken on these samples using 
recombinant p25/Cdk5 and incubated at 30 °C for 30 min. Samples were analysed by SDS gel 
electrophoresis, and exposed to film before western blotting with indicated antibodies.
From these results, CRMP-2 Ser'22 appears the major site for p25/Cdk5 phosphorylation 
of CRMP-2 as introducing the mutation S522A eliminated all observed phosphorylation 
by p25/Cdk5(Fig. 5.16 lane 4). This site is conserved in other CRMP family members 
as well as across species (CRMP-1 & CRMP-4 Fig 5.16) and p25/Cdk5 was found to 
strongly phosphorylate CRMP-1 A (p80) (Fig. 5.16 lane 6).
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CRMP-l (rat) VYEVPATPKH--AAPAPSAKSSPSKHQPPP
CRMP-2 (rat) 503VCEVSVTPKT— VT PAS SAKT S PAKQQAP P
CRMP-3 (rat) VHEVMLPAKP— GSGTQARASCPGKISVPP
CRMP-4 (mouse) VFDLTTTPKG— GTPAGSARGSPTRPNPP-
CRMP-5 (rat) VAIVVHPGKKEMGTPLADTPTRPVTRHGG-
Fig. 5.17 Alignment of CRMP family members
5.D.3 CRMP-2 associates with p35/Cdk5N144 in vivo
To investigate the possible associations of CRMP-2 with p35/Cdk5, 
immunoprecipitations from Cos-7 cells expressing combinations of proteins were 
carried out.
IP: anti-FLAG
(CRMP-2) (kDa)
WB:anti-p35 •  —  -32.5
anti-Cdk5 •  •  -  -  -32'5
anti-FLAG (CRMP-2) A -62
1 2 3 4 5 6 7
Lysate: anti- p35 ■ »  —  —  .32.5
anti-Cdk5 (f t  ! > ■ *  -32’s
1. FLAG-CRMP-2 5. FLAG-CRMP-2 + HA-Cdk5N144
2. p35 + HA-Cdk5 6. FLAG-CRMP-2 + p35 + HA-Cdk5
3. FLAG-CRMP-2 + p35 7. FLAG-CRMP-2 + p35 + HA-Cdk5N144
4. FLAG-CRMP-2 + HA-Cdk5
Fig. 5.18 FLAG-CRMP-2 immunoprecipitations from transfected Cos-7 cells.
Cos-7 were transiently transfected with combinations of FLAG-CRMP-2, p35 and HA-Cdk5. 
16hrs post transfection cells were harvested and immunoprecipitated with anti- FLAG antibody. 
Samples were analysed by SDS gel electrophoresis and western blotted with indicated 
antibodies.
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P35 and Cdk5 were both found to co-precipitate with FLAG-CRMP-2 
immunoprecipitated from Cos-7 cells co-expressing the relevant proteins (Fig. 5.18 lane 
3 and 4). A potential trimeric complex of p35/Cdk5N144 and CRMP-2 was also pulled 
out with use of kinase-dead Cdk5N144 (Fig. 5.18 lane 7) but not with active kinase 
(Fig. 5.18 lane 6). Cdk5N144 forms a more stable complex with p35 than active Cdk5 
and this may account this difference. This result is consistent with a substrate role of 
CRMP-2 for p35/Cdk5 kinase activity.
5.D.4 GSK-3 p phosphorylates CRMP-2 in vitro
The ability of GSK3P to phosphorylate CRMP-2 was investigated. GSK3P is another 
proline directed Ser/Thr kinase, but which mainly phosphorylates primed substrates. 
Priming involves previous phosphorylation by another kinase, 4 residues C-terminus of 
the target site (S/TXXXpS/T) (Harwood et al., 2001). Cdk5 has been shown to 
potentiate GSK3P, phosphorylation of Tau, with both kinases responsible for most of 
the abnormal phosphorylation of Tau observed in tissue extract from Alzheimers 
disease patients. CRMP-2 has also been found hyperphosphorylated associated with 
NFT in tissue from Alzheimers Disease patients. The possibility that p35/Cdk5 could 
cooperate with GSK-3 p to bring about increased phosphorylation of CRMP-2 could 
also have implications in Sema3A induced growth cone collapse where CRMP-2 
(Goshima., et al 1995), Cdk5 (Sasaki., et al 2002) and GSK3P (Eickholt., et al 2002 ) 
activity have all been implicated.
All seven S/TP sites in CRMP-2 (Fig. 5.15) are potential targets of GSK3p. In 
addition phosphorylation of Ser522 could also self prime for Ser518 phosphorylation 
(S518AKTS522PAK). T o investigate this, several more point mutations of CRMP-2 were
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made. FLAG CRMP-2 mutants were expressed in Cos-7 cells and immunoprecipitated. 
These proteins were used in an in vitro kinase assay with recombinant GSK3p (Upstate)
+GSK3P (kDa) -GSK3|3
Radiograph -62-
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WB: anti-FLACi -62- * n r * r -
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Fig. 5.19 GSK3f3 in vitro kinase assay with CRMP-2 proteins
Cos 7 cells were transiently transfected with FLAG constructs and allowed to express for 16hr 
before immunoprecipitations with anti-FLAG antibody were carried out to isolate the substrate 
proteins which were re-suspended in kinase buffer (5pCi 32PyATP, 100pM ATP, 2mM MOPS 
pH7.4, 50pM EDTA, 2.5mM magnesium actetate). In vitro kinase assays were undertaken on 
these samples using recombinant GSK3p (50ng) and incubated at 30°C for 30min. Samples 
were analysed by SDS gel electrophoresis, and exposed to film before western blotting with 
indicated antibodies.
From the results of the in vitro kinase assay, CRMP-2 appears to be a novel substrate 
for GSK3P activity (Fig. 5.19 lane 2). Mutation of CRMP-2 S522A and S518A 
completely eliminated phosphorylation by GSK30 (lane 5 and 6) while T514A 
diminishes phosphorylation levels considerably but not totally (lane 3), implying there 
are possible multiple sites. One possibility is that mutations in this general area of 
CRMP-2 disrupt GSK phosphorylation making it impossible to define the sites by this 
mutational approach. However an alternative model is possible. The total loss of 
phosphorylation by GSK3P of CRMP-2 S522A potentially implicates this as an 
initiating phosphorylation site. However since CRMP-2 S518A mutant also completely 
knocks out all GSK3P phosphorylation, this may imply that Ser is not actually a site
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for GSK3(3 activity, but is in fact an essential phosphorylation/priming site for 
subsequent GSK3P mediated phosphorylation.
Previous work had ruled out the possibility of GSK3P phosphorylating CRMP-2 
in vitro (Gu et al., 2000). These authors used recombinant CRMP-2 protein as a 
substrate which would yield negative results if previous priming was required, as 
suggested by results described here (Fig. 5.19). Cos-7 lysates have been shown to 
posses endogenous kinases capable of phosphorylating CRMP-2 (Gu et al., 2000). Thus 
having immunoprecipitated FLAG-CRMP-2 constructs from Cos-7 it is conceivable 
that they were phosphorylated on Ser within the cell, priming for subsequent GSK3P 
phosphorylation of Ser518 followed by Thr514. The use of the mutant GSK3P R96A 
which has a reduced ability to phosphorylate primed but not unprimed sites (Frame et 
al., 2001) could clarify this.
p25/Cdk5 kinase assays were repeated with CRMP-2 T514A and S518A to 
confirm they were still capable substrates for Cdk5 activity (Fig. 5.10).
+p25/Cdk5 (kDa) -P25/Cdk5
•  -
-62-
FLAG-CRMP-2 W T  T 5 0 9 A  T 5 I4 A  S S18A  S 5 2 2 A T 5 5 5 A - W T  T 5 0 9 A  T 5 1 4 A  S 5 1 8 A S 5 2 2 A T 5 5 5 A
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W B: anti-FLAG 
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Fig.5.20 p25/Cdk5 in vitro Kinase Assay with Mutated CRMP-2 Proteins.
Cos 7 cells were transiently transfected with FLAG constructs and allowed to express for 16hr 
before immunoprecipitations with anti-FLAG agarose conjugated antibody were carried out. 
The isolated substrate proteins were re-suspended in kinase buffer (5 pCi 32PyATP, 100 pM 
ATP, 20 mM MOPS pH7.4, 5 mM MgCI2)) and in vitro kinase assays were undertaken, using 
recombinant p25/Cdk5, incubating at 30 °C for 30min. Samples were analysed by SDS gel 
electrophoresis, and exposed to film before western blotting with indicated antibodies.
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Phosphorylation of both CRMP-2 S518A and T514A by p25/Cdk5 was observed (Fig. 
5.20 lane 4 and 5) confirming specificity of the two kinases and the general 
maintenance of protein properties/structure by these mutations.
In vitro phosphorylation by GSK3P appeared to reduce the mobility of CRMP-2 
in SDS gels, and phosphorylated bands aligned with the reduced mobility species (Fig. 
5.19 lane 2, 3 and 7). To examine whether GSK3P could phosphorylate CRMP-2 in 
vivo, Cos-7 cells were transiently transfected with CRMP-2, GSK3P and p35/Cdk5 
cDNAs and cell lysates analysed (Fig. 5.21).
kDa
« s — -62.5
W B: anti-FLAG
-32.5
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r n-32.5
1 2  3 4
FLAG-CRMP-2 + + + +
HA-GSK3p + - +
FLAGp35/HACdk5 + +
Fig. 5.21 Lysates from Cos-7 cells expressing CRMP-2, GSK3|3 and p35/Cdk5.
Cos-7 cells were transiently transfected with indicated plasmids and 16 hrs post transfection cell 
lysates were analysed by 9% acrylamide SDS gel electrophoresis and western blotted with 
indicated antibodies
From the cell lysates of Cos-7 cells over-expressing FLAG-CRMP-2 alone (Fig. 5.21 
lanel), the majority of expressed protein migrates as a single band with a very faint 
band of reduced motility. However when co-expressed with GSK3P, CRMP-2 
appeared as a prominent doublet (Fig. 5.21 lane 2). From the previous in vitro kinase
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assay (Fig. 5.19) and published results (Gu et al., 2000) it is possible these bands with 
reduced mobility represent phosphorylated forms of CRMP-2. Interestingly p35/Cdk5 
expression, which probably phosphorylates a single site, did not induce a mobility shift 
in CRMP-2 when co-expressed but led to reduced levels of CRMP-2 making the 
visualisation of the faint doublet clearer (Fig. 5.21 lane 3). Expression of CRMP-2 with 
p35/Cdk5 and GSK3(3 led to a further reduction in CRMP-2 expression levels but with 
resolution of three clear bands of varying phosphorylation (Fig. 5.21 lane 4).
The effects of the various point mutations on in vivo phosphorylation of CRMP- 
2 by GSK3P, were undertaken by transfecting Cos-7 cells and analysing the mobility of 
FLAG-CRMP-2. Cdk5 is expressed endogenously in Cos-7 cells, although presumed to 
be inactive due to the lack of expression of its activators p35/p39.
(kDa)
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Fig. 5.22 Lysates from Cos-7 cells expressing mutated CRMP-2 proteins with GSK3p.
Cos-7 cells were transiently transfected with indicated CRMP2 constructs +/- GSK3J3 and in one 
instance treated with 10 jiM Roscovitine (+Rosc). 16 hrs post transfection, cell lysates were 
analysed by 9% acrylamide SDS gel electrophoresis and western blotted with indicated 
antibodies
Mutations of CRMP-2 S522A, S518A and T514A, all showed reduced in vitro 
phosphorylation by GSK3P, to various extents (Fig. 5.19) and no mobility shift induced 
by the co-expression of GSK3p in Cos-7 cells (Fig. 5.22 lanes 4, 5 and 6). This implies
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phosphorylation of all three sites is required for reduced mobility of CRMP-2, as a 
presumed result of a conformational change. Mutations of Ser/Thr phosphorylation 
sites to charged glutamate residue have been used to mimic phosphorylation. However 
mutations of either CRMP-2 S522E, S518E or T514E had no effect on mobility in SDS 
gels (Fig. 5.22 lanes 8, 9 and 10). If these mutations do mimic phosphorylation this 
would argue that a single phosphorylation event at any of these sites is insufficient for a 
conformational change/mobility shift, but rather a sequential phosphorylation process is 
required. It is of interest that CRMP-2 T555E also does not induce a conformational 
change in CRMP-2 (Fig. 5.22 lane 7). Thr555 phosphorylation by ROK is implicated in 
LPA induced growth cone collapse. Phosphorylation of Thr555 is apparently not 
sufficient for conformational change but is required for collapse (Aimura et al., 2000).
The possibility that an endogenous kinases in Cos-7 cells, either Cdk5 or Cdk 
family member, primes for subsequent GSK3p phosphorylation was investigated using 
the Cdk inhibitor roscovitine (Fig. 5.22 lane 3). Roscovitine is a powerful inhibitor of 
Cdk 1, 2, 5, 7 and 9 (Wang et al., 2001) but, unlike many Cdk5 inhibitors, shows 
minimal activity towards GSK3P in vitro (de Azevedo et al., 1997). Treatment with 
roscovitine did significantly reduce the appearance of the doublet in Cos-7 cells but not 
completely, possibly implying that endogenous Cdkl,2 5, 7 or 9 and other kinases may 
phosphorylate Ser522 of CRMP-2. The possibility that roscovitine inhibits GSK3-P in 
vivo can also not be entirely ruled out because minimal in vitro targets were found to be 
major in vivo targets for the Cdk inhibitor purvalanol (Knockaert et al., 2000).
To further study phosphorylation of CRMP-2 in vivo it was sought to investigate 
the use of phosphospecific antibodies. Cell signalling Technology’s Phospho-Thr-Pro 
antibody has been used to investigate numerous Cdk substrates including Cdk5 
phosphorylation of PAK (Rashid et al., 2001). A monoclonal antibody (3F4) had also
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been raised against paired helical filaments and the antigen identified as CRMP-2 
(Yoshida., et al 1998). It was subsequently realised the antigen represented 
phosphorylated CRMP-2 at residues T h r09, Ser518 and Ser522 (Gu et al., 2000). Thus 
3F4 represented a good candidate phospho-antibody to study Cdk5 and GSK3P 
mediated phosphorylation of CRMP-2. Cos-7 cells were transfected with GST-CRMP- 
2 and combinations of GSK3(3, p35 and Cdk5. GST pulldowns were then carried out, 
analysed by SDS gel electrophoresis and western blotted with these antibodies.
GST Pulldown
WB: anti-pThr/Pro
1 2 3 4 5 6 7 8 (kDa) 1 2 3 4 5 6 7
-83-
ft—
-25-
-83
anti-G ST
Lysate: 3F 4‘
anti-H A
anti-FLA G
-25
-83
-47.5
-32.5
-32.5
3F4
1 =GST
2 =  GST + HA-GSK3P
3 = GST-CRMP-2
4 = GST-CRMP-2 + HA-GSK3p
5 = GST-CRMP-2 + FLAG-p35 + HA-Cdk5
6 = GST-CRMP-2 + HA-GSK3p + FLAG-p35
7 = GST-CRMP-2 + HA-GSK3b + FLAG-p35
+ HA-Cdk5
8 = GST + FLAG-p35 + HA-Cdk5
Fig. 5.23 Phosphorylated CRMP-2 detection using phospho-specific antibodies.
Cos-7 cells were transiently transfected with indicated GST-CRMP2 constructs +/- GSK3P +/- 
FLAG-p35/HA-Cdk5. 16 hrs post transfection, GST pulldowns were carried out and analysed 
by 9% acrylamide SDS gel electrophoresis and western blotted with indicated antibodies
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GST pulldowns from Cos-7 cells over-expressing GST-CRMP-2 plus GSK3P (Fig. 5.23 
lane 4) compared with GST-CRMP-2 alone (Fig. 5.23 lane 3) followed by western 
blotting with phosphospecific antibodies, confirmed increased in vivo phosphorylation 
of CRMP-2 in the presence of GSK3p. Both antibodies recognise this increased 
phosphorylation. Detection with phosphoThr-Pro antibody is consistent with 
phosphorylation of Thr-514 by GSK3P (Fig. 5.15) while 3F4 recognition is consistent 
with phosphorylation of Ser-518 and Ser-522. 3F4 antibody also detects the
phosphorylated CRMP-2 in the cell lysates of the over-expressing Cos-7 cells. Both 
antibodies do react with expressed CRMP-2 alone (Fig.5.23 lane 3) implying CRMP-2 
is a target of kinases in Cos-7 cells which is consistent with Gu et al., 2000
Neither antibody could detect any potential increase in phosphorylation of 
CRMP-2 by p35/Cdk5 (Fig. 5.23 lane5). This is consistent with the specificity of the 
phosphoThr/Pro antibody. 3F4 recognises phosphorylated CRMP-2 on three residues
f/VJThr , Ser and Ser with elimination of any site dramatically reducing affinity. 
Phosphorylation by GSK3P of two sites (Fig.5.23 lane4) does allow some degree of 
binding while phosphorylation of Ser 522 alone is probably not sufficient (Fig.5.23 lane 
5)-
Expression of CRMP-2 with GSK3P plus p35 or p35/Cdk5 did not significantly 
enhance detection of phosphorylated CRMP-2 (Fig. 5.23 lane 6 + 7) compared with 
CRMP-2 + GSK3p (lane 4) potentially as a result of reduced expression of CRMP-2.
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5.E Summary of Results 111
CRMP-2 was identified as an in vivo interactor of a2 chimaerin SH2 domain, through 
immunoprecipitation studies. The model of a closed conformation of a2 chimaerin was 
also further supported by the lack of interaction between CRMP-2 and a2 chimaerin in 
the absence of PMA, although a difference in sub-cellular localisation could also 
account for this. Although the SH2 domain of a2 chimaerin is required for its 
interaction with CRMP-2, it is still not clear how or whether tyrosine phosphorylation 
regulates this interaction. Elimination of the ability of a2chimaerin SH2 domain to 
bind tyrosine phosphorylated residues does not abolish interactions with CRMP-2 in the 
presence of PMA in an over expressed system. However treatment with pervanadate, 
enhancing tyrosine phosphorylation of CRMP-2 and a l  chimaerin, enhanced their 
association only in neuroblastoma cells and not Cos-7 cells. It is also possible a2 
chimaerin interacts with multiple or N and C-terminal regions of CRMP-2.
a l  chimaerin was found to associate with numerous phosphotyrosine containing 
proteins in vivo and itself appears a substrate for tyrosine kinases, with Fyn identified as 
one potential kinase, potentially phosphorylating a l  chimaerin within amino residues 
39-196. The amino terminal (1-39) residues were implicated in conformational 
dependencies.
CRMP-2 did not serve as a substrate for Fyn tyrosine kinase in vitro but was 
identified as a novel substrate for Cdk5 activity in vitro and the site of phosphorylation 
mapped to Ser . GSK3(3 was found to phosphorylate CRMP-2, in vitro and in vivo. 
GSK3P phosphorylation potentially requires previous phosphorylation of Ser522,
r i o
possibly by Cdk5, allowing for subsequent GSK3(3 phosphorylation of Ser and
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Thr514, which together brings about a conformational change in CRMP-2, reducing 
mobility in SDS gels.
Chanter Six 
Discussion
Discussion
6.A  al ch im aerin
a2 chimaerin consist of three distinct protein domains. A catalytic Rho GAP domain is 
believed largely specific towards Racl, with little activity towards Cdc42 and none 
towards Rho in vitro (Diekeman et al., 1991, Manser et al., 1992), although a complete 
investigation against all the Rho GTPase members, remains to be undertaken. The 
presence of a Cl domain and a putative SH2 domain also implicate regulatory lipid and 
protein interactions associated with tyrosine phosphorylation pathways.
6.A.1 Lipid Interactions
Rho GTPases cycle between GTP and GDP bound forms and flip from cytosolic to 
membrane distributions. It is generally believed Rho GTPases must be GTP bound and 
associated with membranes to elicit downstream signalling, with prenylation or GDI 
association determining location. Evidence favours the model of GDI dissociation with 
subsequent Rho GTPase translocation, followed by GTP exchange on the membrane 
(Robbe et al., 2003). Numerous regulators of Rho GTPases thus require lipid 
localisation, with many exchange factors possessing PH domains, for this function.
The Cl domain of the Rac GAP chimaerins is involved in lipid and phorbol 
ester associations (Ahmed et al., 1990). a l  chimaerin adopts a predominantly insoluble 
subcellular localisation (Hall et al., 2001). Conversely a2 chimaerin is largely soluble, 
presumably through influences of its variant N-terminus, encompassing a SH2 domain. 
A mutation within the SH2 domain, maintaining phosphotyrosine binding, but 
potentially locally altering charges surrounding the phosphotyrosine pocket (N94H), 
translocates a2 chimaerin, promoting lipid associations (Hall et al., 2001, Fig.3.1). 
Phosphotyrosine binding knock out mutations (R56L, R73L) have no effect on a2
162
Discussion
chimaerin localisation (Hall et al., 2001), implying phosphotyrosine dependent 
associations of the SH2 domain are not responsible for the cytosolic location, at least 
under these over- expressed, non stimulated conditions in Cos-7 cells. In this study, a 
second mutation of the GAP domain, a deletion of three residues (A303-305), was also 
found to translocate a2 chimaerin, while the point mutation R304G was without any 
effect on distribution (Fig.3.1). Both these mutations abolish GAP activity but maintain 
Rac binding (Ahmed et al., 1994) implying the differences are independent of Rac 
association and GAP activity. The loss of Tyr303 through A303-305 with subsequent 
translocation, could implicate an intramolecular interaction between the SH2 domain 
and Tyr Although the critical nature of this residue was not investigated, 
phosphorylation of this site could potentially serve as a negative regulatory mechanism 
for a2 chimaerin activity, increasing intramolecular interactions. Alternatively loss of 
the critical 303-305 may be such a drastic mutation that loss of native conformation is 
inevitable.
Exogenous expression of a2 chimaerin A303-305 or a2 chimaerin N94H in 
Cos-7 cells revealed a perinuclear punctuate accumulation of these translocated 
proteins, in contrast to the uniform cytosolic staining of a l  chimaerin (Fig. 3.1). PMA 
treatment of N1E-115 neuroblastoma cells over-expressing a l  chimaerin also resulted 
in a clear translocation of this phorbol ester receptor from the cytoplasm to Triton-x-100 
soluble and insoluble fractions, representing both membrane and cytoskeletal elements 
(Fig. 3.2). PKC involvement in this PMA induced translocation was not ruled out but 
other published results have shown this is PKC independent for the highly related (32 
chimaerin (Caloca et al., 1997, 1999, 2001). Exogenous expression in Cos-7 cells and 
live cell fluorescent imaging also showed a punctate aggregation of GFP-a2 chimaerin
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in the cytoplasm concentrating around the nucleus upon PMA treatment (Fig.3.9), with 
no observable plasma membrane association.
The Golgi complex is the central protein sorting structure of the cell, a l  
chimaerin has been shown to regulate Golgi stability during interphase (Alonso et al.,
1998) while (52 chimaerin translocation to Golgi as well as plasma membrane in over 
expressing Cos cells has also been observed upon PMA treatment (Caloca et al., 2001). 
P2 chimaerin associates with the transmembrane protein Tmp21-I via the Cl domain 
(Wang et al., 2002). The transgolgi network is rich in DAG, which is required for the 
recruitment of the vesicle biogenesis factor, PKD (Protein kinase D), via its Cl domain 
(Baron et al., 2002). The majority of DAG production at the Golgi is believed mediated 
by two separate pathways. PLD is localised to the Golgi (Freyberg et al., 2001) and 
converts the abundant phosphatidylcholine (PC) into phosphatidic acid (PA), which is 
subsequently dephosphorylated by PA phosphatases (PAPs), resulting in DAG 
production. Alternatively, the Golgi enzyme sphingomyelin (SM) synthesase 
interconverts PC and SM, which in the production of the vast amount of Golgi SM 
(Pagano et al., 1988), liberates DAG. Thus various Cl containing proteins, including 
PKC e (Lehel et al., 1995) and human Muncl3 (Song et al., 1999) may be translocated 
to Golgi as well as plasma membranes. In the case of RasGRP, the translocating 
membrane was determined by the concentration of PMA (Lorenzo et al., 2001) while 
specificity of phorbol ester anologues can also modulate targeting as shown by 
PKC5 which translocates to plasma or nuclear membranes accordingly (Wang et al.,
1999). Thus it is likely that in vivo the concentration and specificity of DAG production 
plays a major role in targeting these phorbol ester receptors.
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Until recently, Ras activity was thought restricted to the plasma membrane, but 
has recently been found active on the Golgi complex (Chiu et al., 2002) through PLCy 
production of DAG and recruitment of the Cl containing Ras exchange factor, 
RasGRPl. Cdc42 activity has also been localised to the Golgi apparatus (Erickson et al., 
1996, Musch et al., 2001) along with its GEF, Fgdl (Estrada et al., 2001) and effector 
IQGAP (McCallum et al., 1998). Rac activity has so far been largely localised to the 
plasma membrane, although cross talk does exist between Rac and ARF/Rab family 
members (Radhakrishna et al., 1999) implicating a role for Rac in membrane 
trafficking. Several Rac GAPs have also been localised to the perinuclear region 
including MgcRacGAP (Naud et al., 2003), ARHGAP4 (Foletta et al., 2002) and 
OCRL1 (Faucherre et al., 2003). Interestingly a large pool of inactive Rac-GDP also 
exists within the perinuclear region of fibroblast cells (Kraynov et al., 2000). a2 
chimaerin may thus serve to regulate Rac signalling on endomembranes, controlling 
vesicle trafficking and it is tempting to speculate a possible involvement in maintaining 
a perinuclear Rac-GDP pool in neuronal cells.
a2 chimaerin is not endogenous to Cos-7 cells but is expressed in N1E-115 
neuroblastoma cells. Neuroblastoma cells permanently over-expressing a l  chimaerin 
(a2.10) are flattened adhesive cells which were found to display dynamic peripheral 
activity, indicative of dynamic Rac signalling (Fig. 3.3). Cell staining revealed a 
predominantly uniform cytoplasmic distribution of a l  chimaerin extending to the 
leading edge of peripheral lamellipodiall structures (Fig.3.2B). Although difficult to 
visualise in live cell imaging, due to dramatic morphological effects on activation, fixed 
cell staining showed a l  chimaerin redistribution with a punctuate accumulation towards 
the periphery of the cell, upon PMA treatment. The exact nature of this translocation 
remains unclear but could imply targeting of translocation is cell specific, potentially
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determined by local interacting proteins. Over-expression of the a2 chimaerin A303- 
305 mutant in neuroblastoma cells displayed punctate accumulation along the neurite 
(Fig. 3.8), which suggests a role in vesicle trafficking along neurites.
In summary, either specific mutations of a2 chimaerin or its association with 
phorbol ester results in translocation to lipid membranes, implying the native protein 
may reside in a conformation masking the Cl domain from lipid associations.
6.A.1.1 Lipid association and a2 chimaerin GAP activity
The lack of effect of transiently over-expressed a2 chimaerin in Cos-7 (Fig. .31) and 
N1E-115 neuroblastoma cells (Fig. 3.8), on cell morphology is of interest. Over- 
expression of an active Rac GAP, in theory, should down regulate Rac activity with 
presumed dramatic morphological consequences. N1E-115 neuroblastoma cells 
deprived of serum undergo differentiation and neuritogenesis in a Rac/Cdc42 dependent 
manner (Kozma et al., 1997), which is inhibited by the over-expression of a l  chimaerin 
(Hall et al., 2001) but not a2 chimaerin (Fig. 3.6 and 3.7). This implies the proposed 
closed conformation of a2 chimaerin inhibits GAP activity as well as lipid associations. 
Although speculative it is feasible that there is an association of SH2 domain with GAP 
domain (Tyr ) which could stearically hinder the essential Arg required for GAP 
activity. Numerous Rho GAPs appear to reside in an inactive conformation including 
TCGAP (Chiang et al., 2003) and OPHN-1 (Fauchereau et al., 2003). The N-terminal 
GTP binding domain of pl90RhoGAP has also been found to regulate C-terminal GAP 
activity (Tatsis et al., 1998) with tyrosine phosphorylation by Src reducing GTP binding 
(Roof et al., 2000). Thus GAP activity may be transiently and tightly controlled.
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Cellular responses to PMA appear varied; Swiss3T3 fibroblasts undergo 
dramatic ruffling with accompanied macropinocytosis (Ridley et al., 1992), GT1 
hypothalamic neurones extend neurites (Choe et al., 2002), human neuroblastoma cells 
SHSY5Y differentiate (Pahlman et al., 1981) and in DRG and RGC neurones (retinal 
ganglion cells) neuronal growth cones undergo collapse, with associated endocytosis 
(Fournier et al., 2000). This is probably in part due to the cell specific or variable 
expression of different phorbol ester receptors. PKC isozymes were long thought the 
primary phorbol ester effectors and have been implicated in numerous PMA induced 
cellular responses, including neurite outgrowth (Choe et al., 2002, Pahlman et al., 
1981). The discovery of novel phorbol ester receptors (chimaerins, PKDs, RasGRP, 
Muni3, DAG kinase y and MRCK) has meant a re-evaluation of pharmacological 
studies with these agents. PMA induced fibroblast ruffling may be partially influenced 
by the Cl containing Ras exchange factor, RasGRP, which is activated by phorbol 
esters (Lorenzo et al., 2001). Ras activation in turn can lead to Rac activation and 
lamellipodia formation (see 1 .E).
The chimaerins were the first identified non-PKC phorbol ester receptors (Hall 
et al., 1990). In-vitro, lipid association was shown to regulate a  chimaerin GAP activity 
(Ahmed 1993). The acidic phospholipids, phosphatidylserine and phosphatidic acid, 
were found to up-regulate GAP activity while neutral phospholipids such as 
phosphatidylcholine and phosphatidylethanolamine were non-regulatory. Numerous 
other lipids were also found to inhibit GAP activity in vitro via Cl association, 
including LPA, phosphatidylinositol, PI4P and PI(4,5)P2 (Ahmed et al., 1993). 
Arachidonic acid was the most potent inhibitor of the catalytic domain, but was 
independent of the Cl domain. Phorbol ester association, which is lipid dependent, 
does not directly regulate GAP activity in vitro although some synergism with
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phospholipids is observed in the presence of limited amounts of phospholipids (Ahmed 
etal., 1993).
Treatment of Cos-7 cells with PMA results in dramatic lamellipodia formation 
(Fig. 3.10), indicative of increased Rac signalling. This phorbol ester mediated 
morphological effect was abolished with the exogenous expression of wild type, but not 
GAP inactive, a2 chimaerin, directly implicating a l  chimaerin GAP activity. High 
concentrations of PMA, in Cos-7 cells expressing a l  chimaerin, resulted in cellular 
collapse. Similarly neuroblastoma cells, where a l  chimaerin is endogenously 
expressed, underwent rapid neurite retraction upon PMA treatment (Fig.3.5). a2.10 
neuroblastoma cells also underwent rapid collapse with associated loss of Rac-GTP 
upon PMA treatment, consistent with a l  chimaerin GAP activation (Fig. 3.3).
From this and previous work it appears a l  chimaerin resides GAP inactive in 
the cytosol, but is translocated to lipid membranes upon phorbol ester treatment, where 
its substrate, Rac-GTP, is localised. Lipid association consequently up regulates GAP 
activity with subsequent down regulation of Rac signalling. The observed collapse of 
a2.10 neuroblastoma cells and transfected Cos-7 cells expressing a l  chimaerin, 
occured in the presence of 10% serum where Rho signalling would be prevalent. Thus 
the removal of the antagonistic active Rac could enhance Rho signalling pathways, 
leading to actin/myosin contraction. SHSY5Y neuroblastoma cell response to PMA 
appears regulated by the presence of serum (Muir et al., 1989).
a l  chimaerin is expressed predominantly in the adult brain and is associated 
with areas of high plasticity (Lim et al., 1992, Hall et al., 2001). a l  chimaerin associates 
with membranes, inhibiting serum withdrawal induced neuritogenesis of N1E-115 
neuroblastoma cells (Hall et al., 2001). Thus in vivo, a l  chimaerin does not appear to 
be regulated by autoinhibition. Regulation must therefore occur through alternative
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mechanisms and it is possible protein concentration modulation of a l  chimaerin may be 
critical.
6.A.2 a2 Chimaerein GAP Activity and Neuronal Morphology 
6.A.2.1 Neurites
Neurite retraction of N1E-115 neuroblastoma cells occurred upon PMA treatment. GAP 
inactive a2 chimaerin mutants, maintaining Rac binding; potentially serve as dominant 
negative constructs (Ahmed et al., 1994). The results obtained by expression of these 
mutants implicated a role for a2 chimaerin in this PMA induced neurite retraction, 
indicative of a novel, non PKC phorbol ester effect (Fig. 3.6). However the use of a 
PKC kinase inhibitor did not exclude PKC kinase activity in this response. Inhibition of 
PKC lead to dramatic filopodia formation and neuritogenesis of N1E-115 
neuroblastoma cells with no significant collapse upon PMA treatment (Fig. 3.6). PKC 
inhibition in chick DRG growth cones also induced filopodia extensions while PMA 
treatment caused filopodia shortening (Bonsall et al., 1999). PMA and PKC kinase 
activity have been implicated in neuronal growth cone collapse and neurite retraction 
(Fournier et al., 2000, Zhou et al., 2001, Xiang et al., 2002) but also in neurite 
outgrowth (Choe et al., 2002). PKCe induces neuritogenesis of neuroblastoma cells 
independent of kinase activity but dependent on actin binding (Zeidman et al., 1999, 
Zeidman et al., 2002). PMA treatment induces differentiation and neurite outgrowth of 
SH-SY5Y neuroblastomas in the presence of serum but also serves to inhibit serum 
deprived induced neurite outgrowth of these cells (Muir et al., 1989).
The effects of GAP inactive a2 chimaerin constructs implies inhibition of 
endogenous a2 chimaerin is sufficient to induce neuritogenesis in N1E-115 
neuroblastoma cells. In accordance with this, the over-expression of the “active” a2
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chimaerin mutant N94H, supported that a l  chimaerin GAP activity serves to inhibit 
neuritogenesis. However a possible effector/adaptor function of a2 chimaerin in neurite 
outgrowth, independent of GAP can not be ruled out. Neuritogenesis requires the forces 
generated from the cytoskeleton to break the neuronal sphere and, in the case of N1E- 
115 neuroblastomas, is Rac/Cdc42 dependent (Kozma et al., 1997). In primary 
hippocampal neurones lamellipodia are the observed direct precursors to neurites 
(Dehmelt et al., 2003). Consequently, promoters of Rac signalling and actin 
polymerisation such as Tiam, a Rac GEF, induce neuritogenesis (Leeuwen et al., 1997) 
which a2 chimaerin, through its GAP domain appears to inhibit it.
Over-expression studies can be misleading since there are numerous associated 
problems, including mislocalisation and possible sequestration of endogenous signalling 
pathways. Transiently over-expressed a2 chimaerin does not appear to sequester Rac or 
DAG, as the expressing neuroblastoma cells still appear to respond normally to serum 
withdrawal. Thus observed effects from expression of GAP inactive a2 chimaerin 
constructs are presumably through specific competition with endogenous a l  chimaerin 
for DAG recruitment or Rac-GTP association. siRNA studies would be an alternative 
approach to examine knock out of a l  chimaerin function in these cells.
Dynamic Rho GTPase activity is required for proper functioning. In theory a l  
chimaerin, in coordination with a GEF (eg.Vav/Tiam), could promote Rac cycling and 
signalling and, in the case of neuroblastoma cells, cause neuritogenesis. This was not 
observed in transient over-expression studies. However enhanced expression does not 
necessarily result in enhanced signalling, especially where dynamic activity is required, 
involving a delicate balance of factors. It is noteworthy that permanent neuroblastoma 
cells over-expressing a l  chimaerin to a much lower degree, do display increased
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neuritogenesis (Hall et al., 2001). In these cells a2 chimaerin is localised to fluctuating 
lamellipodia, indicative of dynamic Rac signalling (Fig 3.3).
The observed neurite retraction of N1E-115 neuroblastoma cells in response to 
PMA could implicate a role for a l  chimaerin activity in axonal retraction. 
Neuritogenesis and elongation require co-ordination between actin and microtubule 
cytoskeletons and thus proteins which can interact with both cytoskeletons are likely to 
play major regulatory roles. Microtubules have a known role in neurite stabilisation and 
evidence for Rho GTPase regulation of microtubules is emerging (l.E.2.5). Rac-GTP 
binds tubulin in vitro (Best et al., 1996) and a l  chimaerin also associates with tubulin 
via its SH2 domain in vitro (Ferrari Thesis 1999) and could therefore regulate Rac 
function there. The localisation of a l  chimaerin to endomembranes could also 
implicate a role in vesicle trafficking along neurites, where microtubule based 
membrane transport is a limiting factor for axonal outgrowth. Axonal 
extension/retraction is also regulated by a balance of forces generated from actin and 
microtubule based motor proteins (Gallo et al., 2002). Rho serves to regulate myosin II 
activity in neurones, promoting retraction. Thus activation of a l  chimaerin at the 
leading edge of neurites and down regulation of the Rho antagonist Rac, would favour 
actomyosin induced retraction.
6.A.2.2 Growth cones
F-actin appears to be a major target of extracellular guidance cues. It was thought 
guidance cues on binding their receptor, and through the recruitment of GEFs/GAPs, 
would regulate the Rho GTPases and subsequently the actin cytoskeleton, leading to 
either protrusive or collapse activities (see Fig. 6.1). a l  chimaerin is a neuronal specific 
Rac GAP which could be recruited to activated receptors either through receptor
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tyrosine phosphorylation or localised DAG production. Thus if Rac caused outgrowth, 
through induced actin polymerisation, antagonised by Rho collapse mediated by 
actomyosin contraction, it could be theorised a2 chimaerin recruitment and activation 
would lead to decreased Rac signalling and growth cone collapse through Rho 
activation.
Membrane
GEFs GAPs
RhoGTPases
Actin Dynamics
Fig. 6.1 Growth cone guidance and the Rho GTPases
However a paradoxial requirement for Rac in growth cone collapse, in response to some 
negative guidance cues is now emerging (Jin et al., 1997, Jumey et al., 2002). It 
appears growth cone collapse requires the co-ordinated activation of several distinct 
signalling pathways including inhibition of protrusive activity, F-actin depolymerisation 
and re-organisation, loss of attachment and endocytosis. F-actin depolymerisation is not 
sufficient for collapse but rather its reorganisation, loss of attachment and possibly 
endocytosis is (Jumey et al., 2002).
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PMA is a powerful growth cone collapsing agent (Fournier et al., 2000) with 
PKC implicated in downstream signalling (Zhou et al., 2001). PKC activation has been 
shown to promote microtubule advance in neuronal growth cones (Kabir et al., 2001) 
and growth cone response to PMA appears regulated by cytosolic cGMP levels (Xiang 
et al., 2002). Various collapsing factors including PMA, induce loss of actin bundles 
within the growth cone without depolymerisation of actin (Zhou et al., 2001). In 
response to PMA and other collapsing agents such as Serna 3A and Ephrin A-2, 
endocytosis is activated with accompanying reorganisation of F-actin and Rac into 
distinct vacuole structures (Fournier et al., 2000, Jumey et al., 2002). Measurement of 
Rac-GTP levels indicated there is an initial reduction in Rac activity with loss of actin 
polymerisation (l-3min) followed by a recovery (6-12min) with induction of 
endocytosis and reorganisation of F-actin (Jumey et al., 2002). Rac signalling is not 
involved in the depolymerisation of F-actin but is required for endocytosis and F-actin 
reorganisation. This has been put forward to explain the involvement of Rac in growth 
cone collapse in response to Serna 3A and Ephrin A-2 (Jumey et al., 2002). a2 
chimaerin is endogenous to DRGs (Hall et al., 2001) and it is possible that a2 chimaerin 
plays a role in the initial decrease in Rac-GTP levels involved in cessation of protrusive 
activity. Inactivation of Rac is not sufficient to cause growth cone collapse (Jin et al., 
1997, Kuhn et al., 1999, Jumey et al., 2002) but may allow the dissociation of existing 
actin polymerisation complexes surrounding Rac, to re-establish a role in driving F- 
actin reorganisation and endocytosis. Endocytosis is probably required for the 
internalisation of receptor bound ligand, which a2 chimaerin may regulate through lipid 
and protein interactions.
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PI(4,5)P2 associates with numerous proteins involved in actin polymerisation, 
such as N-WASP, profilin, gelsolin and CapZ to overall promote polymerisation. 
Considerable evidence implicates interplay between Rho GTPases and PI(4,5)P2 
synthesis pathways in actin cytoskeleton remodelling (see review Sechi et al., 2000). 
PI(4,5)P2 has been shown to dissociate Rac from Rho GDI (Chuang et al., 1993) and in 
addition, Rac has been found to associate with numerous enzymes involved in PI(4,5)P2 
metabolism. Rac associated with PIP5K in vitro (Tolias et al., 1995) and in cells, Rac 
GTP translocates PIP5K to the cell membrane (Chatah et al., 2001) for localised actin 
polymerisation through PI(4,5)P2 synthesis (Tolias et al., 2000). Phosphatidic acid 
(PA), generated from either PLD or DAG kinase activities, is a potent activator of 
PIP5K. DAG kinase also binds Rac (Tolias et al., 1998) and Rac-GTP has been found 
to associate with a lipid kinase complex including PIP5K and DAG kinase (Carpenter et 
al., 1999). Thus Rac may bring PIP5K and PA in close proximity for localised 
PI(4,5)P2 production. Conversion of PI(4,5)P2 to PI(3,4,5)P3 by PI3K activity may also 
recruit WAVE2 for lamellipodia formation (Oikawa et al 2004) or Rac-GEFs to 
maintain signalling. The system is thus set to promote PI(4,5)P2 production and actin 
polymerisation at the leading edge, with the removal of DAG and the production of 
chimaerin inhibitors PA, PI(3,4,5)P3 and PI(4,5)P2 (Ahmed et al., 1993). A burst of 
DAG production could recruit and activate a2 chimaerin down regulating Rac 
signalling, collapsing the system. This could occur either through the recruitment and 
activation of PLC, cleaving PI(4,5)P2, or by the actions of PA phosphatases (PAPs). 
Thus Rac-GTP, promotion of actin polymerisation, via PIP5K activity, can be rapidly 
quenched with the activation of a2 chimaerin.
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Fig. 6.2 Lipid Metabolism, Rac and Actin Polymerisation. (A) Rac/PIP5K induced PIP2 
synthesis, promotes actin polymerisation and growth cone advance. (B) DAG production via 
PLC or PAP activities, induces a 2  chimaerin GAP activity with subsequent cessation of actin 
polymerisation.
However, evidence so far appears to be favour PIP5K as a negative regulator o f  neurite 
outgrowth, inhibiting neuritogenesis and acting downstream  o f negative guidance cues 
including Sema3A, through the destabilisation o f  focal adhesions possibly via 
influences on vinculin (van-Horck et al., 2002).
Rac is also directly involved in PI(4,5)P2 depletion through its PI(4,5)P2 
phosphatase effector, Synaptojanin 2 (M alecz et al., 2000) and possibly through 
OCRL1, a bifunctional PI(4,5)P2 5 phosphatase and RacGAP (Faucherre et al., 2003). 
Thus dynamic Rac activity is crucial for PI(4,5)P2 turnover, possibly regulating actin 
polymerisation, endocytosis, vesicle trafficking and focal adhesions, which a 2
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chimaerin in turn may modulate. a2 chimaerin thus possibly plays an initial regulatory 
role in neuritogenesis which continues through neurite development as a negative 
guidance mediator.
6.A.3 Protein Interactions
a2 chimaerin GAP activity causes dramatic morphological effects and consequently 
must be tightly regulated, which the proposed model of an auto-inhibited conformation 
would allow. DAG/phorbol ester association induces translocation to lipids with 
subsequent GAP activation. How is translocation regulated to bring a2 chimaerin in 
close proximity to the specific membrane at the right location for DAG association and 
lipid insertion? Selectivity of DAG associations could confer a degree of specificity 
upon translocation but protein interactions are also likely to be modulatory. In the case 
of PKC there are three distinct groups of interacting proteins: receptors for activated C 
kinase (RACKs), substrates and inactive PKC anchoring proteins. It is conceivable the 
same applies for a2 chimaerin. Rac represents the only identified substrate although 
others may exist, while the transmembrane Golgi protein Tmp21 serves as a Golgi 
anchoring protein for (32 chimaerin, through associations with the Cl domain (Wang et 
al., 2002).
During this study three novel interactors of oc2 chimaerin were identified. P35 
and Cdk5 were both found to associate with the GAP domain of a2 chimaerin (Fig.4.1, 
Fig.4.9) while CRMP-2 was identified as a novel SH2 domain interactor in cells (Fig. 
5.2). These protein interactions of a2 chimaerin were increased in the presence of 
phorbol ester. An increase in (32 chimaerin binding to both Rac and Tmp-21 in the 
presence of phorbol ester has been previously noted (Caloca et al., 2001, Wang et al.,
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2002). PMA has been shown to translocate a2 chimaerin and therefore an increase in 
co-localisation of chimaerin with membranous p35 or CRMP-2 might explain this 
increased association. Alternatively, a conformational change upon PMA association 
could unmask protein interacting regions, allowing associations with cytosolic Cdk5 as 
well as p35, CRMP-2 and lipids. Increased binding in the presence of PMA suggests 
these interactions only occur with the active form of a2 chimaerin (i.e. analogues to 
RACKs) and may thus serve to localise GAP activity within the membrane or regulate 
GAP activity.
6.A.3.1 p35/Cdk5
In this study a2 chimaerin did not serve as a substrate for Cdk5 activity in vitro and is 
therefore an unlikely in vivo substrate. However due to conformational importance of 
a2 chimaerin Cdk5 phosphorylation can not be discounted (Qi et al 2004). Despite 
associations with p35 and Cdk5 separately, a2 chimaerin could not associate with the 
active p35/Cdk5 complex, implying competitive binding with much lower affinities of 
a2 chimaerin for p35 or Cdk5. Only in the presence of high concentrations of PMA 
could a2 chimaerin associate with p35 in the presence of Cdk5 (Fig. 4.11). Whether 
this represents a trimetric complex or the pull down of two separate complexes remains 
unclear. In vivo in the presence of DAG, a l  chimaerin could compete with Cdk5 for its 
activator, thus modulating kinase activity. Results with the inactive kinase mutant 
Cdk5D144N imply p35 and a l  chimaerin association may be negatively regulated 
through Cdk5 phosphorylation of p35 (Fig. 4.3). Under the appropriate conditions 
a l  chimaerin could also conceivably regulate Cdk5 activity through modulation of Rac 
signalling, as p35/Cdk5 activity towards PAK was increased in the presence of Rac- 
GTP through unknown mechanisms (Nickolic et al., 1998). a l  chimaerin could also
177
Discussion
potentially aid in the translocation of p35 or Cdk5 to the membrane. Protein 
interactions of p35/Cdk5 have been found to both stimulate (Qu et al., 2002) and inhibit 
(Ching et al., 2002) kinase activity.
Studies have implicated Cdk5 activity in neurite outgrowth and neuronal 
migration, while recently, a role in growth cone collapse is emerging with downstream 
Tau phosphorylation (Nakayama et al., 1999, Sazaki et al., 2002, Cheng et al., 2003). 
In this study Cdk5 activity was not required for neuritogenesis of N1E-115 
neuroblastoma cells, and over-expression of p35/Cdk5 inhibited neuritogenesis, causing 
rounding up of cells (Fig. 4.19). P35/Cdk5 and a2 chimaerin may thus coordinate 
activities to inhibit neuroblastoma cell differentiation. Cdk5 activity has been found to 
regulate cadherin mediated adhesion and has recently been placed upstream of FAK 
(Xie et al., 2003), while neuroblastoma cells continually expressing a2 chimaerin 
display increased adhesive properties. a2 chimaerin via its SH2 domain may be 
recruited to tyrosine phosphorylated cadherin-catenin or integrin complexes, regulating 
cell adhesion and neuronal migration in coordination with p35/Cdk5. P35/Cdk5 is 
found inactive in a large multiprotein complex (~600kDa) within the cytosol (Lee et al., 
1996) and it is possible a2 chimaerin is also present within this complex. P35/Cdk5 
activity has also been localised to the Golgi (Paglini et al., 2001) and implicated in 
vesicle formation and trafficking, which a2 chimaerin could possibly regulate. Recent 
evidence has implicated Cdk5 activity in synaptic vesicle endocytosis with the re- 
phosphorylation of endocytic proteins dynaminl (Tan et al., 2003), amphiphysin 
(Tomizawa et al., 2003) and Synaptojanin 1 (Lee et al., 2004).
This study also highlighted a potential novel role for p35 and Cdk5, whose 
associations with a2 chimaerin C-terminus could regulate GAP activity. Both these 
proteins interact with the GAP domain of active a2 chimaerin and could possibly
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stearically hinder Rac-GTP associations. It was of interest to note the dissociation of a2 
chimaerin from membrane fractions in the presence of increasing concentrations of p35 
(Fig. 4.17). Although not definitive this result may suggest p35 interaction with a2 
chimaerin could inhibit lipid binding of the Cl domain, thus dissociating a2 chimaerin 
from the membrane. Thus p35/Cdk5 could function upstream and downstream of Rac.
6.A.3.2 CRMP-2
CRMP-2 was identified as a novel SH2 domain interactor of a2 chimaerin. a2 
chimaerin was found to interact with both N and C terminal halves of CRMP-2 and 
residues 1-112 was sufficient for interaction making it difficult to map the site(s) of a2 
chimaerin association (Fig. 5.5). This is in accordance with CRMP oligomerisation, 
where almost intact protein is required for strong associations, with both N- and C- 
terminal regions implicated (Wang et al., 1997).
Initially it appeared CRMP-2 and a2 chimaerin association was one of the few 
phosphotyrosine independent SH2 domain interactions, as mutation of a2 chimaerin 
preventing phosphotyrosine binding did not knock out CRMP-2 association in Cos-7 
cells, in the presence of phorbol ester (Fig. 5.6). Furthermore inhibiting tyrosine 
phosphatases with pervanadate treatment in Cos-7 cells over expressing both CRMP-2 
and a2 chimaerin also did not enhance their interaction despite increased tyrosine 
phosphorylation of CRMP-2 (Fig. 5.7). However, this treatment in N1E-115 
neuroblastoma cells did enhance interactions (Fig. 5.8), therefore implying tyrosine 
phosphorylation may be regulatory in neuronal cells. Of interest was the association 
with CRMP of a ~p80 tyrosine phosphorylated protein in neuroblastoma cells. CRMP 
members have been shown to form heterooligomers and the recent identification of N- 
terminal spice variant (~80kDa) suggests this band could represent a CRMP family
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member. Alternatively this may be a tyrosine binding SH2/PTB domain protein. This 
result does not answer whether the p80 phosphotyrosine protein detected upon 
pervanadate treatment represents increased binding or increased phosphorylation. 
CRMP-2 is tyrosine phosphorylated in response to Serna 3A treatment and Fps/Fes has 
been identified as a potential kinase (Mitsui et al., 2002). This study reveals tyrosine 
phosphorylation of CRMP-2 may recruit SH2/PTB domain containing proteins, 
including a2 chimaerin.
CRMP-2 is both cytosolic, membranous and is now known to be associated with 
dynamic microtubules within axons where it is implicated in growth cone guidance and 
axonal branching (Yuasa-Kawada et al., 2003). a2 chimaerin through interactions of its 
SH2 domain has also been found to associate with tubulin (Ferrari Thesis 1999), which 
Rac also binds in vitro (Best et al., 1996). It is thus tempting to speculate a role of a2 
chimaerin in coordination with CRMP-2 and Rac to regulate microtubule dynamics in 
growth cones and neurites. Microtubule and actin cytoskeletal cross talk is essential for 
proper guidance and outgrowth, where stabilisation of actin filament promotes 
microtubule advance into the growth cone periphery. CRMP-2 also associates with 
Numb to mediate endocytosis of the adhesion molecule LI (Nishimura et al., 2003), 
which a2 chimaerin may also be involved in since this may be a Rac dependent process. 
No apparent effect on a2 chimaerin GAP activity was evident upon CRMP-2 
association (Fig.4.15 and Fig.4.16). CRMP-2 associates with and inhibits PLD2 activity 
which may indirectly regulate a2 chimaerin GAP activity.
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6.A.4 Tyrosine Phosphorylation
SH2 domain interactions of a2 chimaerin have been previously investigated in vitro 
(Ferrari Thesis 1999). Only weak binding of full length GST-a2-chimaerin to 
phosphotyrosine-agarose was demonstrated, to which the isolated GST-a2 SH2 domain 
bound with considerably increased affinity. This is consistent with the proposed closed 
conformation of a2 chimaerin. Using a GSTa2 SIC domain column, tubulin and actin 
from rat brain extracts, were identified as potential interactors, but this may be an 
indirect association.
In this study an attempt was made to further investigate the role of the SIC 
domain in phosphotyrosine associations in cells. Experiments using pervanadate to 
inhibit tyrosine phosphatases were carried out, which highlighted the likely tyrosine 
phosphorylation of a2 chimaerin in vivo. (Fig.5 .10). This implies a2 chimaerin exists 
in a dynamic state of tyrosine phosphorylation/dephosphorylation within cells. 
Phosphorylation of GAPs has been reported (see l.E .l.2.2.3). In the case of 
pl90RhoGAP, Src phosphorylation occurs close to the GAP domain (Roof et al., 1998) 
which recruits pl20RasGAP, leading to activation. Ser/Thr GAP phosphorylation has 
also been demonstrated to alter specificity in the case of MgcRacGAP (Minoshima et 
al., 2003). Interestingly a2 chimaerin appears to be tyrosine phosphorylated within the 
SIC containing N-terminus (1-196) in vitro by Fyn (Fig. 5.12). Consistent with a 
closed conformation model, tyrosine phosphorylation of full length a2 chimaerin by 
Fyn, or by pervanadate treatment was minimal. Deletion of the N-terminal 38 residues 
resulted in significantly increased phosphorylation by Fyn, thereby also potentially 
implicating these residues in native conformational regulation. Thus a2 chimaerin may 
only be a significant target for tyrosine kinases in its active state, attached to 
membranes. Tyrosine phosphorylation may serve to recruit further regulatory SH2/PTB
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domain containing proteins (adaptor function) or may regulate a2 chimaerin GAP 
activity or SH2 domain /lipid associations. Fyn has been implicated in FAK and 
paxillin phosphorylation (Thomas et al., 1995) and a2 chimaerin may thus represent a 
further downstream target to regulate growth cone adhesion and migration.
As well as observed tyrosine phosphorylation of a2 chimaerin, numerous other 
associated phosphotyrosine proteins were present upon pervanadate treatment (Fig.5.10 
and Fig. 5.11). These may represent associated phosphotyrosine proteins interacting via 
a2 chimaerin SH2 domain, but may equally represent associated proteins becoming 
phosphorylated upon treatment or alternatively the recruitment of other SH2/PTP 
containing proteins to bind tyrosine phosphorylated a2 chimaerin. By which ever 
mechanism, a2 chimaerin appears to interact with numerous proteins involved in 
phosphotyrosine signalling pathways.
Numerous SH2 domain proteins are recruited to activated RTKs, where Rac 
activity is also localised (Ridley et al., 1992). PI3K is directly recruited to RTKs, 
whose lipid products recruit GEFs such as Sos-1. Sos-l/Grb2 plays a role in RTK 
mediated activation of Ras but Sos-1 activity can be re-directed towards Rac when in 
complex with E3bl/Eps8 (Innocenti et al., 2002). The SH2 domain of the GEF, Vav 
constitutively interacts with the receptor tyrosine kinase Mer, independent of tyrosine 
phosphorylation. Activation of Mer phosphorylates and releases active Vav (Mahagan 
et al., 2003). PLCy is also recruited to numerous RTK via SH2 domain interactions 
(Mohammadi et al., 1993) but it also requires PI3K products, for PH domain mediated 
lipid localisation (Falasca et al., 1998), leading to localised DAG production. Thus the 
SH2 and Cl domain of a2 chimaerin could potentially corporate to efficiently recruit 
a2 chimaerin to transmembrane tyrosine phosphorylated proteins including RTKs, 
where Rac activity is localised. It is also possible upon recruitment to activated RTKs,
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direct tyrosine phosphorylation of a2 chimaerin could occur which may regulate 
activity.
Rac 
 __
Membrane
KJJ PLCy ) 
0
GAP
Fig. 6.3 Model of a2 Chimaerin domain cooperativity.
a2 chimaerin SH2 domain and C1 domain cooperate for efficient targeting to phosphotyrosine 
receptors for localised downregulation of Rac signalling. Receptor tyrosine kinase or 
associated tyrosine kinases may further regulate a2 chimaerin through tyrosine phosphorylation
6.A.4 Proteolytic Cleavage
During the course of this study it became clear a2 chimaerin is susceptible to 
proteolytic cleavage by the frequent immunoprecipitation of a N-terminal fragment of 
a2 chiamerin from cells expression full length protein (Fig. 4.12, Fig.5.11). The 
detection of an N-terminal ~20kDa fragment potentially implies cleavage could release 
a ~30kDa C-terminus peptide encompassing the Cl domain and GAP domains, 
although further proteolysis has not been ruled out. Loss of the SH2 domain through 
proteolytic cleavage could relieve autoinhibition, releasing the active Cl-GAP and may 
thus be a further regulatory role for this phorbol ester receptor (proteolytic activation). 
This is reminiscent of PKC regulation, where the hinge region between the catalytic C- 
domain and the N-terminal regulatory domains is highly sensitive to cellular proteases 
leading to activation (Ron et al., 1999).
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6.B CRMP-2 Phosphorylation
CRMP-2 exists in variable phosphorylated forms in vivo (Gu et al., 2000) which is more 
apparent in the foetal rat brain compared with the adult brain. CRMP-2 has been 
identified as a target for both ROK (Aimura et al., 2000) and Fps/Fes (Mitsui et al., 
2002) kinases. In this study CRMP2 was identified as a novel substrate for both Cdk5 
(Fig.5.14) and GSK3P (Fig.5.19) activity in vitro. Cdk5 was found to exclusively 
phosphorylate Ser522, which potentially could prime for GSK3P mediated 
phosphorylation of Ser518 and Thr514. These sites are conserved among some CRMP 
members (see Fig 5.17) implying other CRMP members may also serve as substrates 
for these kinases. Phosphorylation of all three sites in vivo and in vitro was required for 
a mobility shift in CRMP-2, upon SDS gel electrophoresis, as a presumed result of a 
conformational change (Fig. 5.22). CRMP-2 phosphorylation could conceivably serve 
to regulate location or protein interactions. CRMP members form heteroligomers and 
CRMP-2 associates with Numb, PLD2, tubulin heterodimers and a2 chimaerin all of 
which may be regulated by phosphorylation, thus potentially regulating endocytosis, 
PLD2 activity, microtubule dynamics and GAP activity respectively.
Cdk5 and GSK3P are two kinases linked to microtubule dynamics. Both kinases 
phosphorylate Tau and MAP1B (Paglini et al., 1998, Lucas et al., 1998) which have 
been linked to the stabilisation of microtubules and actin filaments in growth cones 
(Owen et al., 2003). Adenomatous polyposis coli (APC) phosphorylation by GSK3P 
reduces its affinity for plus end microtubules (Zumbrunn et al., 2001). In non neuronal 
cells this signalling pathways is regulated by Cdc42 (Etienne Manneville et al., 2003). 
CRMP-2 binds preferentially to tubulin heterodimers, rather than polymerised 
microtubules, promoting polymerisation (Fukata et al., 2002). CRMP-2 thus represents 
a further substrate implicating p35/Cdk5 and GSK3(3 in dynamic microtubule regulation
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via modulation of both polymerisation and stabilisation. Sequential CRMP-2 
phosphorylation also confirms a regulatory relationship between these two kinases as 
previously demonstrated with Tau (Cho et al., 2003, Hallows et al., 2003).
6.B.1 Sema3A Signalling
Thr555 CRMP-2 phosphorylation by ROK is observed in LPA induced growth cone 
collapse but not Sema3A induced collapse (Aimura et al., 2000). However CRMP-2, 
p35/Cdk5 and GSK3P have all been implicated in Sema3A signalling (Goshima et al., 
1995, Sasaki et al., 2002, Eickholt et al., 2002). In this study potential sequential 
phosphorylation of CRMP-2 by Cdk5 and GSK3P was observed in vitro which could 
conceivably partly mediate Serna 3A induced growth cone collapse. Cdk5 activity is 
stimulated in response to Serna 3A, via Tyr15 phosphorylation (Sasaki et al., 2002), 
while GSK3P lies poised inactive at the leading edge of the growth cone, through 
potential PI3K pathways (Eickholt et al., 2002). PI3K inhibition with resulting GSK3P 
activation could be PLC mediated, through removal of PI3K substrate PI(4,5)P2 and 
production of DAG. This could also activate a2 chimaerin. Phosphorylation within 
CRMP-2 C-terminus, either by ROK or Cdk5/GSK3(3, maybe required or sufficient for 
growth cone collapse. Sequential phosphorylation by two distinct kinases provides a 
stringent regulatory mechanism. Growth cone collapse can be mediated by both the 
actin and microtubule cytoskeletons. CRMP-2 binds tubulin heterodimers and thus 
collapse may be mediated through microtubule regulation or through Numb mediated 
endocytosis or inhibition of PLD activity (two other associated proteins). Tau is a 
sequential target of both these kinases which could also mediate growth cone collapse 
and which is phosphorylated downstream of a number of negative guidance cues 
including Sema3A (Nakayama et al., 1999, Sazaki et al., 2002, Cheng et al., 2003).
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Fig. 6.4 Phosphorylation Pathways Downstream of Sema3A Signalling.
(i)GSK3p is maintained inactive through PI3K/Akt signalling. (ii)Sema3A association with 
neuropilin (NP) leads to NP/Plex coupling with downstream activation of p35/Cdk5 and 
phosphorylation of Tau and CRMP-2. This priming event combined with removal of PI3K 
dependent inhibition of GSK3p allows further phosphorylation of CRMP-2 Ser618 and Thr514 and 
Tau, possibly regulating functional interactions and downstream signalling.
Fyn activity has also been implicated in Sema3A signalling (Sasaki et al., 2002) but was 
shown here incapable of phosphorylating CRMP-2 in vitro (Fig.5.12). The CRMP-2 
interacting protein, a2 chimaerin, however was phosphorylated by Fyn in vitro. 
Because of its association with numerous Sema3A signalling components (CRMP-2, 
p35/Cdk5 and Fyn) and its role in neurite retraction, it is conceivable a2  chimaerin is 
also involved in Sema3A signalling which CRMP-2, p35/Cdk5 or Fyn activities may 
recruit or regulate. Alternatively tyrosine phosphorylation of the Sema3A receptors 
PlexAl+2 has been observed (Mitsui et al., 2002, Sasaki et al., 2002) which could 
recruit a2 chimaerin via SH2 domain interactions. As well as inhibiting actin 
polymerisation as previously discussed (Fig. 6.1) a2  chimaerin could regulate p35/Cdk5 
activity towards PAK, Tau or CRMP-2 with possible subsequent effects on actin/tubulin 
dynamics and vesicle trafficking during collapse.
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6.B.2 Neurodegeneration
Cell signalling involves delicate balances, which if disturbed can be disasterous. 
Neurodegeneration in some cases appears a disruption of phosphorylation equilibriums, 
with apparent upregulation of certain kinase activities, leading to hyperphosphorylation 
of cytoskeletal proteins and neuronal death. Hyperphosphorylation of CRMP-2 on 
Thr509, Ser518 and Ser522 has been associated with neofibrillary tangle (NFT) in 
Alzheimers disease (Yoshida et al., 1998, Gu et al., 2000). As with Tau, Cdk5 and 
GSK3P activity could be responsible for the majority of this hyperphosphorylation of 
CRMP-2 in AD (Ser518 and Ser522) again implicating these kinases in 
neurodegeneration. Tau hyperphosphorylation disrupts microtubule associations, 
leading to microtubule destabilisation. CRMP-2 binds tubulin heterodimers, promoting 
polymerisation and axonogenesis and it would be of interest to determine how 
phosphorylation by Cdk5 and GSK3P affect this.
Conclusions
This study has revealed a2 chimaerin to be a tightly regulated molecule probably 
existing in an autoinhibited state in the cytosol. Activation is achieved through 
localised DAG production which associates with a2 chimaerin Cl domain, promoting 
lipid interactions. a2 chimaerin was also found to interact in vivo with both p35/Cdk5 
and CRMP-2. These protein interactions were enhanced in the presence of phorbol 
ester and could conceivably serve to target or regulate GAP activity. Tyrosine 
phosphorylation of a2 chimaerin by Fyn in vitro was also demonstrated which is a 
further likely regulatory mechanism.
a2 chimaerin was shown to be a regulator of neuronal morphology, promoting 
neurite retraction of N1E-115 neuroblastoma cells. This may implicate a2 chimaerin as
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a mediator of negative guidance cues and possibly more specifically Sema3A 
signalling, where Fyn, CRMP-2 and p35/Cdk5 activities have all been demonstrated.
CRMP-2 was also identified as a substrate for both p35/Cdk5 and GSK3P 
activities with a possibility of sequential phosphorylation. This sequential 
phosphorylation mechanism could be a key regulatory point during Sema3A induced 
growth cone collapse. Hyperphosphorylation of a number of these Cdk5/GSK3p 
CRMP-2 sites is also associated with NFTs in tissue from Alzhiemers disease patients, 
further implicating deregulation of both these kinases in neurodegeneration.
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